レニン・アンジオテンシン系と高血圧

出版社： 先端医学社
著者：
発行日： 1998-10-20
分野： 臨床医学：内科  >  血管
ISBN： 9784915892707
電子書籍版： 1998-10-20 （第1版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

商品紹介

腎臓・高血圧に関連の深い「レニン」発見100周年を記念した本邦初の画期的教科書。
レニン・アンジオテンシン研究の歴史から現在の研究動向までを網羅した本邦初の成書。過去30年間における日本人研究者が果たした役割にも触れた充実の内容。RA系とさまざまな疾患との関連からRA系抑制の臨床的意義にも触れた、これからRA系の研究に携わろうとする医療従事者必読の書。

目次

  • 表紙
  • 序
  • 執筆者一覧
  • 目次
  • Part1 / レニン・アンジオテンシン系研究の歴史
  • [1] レニン・アンジオテンシン系研究の主要年代一覧
  • [2] 歴史的総括
  • はじめに
  • I. レニン・アンジオテンシン系の発見への道程
  • II. レニンの発見
  • III. アンジオテンシンの発見
  • IV. レニン・アンジオテンシン・アルドステロン系の発見
  • V. 二次性高血圧とレニン・アンジオテンシン・アルドステロン系
  • VI. 本態性高血圧症とレニン・アンジオテンシン系
  • VII. アンジオテンシンII生成のバイパス経路
  • おわりに
  • Part2 / 私にとってのレニン・アンジオテンシン系
  • 阿部圭志
  • 荒川規矩男
  • 伊藤貞三
  • 飯村攻
  • 石井當男
  • 稲上正
  • 鈴木文昭
  • 荻原俊男
  • 尾前照雄
  • 金子好宏
  • 猿田享男
  • 竹田亮祐
  • 成瀬光栄
  • 藤田敏郎
  • 村上和雄
  • 日和田邦夫
  • 福地総逸
  • 藤井潤
  • 松岡博昭
  • 宮崎瑞夫
  • 山本研二郎
  • 柊山幸志郎
  • Part3 / レニン・アンジオテンシン系と高血圧
  • [1] レニン・アンジオテンシン系の分子生物学
  • 1. レニン:遺伝子,構造と機能
  • はじめに
  • I. レニン遺伝子
  • II. レニンの精製
  • III. レニンの諸性質と反応特性
  • IV. レニンの立体構造
  • V. レニンの反応機構
  • VI. 基質の側からみたレニン反応
  • VII. プロレニンの構造と機能
  • おわりに
  • A. レニンの発現調節と分泌の生理学
  • はじめに
  • I. レニンの発現および産生分泌調節
  • II. 圧受容体
  • III. マクラデンサ機序
  • IV. 交感神経系
  • V. 液性因子
  • 1. プロスタグランジン
  • 2. 一酸化窒素
  • 3. アデノシン
  • 4. アンジオテンシンII
  • VI. 腎内ヘテロジェネイティー
  • おわりに
  • 2. アンジオテンシノーゲン:遺伝子,構造と機能
  • はじめに
  • I. アンジオテンシノーゲン遺伝子の構造
  • II. 肝細胞特異的アンジオテンシノーゲン遺伝子転写制御機構
  • III. 肝細胞以外の組織におけるアンジオテンシノーゲン遺伝子の組織特異的転写制御機構
  • IV. アンジオテンシノーゲン遺伝子におけるgain of functionとloss of function
  • おわりに
  • 3. アンジオテンシン変換酵素(ACE):遺伝子,構造と機能
  • はじめに
  • I. ACE遺伝子とその発現調節
  • 1. ACEの蛋白構造と遺伝子構造
  • 2. ACEの発現分布と発現調節
  • II. ACE遺伝子多型と循環器疾患
  • III. ACE遺伝子欠損マウス
  • 1. 発生工学的手法によるレニン・アンジオテンシン系の研究
  • 2. ACE遺伝子欠損マウス
  • おわりに
  • 4. アンジオテンシンIIとその関連ペプチドの生理学
  • はじめに
  • I. アンジオテンシンIIの生理作用
  • II. アンジオテンシンIII
  • III. アンジオテンシン(1-7)
  • 1. アンジオテンシン(1-7)の中枢作用
  • 2. プロスタグランジン生成に及ぼす影響
  • 3. 血管への作用
  • 4. 腎および水・電解質への作用
  • 5. 培養血管平滑筋に対する抗増殖作用
  • 6. アンジオテンシン(1-7)の降圧作用
  • IV. アンジオテンシンIV
  • 1. 血管への作用
  • 2. 中枢作用
  • 3. 心臓に及ぼす影響
  • 4. アンジオテンシンIV受容体
  • おわりに
  • 5. アンジオテンシンII受容体:遺伝子,構造と機能
  • はじめに
  • I. アンジオテンシンII受容体亜型
  • II. アンジオテンシンII受容体遺伝子のクローニング
  • III. アンジオテンシンII受容体遺伝子の構造
  • IV. 組織別発現
  • V. アンジオテンシンII受容体の構造と機能
  • 1. リガンドの結合部位
  • 2. 受容体の活性化
  • 3. 受容体の不活化と取り込み
  • VI. アンジオテンシンIIタイプ1受容体を介したシグナリング(とくにチロシンキナーゼ系について)
  • VII. 受容体遺伝子のノックアウト
  • おわりに
  • 6. アンジオテンシナーゼ:その病態生理的意義
  • はじめに
  • I. アミノペプチダーゼ
  • 1. グルタミルアミノペプチダーゼ
  • 2. アルギニルアミノペプチダーゼ
  • II. その他のアミノペプチダーゼ
  • III. エンドペプチダーゼ
  • IV. カルボキシペプチダーゼ
  • V. アンジオテンシナーゼの病態生理的意義
  • 1. アンジオテンシナーゼ
  • 2. アミノペプチダーゼ
  • 3. カルボキシペプチダーゼ
  • おわりに
  • 7. レニン・アンジオテンシン系の遺伝子操作
  • はじめに
  • I. 遺伝子工学の導入
  • 1. ヒトレニンcDNAのクローニング
  • 2. ヒトレニンの動物培養細胞を用いる大量生産
  • 3. 核の中のレニン遺伝子の構造
  • 4. レニン基質,アンジオテンシノーゲン
  • II. 個体レベルの研究
  • 1. 遺伝子導入マウス
  • 2. 遺伝子欠損マウス
  • おわりに
  • [2] 組織レニン・アンジオテンシン系
  • はじめに
  • I. 組織レニン・アンジオテンシン系
  • II. 非レニン・アンジオテンシン系組織アンジオテンシンII産生系の概念
  • III. アンジオテンシン変換酵素依存性アンジオテンシンII産生系
  • IV. キマーゼ依存性アンジオテンシンII産生系
  • 1. 多様なアンジオテンシンII産生酵素
  • 2. キマーゼ
  • 3. アンジオテンシンII産生型キマーゼ
  • 4. キマーゼの病態機能
  • おわりに
  • 1. 中枢神経系とレニン・アンジオテンシン系
  • はじめに
  • I. 脳内レニン・アンジオテンシン系の構成成分
  • II. アンジオテンシンペプチドの中枢性作用
  • 1-a. アンジオテンシンIIの脳内分布とその中枢性作用
  • 1-b. アンジオテンシンIIと圧受容体反射
  • 1-c. アンジオテンシンIIによるナトリウムバランスの調節
  • 2. アンジオテンシンIIIの脳内分布とその中枢性作用
  • 3. アンジオテンシンIVの脳内分布とその中枢性作用
  • 4. アンジオテンシン(1-7)の脳内分布とその中枢性作用
  • おわりに
  • [3] レニン・アンジオテンシン系と循環系生理活性物質との関わり
  • 1. レニン・アンジオテンシン系とカリクレイン・キニン系
  • はじめに
  • I. 腎カリクレイン・キニン系
  • 1. 分子基盤
  • 2. 腎カリクレイン生成
  • 3. 腎生理作用
  • 4. 分子生理学
  • II. ヒト高血圧におけるレニン・アンジオテンシン系とカリクレイン・キニン系の相互作用
  • おわりに
  • 2. レニン・アンジオテンシン系とプロスタグランジン系
  • はじめに
  • I. エイコサノイド代謝
  • II. エイコサノイドと循環調節
  • III. レニン・アンジオテンシン系とプロスタグランジン系の相互作用
  • IV. プロスタグランジン系と臓器保護作用
  • おわりに
  • 3. レニン・アンジオテンシン系とナトリウム利尿ペプチドの拮抗関係
  • はじめに
  • I. ナトリウム利尿ペプチドシステムとその作用
  • II. 循環ホルモンおよび組織局所調節因子としてのアンジオテンシンIIとナトリウム利尿ペプチド
  • III. 脳内レニン・アンジオテンシン系とナトリウム利尿ペプチド系
  • 1. 中枢性血圧調節
  • 2. 飲水行動・食塩嗜好性
  • 3. 下垂体ホルモン分泌
  • IV. 血管壁レニン・アンジオテンシン系とナトリウム利尿ペプチド系
  • おわりに
  • 4. レニン・アンジオテンシン系とエンドセリン
  • はじめに
  • I. 血管壁でのレニン・アンジオテンシン系とエンドセリンの関わり
  • II. 心臓におけるレニン・アンジオテンシン系とエンドセリン-1の関わり
  • III. 腎臓でのレニン・アンジオテンシン系とエンドセリン-1の関わり
  • おわりに
  • 5. レニン・アンジオテンシン系と一酸化窒素
  • はじめに
  • I. 血管壁におけるレニン・アンジオテンシン系と一酸化窒素系の存在様式
  • II. 血管トーヌス調節におけるアンジオテンシンIIと一酸化窒素の相互作用
  • III. 細胞接着におけるアンジオテンシンIIと一酸化窒素の相互作用
  • IV. 血管平滑筋細胞の増殖肥大シグナルにおけるアンジオテンシンIIと一酸化窒素の相互作用
  • V. 血管平滑筋細胞の遊走およびアポトーシスにおけるアンジオテンシンIIと一酸化窒素の相互作用
  • おわりに
  • 6. レニン・アンジオテンシン系とアドレノメデュリン
  • はじめに
  • I. レニン・アンジオテンシン系とアドレノメデュリンの作用
  • II. 悪性高血圧と心不全におけるレニン・アンジオテンシン系とアドレノメデュリン
  • III. レニン分泌に及ぼすアドレノメデュリンの作用
  • IV. 心筋および血管壁におけるレニン・アンジオテンシン系とアドレノメデュリン
  • おわりに
  • [4] 実験的高血圧動物とレニン・アンジオテンシン系
  • 1. Goldblatt高血圧ラットとレニン・アンジオテンシン系
  • はじめに
  • I. Goldblatt高血圧モデルの作製
  • II. Goldblatt高血圧モデルの病態
  • 1. 1腎1狭窄型高血圧ラット
  • 2. 2腎1狭窄型高血圧ラット
  • III. Goldblatt高血圧からの回復
  • IV. Goldblatt高血圧類似の実験モデル
  • 1. 大動脈縮窄症モデル
  • 2. Page高血圧モデル
  • おわりに
  • 2. 高血圧自然発症ラットとレニン・アンジオテンシン系
  • はじめに
  • I. 前離乳期のSHRにおけるレニン・アンジオテンシン系の生理的動態
  • 1. 前離乳期のSHRの水・電解質平衡とレニン・アンジオテンシン系
  • 2. レニン・アンジオテンシン系と交感神経系との相互作用
  • 3. 前離乳期のSHRのレニン・アンジオテンシン系に関する薬理学的研究
  • II. 高血圧の成因に関するレニン・アンジオテンシン系の遺伝的意義
  • 1. 高血圧ラットを用いた分子遺伝学的研究の原理
  • 2. レニン
  • 3. アンジオテンシン変換酵素
  • 4. アンジオテンシノーゲン
  • 5. アンジオテンシンII受容体
  • おわりに
  • [5] レニン・アンジオテンシン系遺伝子多型と疾患
  • はじめに
  • I. レニン遺伝子多型と疾患
  • 1. ラットレニン遺伝子多型
  • 2. ヒトレニン遺伝子多型
  • II. アンジオテンシノーゲン遺伝子多型と疾患
  • III. アンジオテンシン変換酵素遺伝子多型と疾患
  • 1. 高血圧との関連
  • 2. 虚血性心疾患との関連
  • 3. 左室肥大
  • 4. 心筋症
  • 5. その他の病態との関連
  • IV. アンジオテンシンIIタイプ1受容体遺伝子多型と循環器疾患
  • V. アンジオテンシンIIタイプ2受容体遺伝子多型と循環器疾患
  • おわりに
  • [6] 高血圧とレニン・アンジオテンシン系
  • 1. 本態性高血圧とレニン・アンジオテンシン系
  • はじめに
  • I. 本態性高血圧に指摘されているおもな病態
  • II. 本態性高血圧における交感神経系の役割
  • III. 本態性高血圧におけるレニン・アンジオテンシン系の変化
  • IV. 本態性高血圧における高血圧の発症に果たすレニン・アンジオテンシン系の役割
  • 1. 心・血管壁への作用
  • 2. 腎臓におけるレニン・アンジオテンシン系の作用
  • V. 本態性高血圧におけるレニン・アンジオテンシン系遺伝子面からの検討
  • おわりに
  • 2. 二次性高血圧とレニン・アンジオテンシン系
  • はじめに
  • I. レニン・アンジオテンシン系の構成因子が直接関係している疾患
  • 1. レニンの合成分泌亢進が起こる疾患
  • 2. 腎血管性高血圧ではいかにレニンの合成分泌が亢進するのか
  • 3. レニン-食塩との関連
  • 4. レニンの合成・分泌はレニン・アンジオテンシン系をゆさぶることで変化するか
  • 5. 悪性高血圧
  • 6. 多発性嚢胞腎
  • II. レニン合成分泌が抑制される病態
  • 1. Liddle症候群
  • 2. Syndrome of Apparent Mineralocorticoid Excess
  • 3. グルココルチコイド奏効性アルドステロン症
  • 4. 原発性アルドステロン症
  • III. アンジオテンシンII受容体を介した作用が増加する疾患
  • 1. Cushing症候群
  • IV. 腎臓でのレニン・アンジオテンシン系と血圧との関連
  • V. 糖尿病における血圧とレニン・アンジオテンシン系との関連
  • 1. 糖尿病性腎症
  • VI. レニン・アンジオテンシン系の遺伝子レベルでの高血圧との関連
  • 1. アンジオテンシン変換酵素(ACE)
  • 2. アンジオテンシノーゲン遺伝子
  • VII. 膠原病とレニン・アンジオテンシン系との関連
  • [7] 種々の疾患におけるレニン・アンジオテンシン系
  • 1. 心不全とレニン・アンジオテンシン系
  • はじめに
  • I. アンジオテンシンの代謝経路
  • II. 心臓局所におけるレニン・アンジオテンシン系
  • 1. 心筋細胞の肥大
  • 2. 間質の線維化
  • 3. 血管障害による心筋血流の減少
  • III. 心不全におけるレニン・アンジオテンシン系の循環動態への影響
  • 1. 後負荷の増大
  • 2. 心不全の予後とレニン・アンジオテンシン系
  • おわりに
  • 2. 腎臓疾患とレニン・アンジオテンシン系
  • はじめに
  • I. 腎臓におけるレニン・アンジオテンシン系の存在
  • II. 腎臓における新しいアンジオテンシン産生経路の存在
  • III. 腎臓におけるレニン・アンジオテンシン系の活性調節
  • IV. レニン・アンジオテンシン系の病態における役割
  • V. 腎臓疾患におけるレニン・アンジオテンシン系
  • VI. ヒトの腎障害におけるレニン・アンジオテンシン系
  • VII. アンジオテンシン受容体のサブタイプ
  • おわりに
  • 3. 肝臓疾患とレニン・アンジオテンシン系
  • はじめに
  • I. レニン・アンジオテンシン系形成における肝臓の役割
  • II. 肝不全時のレニン・アンジオテンシン系
  • 1. とくに腹水形成との関連について
  • III. 肝腎症候群におけるレニン・アンジオテンシン系の役割
  • IV. ACE阻害薬およびアンジオテンシンII受容体拮抗薬の代謝における肝臓の役割
  • おわりに
  • 4. 糖尿病とレニン・アンジオテンシン系
  • はじめに
  • I. 糖尿病におけるレニン・アルドステロン系
  • II. ACE阻害薬と糖尿病性腎症
  • III. ACE遺伝子の多型性と糖尿病性腎症
  • おわりに
  • 5. Bartter症候群とレニン・アンジオテンシン系
  • はじめに
  • I. Bartter症候群の疾患概念
  • II. Bartter症候群の病態生理(レニン・アンジオテンシン系の関与)
  • おわりに
  • 6. 体液量異常とレニン・アンジオテンシン系
  • はじめに
  • I. 本態性高血圧症の成因としての体液量異常
  • II. 本態性高血圧症の食塩感受性と血漿レニン活性
  • III. 正レニン性および高レニン性本態性高血圧症と食塩感受性
  • おわりに
  • 7. 内分泌疾患とレニン・アンジオテンシン系
  • はじめに
  • I. レニンの発見
  • II. Goldblattの実験高血圧によるレニン再認識とレニン・アンジオテンシン系
  • III. レニン・アンジオテンシン系の測定と各種病態ならび内分泌疾患における評価
  • おわりに
  • [8] 妊娠とレニン・アンジオテンシン系:正常と異常
  • はじめに
  • I. 正常妊娠におけるレニン・アンジオテンシン系
  • 1. アンジオテンシノーゲン
  • 2. レニン
  • 3. レニン・アンジオテンシン・アルドステロン系による妊娠中の体液量の調節
  • 4. アンジオテンシンIIによる子宮・胎盤血流の調節
  • II. 異常妊娠におけるレニン・アンジオテンシン系
  • 1. 妊娠中毒症
  • 2. 混合型妊娠中毒症
  • 3. アンジオテンシン不応性の機構
  • 4. アンジオテンシンII感受性検査
  • 5. 妊娠のアンジオテンシンII感受性に影響するその他の薬剤
  • おわりに
  • [9] レニン・アンジオテンシン系抑制の臨床的意義
  • 1. レニン阻害薬
  • はじめに
  • I. レニン阻害薬開発の経緯
  • II. レニン活性抑制法
  • 1. レニン抗体
  • 2. レニン前駆体のプロセグメント誘導体
  • 3. 天然レニン阻害物質
  • 4. 基質アナログから遷移状態アナログへ
  • III. レニン阻害薬開発の現状
  • IV. レニン阻害薬投与時のレニン・アンジオテンシン系の変化
  • V. レニン阻害薬の降圧効果
  • 1. 正常血圧者への影響
  • 2. 高血圧患者における降圧効果
  • VI. レニン阻害薬開発の展望
  • おわりに
  • 2. ACE阻害薬
  • A. 高血圧治療におけるACE阻害薬
  • はじめに
  • I. ACE阻害薬の薬理作用
  • II. ACE阻害薬による降圧作用の特徴
  • III. ACE阻害薬による心血管系の肥大・肥厚の抑制
  • IV. ACE阻害薬による冠動脈疾患の抑制
  • V. ACE阻害薬による脳血管障害の抑制
  • VI. ACE阻害薬による腎障害の抑制
  • VII. ACE阻害薬によるQOLの改善
  • VIII. ACE阻害薬と他の降圧薬の併用
  • 1. 利尿薬とACE阻害薬
  • 2. Ca拮抗薬とACE阻害薬
  • 3. β遮断薬とACE阻害薬
  • 4. わが国における降圧薬の併用療法
  • おわりに
  • B. 心不全,冠動脈疾患治療におけるACE阻害薬
  • はじめに
  • I. ラットにおけるリモデリングとACE阻害薬の効果
  • II. 臨床における心筋梗塞のACE阻害薬治療
  • III. 急性期におけるACE阻害薬治療
  • IV. ACE阻害薬とアルドステロン受容体拮抗薬との併用療法
  • V. アンジオテンシンII受容体拮抗薬
  • VI. 血管内膜の増殖
  • おわりに
  • C. 慢性腎不全治療におけるACE阻害薬
  • はじめに
  • I. 腎障害進展:過剰濾過仮説
  • 1. 糸球体硬化症
  • 2. レニン・アンジオテンシン系の関与
  • 3. TGF-βとアンジオテンシンII
  • 4. ACE阻害薬と糸球体硬化症の抑制
  • II. ACE阻害薬と腎障害進展の抑制:臨床例における検討
  • III. 内皮細胞機能障害とACE阻害薬
  • IV. ACE遺伝子多型
  • V. 慢性腎不全時の高血圧とACE阻害薬
  • 1. 透析導入以前
  • 2. 慢性透析患者
  • おわりに
  • D. 糖尿病性腎症治療におけるACE阻害薬
  • はじめに
  • I. 腎症治療の基本方針
  • II. ACE阻害薬の意義
  • 1. 高血圧を有する腎症患者の場合
  • III. 高血圧を有さない腎症患者の場合
  • おわりに
  • E. インスリン抵抗性とACE阻害薬
  • はじめに
  • I. インスリン抵抗性の昇圧機序
  • II. インスリン抵抗性と降圧療法
  • III. インスリン抵抗性とACE阻害薬
  • おわりに
  • 3. アンジオテンシンII受容体拮抗薬
  • はじめに
  • I. アンジオテンシンII受容体の分類
  • II. 非ペプチド性アンジオテンシン受容体拮抗薬
  • 1. ロサルタン
  • 2. カンデサルタンシレキセチル
  • 3. バルサルタン
  • 4. イルベサルタン
  • III. アンジオテンシンIIタイプ1受容体拮抗薬とACE阻害薬の作用機序の違い
  • IV. アンジオテンシンIIタイプ1受容体拮抗薬の降圧作用
  • 1. 高血圧モデル動物に対する降圧作用
  • 2. 本態性高血圧症患者に対する降圧作用
  • 3. 高齢高血圧症患者に対する降圧作用と安全性
  • 4. 臓器障害をもつ高血圧症患者に対する降圧作用と安全性
  • V. アンジオテンシンIIタイプ1受容体拮抗薬の臓器保護作用
  • 1. 心保護作用
  • 2. 血管再構築への影響
  • 3. 腎保護作用
  • 4. 脳保護作用
  • VI. アンジオテンシンIIタイプ1受容体拮抗薬の代謝への影響
  • 1. 尿酸代謝への影響
  • 2. 脂質代謝への影響
  • 3. 糖代謝・インスリン抵抗性への影響
  • VII. アンジオテンシンIIタイプ1受容体拮抗薬のQOLに対する影響
  • VIII. アンジオテンシンIIタイプ1受容体拮抗薬の副作用
  • おわりに
  • [10] 各種薬剤のレニン・アンジオテンシン系への影響
  • はじめに
  • I. レニン分泌機構
  • 1. 腎内機序
  • 2. β受容体pathway
  • 3. 液性因子
  • II. 交感神経作動薬
  • 1. α受容体拮抗薬
  • 2. α受容体刺激薬
  • 3. β刺激薬と受容体拮抗薬
  • 4. ドパミン刺激薬と拮抗薬
  • III. ACE阻害薬とアンジオテンシン受容体拮抗薬
  • IV. 利尿薬
  • 1. ループ利尿薬
  • 2. サイアザイド利尿薬
  • V. Ca拮抗薬
  • VI. 血管拡張薬
  • VII. 非ステロイド系抗炎症薬
  • VIII. リチウム
  • IX. シクロスポリン
  • おわりに
  • [11] レニン・アンジオテンシン系の測定法
  • はじめに
  • I. レニン測定法
  • 1. レニン活性測定法
  • 2. レニン活性測定法の問題点
  • 3. レニン直接測定法の開発
  • 4. プロレニン測定法の開発と問題点
  • II. ACEの測定
  • III. アンジオテンシノーゲンの測定
  • 1. 間接法
  • 2. 直接法
  • IV. アンジオテンシンの測定
  • 1. 血中アンジオテンシン
  • 2. アンジオテンシン測定の問題点
  • おわりに
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part1 / レニン・アンジオテンシン系研究の歴史

P.21 掲載の参考文献
1) Tigerstedt R, Bergmann PG:Niere und Kreislauf. Scand Arch Physiol 8:223-271 1898
 
2) Goldblatt H, Lynch J, Hanzal RF et al:Studies on experimental hypertension I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59:347-379, 1934
PubMed
3) Munoz JM, Braum-Menendez E, Fasciolo JC et al:Hypertensin:the substance causing renal hypertension. Nature 144:980, 1939
 
4) Page IH, Helmer OM:A crystal line pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J Exp Med 71:29-42, 1940
 
5) Plentl AA, Page IH, Davis WW:The nature of renin activator. J Biol Chem 147:143-153, 1943
 
6) Simpson SA, Tait JF, Wettstein A et al:Isolierung eines neuen Kristallisierten Hormons aus Nebennieren mit Besonders hoher Wirksamkeit auf den Mineralstoffwechsel. Experientia 9:333, 1953
PubMed
7) Skeggs LT, Marsh WH, Kahn JR et al:The existence of two forms of hypertensin. J Exp Med 99:275-282, 1954
PubMed
8) Howard JE, Berthrong M, Gould DM et al:Hypertension resulting from unilateral vascular disease and its relief by nephrectomy. Bull John Hopkins Hosp 94:51-85, 1954
PubMed
9) Conn JW:Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 43:3-17, 1955
 
10) Skeggs LT, Kahn JR, Shumway NP:The preparation and function of the hypertensin converting enzyme. J Exp Med 103:295-300, 1956
PubMed
11) Braun-Menendez E, Page IH:Suggested revision of nomenclature-angiotensin. Science 127:242, 1958
PubMed
12) Gross F:Renin und Hypertensin, Physiologische oder Pathologische Wirkstoffe? Klin Wochenschr 36:693-706, 1958
PubMed
13) Laragh JH, Angers M, Kelly WG et al:Hypotensive agents and pressor substance. The effect of epinephrine, norepinephrine, angiotensin II and others on the secretory rate of aldosterone in man. JAMA 174:234-240, 1960
PubMed
14) Genest J, Nowaczynski W, Koiw E et al:Adrenocortical function in essential hypertension. In:Essential Hypertension, ed by Bock KD, Cottier PT, Springer-Verlag, Berlin, 1960, pp. 126-146
 
15) Edelman R, Hartroft PM:Localization of renin in juxtaglomerular cells of rabbit and dog through use of the fluorescent-antibody technique. Circ Res 9:1069-1077, 1961
 
16) Robertson PW, Klidjian A, Harding LK et al:Hypertension due to a renin-secreting renal tumor. Am J Med 43:963-976, 1967
PubMed
17) Arakawa K, Nakatani M, Minohara A et al:Isolation and amino acid composition of human angiotensin I. Biochem J 104:900-906, 1967
PubMed
18) Haber E, Koerner T, Page LB et al:Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in mormal human subjects. J Clin Endocrinol Metab 29:1349-1355, 1969
 
19) Lumbers ER:Activation of renin in human amniotic fluid by low pH. Enzymologia 40:329-336, 1971
 
20) Pals DT, Mascuccu FD, Sipos F et al:A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 29:664-672, 1971
 
21) Ganten D, Minnich JL, Granger P et al:Angiotensin forming enzyme in brain tissue. Science 173:64-65, 1971
PubMed
22) Fischer-Ferraro C, Nahmod VE, Goldstein DJ et al:Angiotensin and renin in rat and dog brain. J Exp Med 133:353-361, 1971
 
23) Brunner HR, Laragh JH, Bear L:et al:Essential hypertension:renin and aldosterone, heart attack and stroke. N Engl J Med 286:441-449, 1972
 
24) Murakami K, Inagami T:Isolation of pure and stable renin from hog kidney. Biochem Biophys Res Commun 62:757-763, 1975
PubMed
25) Ondetti MA, Rubin B, Cushman DW:Design of specific inhibitors of angiotensin-converting enzyme:new class of orally active antihypertensive agents. Science 196:441-444, 1977
PubMed
26) Yokosawa H, Holladay LA, Inagami T et al:Human renal renin complete purification and characterization. J Biol Chem 255:3498-3502, 1980
PubMed
27) Peach MJ, Levens NR:Molecular approaches to the study of angiotensin receptors. Adv Exp Med 130:171-194, 1980
 
28) Imai T, Miyazaki H, Hirose S et al:Cloning and sequence analysis of cDNA for human renin precursor. Proc Natl Acad Sci USA 80:7405-7409, 1983
PubMed
29) Kageyama R, Ohkubo H, Nakanishi S:Primary structure of human preangiotensinogen deduced from the cloned DNA sequence. Biochemistry 23:3603-3609, 1984
PubMed
30) Miyazaki H, Fukamizu A, Hirose S et al:Structure of the human renin gene. Proc Natl Acad Sci USA 81:5999-6003, 1984
PubMed
31) Hadman JA, Mort YJ, Catanzaro DF et al:Primary structure of human renin gene. DNA 3:457-468, 1984
 
32) Hobart PM, Fogliano M, O:Connor BA et al:Human renin gene:structure and sequence analysis. Proc Natl Acad Sci USA. 81:5026-5030, 1984
PubMed
33) Soubrier F, Alhenc-Gelas F, Hubert C et al:Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85:9386-9390, 1988
PubMed
34) Gaillard I, Clauser E, Corvol P:Structure of human angiotensinogen gene. DNA 18:87-99, 1989
 
35) Mullins JJ, Peters J, Ganten D:Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344:541-544, 1990
PubMed
36) Ohkubo H, Kawakami H, Hakehi Y et al:Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci 87:5153-5157, 1990
 
37) Hubert C, Houot AM, Corvol P et al:Structure of the angiotensin I-converting enzyme gene. J Biol Chem 266:15377-15383, 1991
 
38) Sasaki K, Yamano Y, Bardhan S et al:Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type 1 receptor. Nature 351:230-233, 1991
PubMed
39) Murphy TJ, Alexander RW, Griendling KK et al:Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233-236, 1991
PubMed
40) Timmermans PBMWM, Carini DJ, Chiu AT et al:The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 4:275S-281S, 1991
 
41) Cambien F, Poirier O, Lecerf L et al:Deletion polymorphysm in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644, 1992
 
42) Jeunemaitre X, Soubrier F, Kotelevtsev YV et al:Molecular basis of human hypertension:role of angiotensinogen. Cell 71:169-180, 1992
PubMed
43) Furuta H, Guo D-F, Inagami T:Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem Biophys Res Commun 13:8-13, 1992
 
44) Kambayashi Y, Bardhan S, Takahashi K et al:Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268:24543-24546, 1993
PubMed
45) Mukoyama M, Nakajima M, Horiuchi M et al:Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-membrane receptors. J Biol Chem 268:24539-24542, 1993
PubMed
46) Bonnardeaux A, Davies E, Jeunemaitre X et al:Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24:63-69, 1994
PubMed
47) Tanimoto K, Sugiyama F, Goto Y et al:Angiotensinogen-deficient mice with hypotension. J Biol Chem 269:31334-31337, 1994
PubMed
48) Krege JH, John SWM, Langenbach LL et al:Male-female differences in fertility and blood pressure in ACE deficient mice. Nature 375:146-148, 1995
 
49) Ito M, Oliverio MI, Mannon PJ et al:Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92:3521-3525, 1995
PubMed
50) Heln L, Barsh GS, Pratt RE et al:Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 377:744-747, 1995
 
51) Ichiki T, Labosky PA, Shiota C et al:Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748-750, 1995
PubMed
52) Clark AF, Sharp MGF, Morley SD et al:Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa morphology. J Biol Chem 272:18185-18190, 1997
 
P.28 掲載の参考文献
1) Howell, Brush:Boston Medical and Surgical Journey, June, 1901
 
2) Fischer.:The diagnostic value of the sphygmomanometer in examination for life insurance. JAMA Nov 14, 1914
 
3) Scholze SB:Notes on arterial hypertension from an American life insurance medicine view point. Proceedings of the 2nd Congress of life insurance physicians. Paris, May, 1939, pp. 18-21
 
4) Arakawa K, Nakatani M, Minohara, A et al:Biochem J 104:900-906, 1967
PubMed
5) Conn JW, Lowis LH:J Clin Endocrinol 10:12, 1950
 
6) Simpson SA, Tait JF, Wettstein A et al:Helv Clim Act 37:1800-1808, 933, 1954
 
7) Conn JW:J Lab Clin Med 4:661-664, 1995
 
8) Arakawa K, Torii S, Naito S et al:Arch Intern Med 125:830-834, 1970
PubMed
9) Hirose M, Arakawa K, Kikuchi M et al:JAMA 230:1288-1292, 1974
PubMed
10) Arakawa K, Ikeda M, Fukuyama J et al:J Clin Endocrinol Metab 42:599-602, 1976
PubMed
11) Arakawa K, Maruta H:Nature 288:705-706, 1980
PubMed
12) Gondo M, Maruta H, Arakawa K:Jpn Heart J 30:219-229, 1989
PubMed
13) Urabe Y, Ideishi M, Sasaguri M et al:Am J Cardiol 72:218-222, 1993
PubMed
14) Urata H, Kinoshita A, Misono KS et al:J Biol Chem 265:22348-22357, 1990
PubMed
15) Arakawa K:J Hypertens 14 (Suppl 5):S3-S7, 1996
 

Part3 / レニン・アンジオテンシン系と高血圧

P.90 掲載の参考文献
1) Inagami T:Purification of renin and prorenin. Hypertension 18:241-251, 1991
PubMed
2) Corvol P, Menard J:Renin purifiction and cloning. Hypertension 18:252-256, 1991
 
3) Morris BJ:Molecular biology of renin. 1:Gene and protein structure, synthesis and processing. J Hypertens 10:209-214, 1992
 
4) Misono KS, Chang JJ, Inagami T:Amino acid sequence of mouse submaxillary gland renin. Proc Natl Acad Sci USA 79:4858-4862, 1982
PubMed
5) Inagami T, Murakami K:Pure renin:isolation from hog kidney and characterization. J Biol Chem 252:2978-2983, 1977
PubMed
6) Cohen S, Taylor JM, Murakami K et al:Isolation and characterization of renin-like enzyems from mouse submaxillary glands. Biochemistry 11:4286-4293, 1972
PubMed
7) Umezawa H, Aoyagi T, Morishima H et al:Pepstatin, a new pepsin inhibitor produced by actinomyces. J Antibiot 23:259-262, 1972
 
8) Yokosawa H, Holladay LA, Inagami T et al:Human renal renin:complete purification and characterization. J Biol Chem 255:2498-3502, 1980
 
9) Dzau VJ, Slater EE, Haber E:Complete purification of dog renal renin. Biochemistry 18:5224-5228, 1979
PubMed
10) Matoba T, Murakami K, Inagami T:Rat renin:purification and characterization. Biochim. Biophys Acta 526:560-571, 1978
PubMed
11) Hirose S, Ohsawa T, Inagami T et al:Brain renin from bovine anterior pituitary:isolation and properties. J Biol Chem 257:6316-6321
 
12) Suzuki F, Nakamura Y, Nagata Y et al:A rapid and large-scale isolation of renin from mouse submaxillary gland by pepstatin-aminohexyl-agarose affinity chromatography. J Biochem 89:1107-1112, 1981
PubMed
13) Poorman RA, Palermo DP, Post LE et al:Isolation and characterization of native human renin derived from Chinese hamster ovary cells. Protein:Structure, Function and Genetics 1:139-145, 1986
 
14) Yamauchi T, Suzuki F, Takahashi A et al:Expression of rat renin in mammalian cells and its purification. Clin Exper Hyper A14:377-392, 1992
 
15) Szelke M, Leckie B, Hallett A et al:Potent new inhibitors of human renin. Nature 299:555-557 1982
PubMed
16) Sielecki AR, Hayakawa K, Fujinaga M et al:Structure of recombinant human renin, a target for cardiovascular-active drug, at 2.5A resolution. Science 243:1346-1351, 1989
 
17) Rahuel J, Prinstle JP, Gruetter MG et al:The crystal structure of recombinant grycosylated human renin alone and in complex with a transition state analog inhibitor. J Struct Biol 107:227-236, 1991
 
18) Dhanaraj V, Dealwis CG, Frazao C et al:X-ray analyses of peptide-inhibitor complex define the structural basis of specificity for human and mouse renins. Nature 357:466-472, 1992
PubMed
19) Misono SK, Inagami T:Characterization of the active site of mouse submaxillary gland renin. Biochemistry 19:2616-2622, 1980
 
20) Inagami T, Misono KS, Michelakis AM:Definitive evidence for similarity in the active site of renin and acid proteases. Biochem Biophys Res Commun 56:503-509, 1974
 
21) James MNG, Sieleckie AR:Stereo-chemical analysis of peptide bond hydrolysis catalyzed by the crystal structure of penicillopepsin. Biochemistry 24:3701-3713, 1985
 
22) Yamauchi T, Nagahama M, Hori H et al:Functional characterization of Asp-317 mutant of human renin expressed in COS cells. FEBS Lett 230:205-208, 1988
PubMed
23) Suzuki F, Goto K, Shiratori Y et al:Tyrosine-83 of renin has an important role in the renin-an-giotensinogen reaction. Protein Pepetide Lett 3:45-49, 1996
 
24) Blundell TL, Cooper J, Foundling SJ et al:On the rational design of renin inhibitors:x-ray studies of aspartic proteases complexed with transition-state analogues. Biochemistry 26:5585-5590, 1987
 
25) Green DW, Aykent S, Gierse JK et al:Substrate specificity of recombinant human renal renin:effect of histidine in the P2 subsite on pH dependence. Biochemistry 29:3126-3133, 1990
PubMed
26) Thaisrivongs S, Mao B, Pals DT et al:Renin inhibitory peptide. A β-aspartyl residue as replacement for the histidyl residue at the P-2 site. J Med Chem 33:1337-1343, 1990
 
27) Sealey JE:Evidence for cardiovascular effects of prorenin. J Hum Hypertens 9:381-384, 1995
PubMed
28) Shinagawa T, Nakayama K, Uchiyama Y et al:Role of cathepsin B as prorenin processing enzyme in human kidney. Hypertens Res 18:131-136, 1995
PubMed
29) Derkx FHM, Deinum J, Lipovski M et al:Non-proteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin specific monoclonal antibody. J Biol Chem 267:22837-22842, 1992
 
30) James MN, Sieleckie AR:Molecular structure of an aspartic proteinase zymogen, porcine pepsinogen, at 1.8 A resolution Nature 319:33-38, 1986
 
31) Yamauchi T, Nagahama M, Ishizuka Y et al:Site directed mutagenesis of human prorenin. Substitution of three arginine residues in the propeptide with glutamine residues yields active prorenin. J Biochem 107:27-31, 1990
PubMed
32) Mercure C, Thibault G, Lussier-Cacan S et al:Molecular analysis of human prorenin prosegment variants in vitro and in vivo. J Biol Chem 270:16355-16359, 1995
PubMed
33) Shiratori Y, Nakagawa S, Hori H et al:Protein modeling of human prorenin using the molecular dynamics method. J Mol Graphics 8:150&163-167, 1990
 
P.98 掲載の参考文献
1) Schnermann J, Briggs JP:Function of the juxtaglomerular apparatus:control of glomerular hemodynamics and renin secretion:In The Kidney; Physiology and Pathophysiology, ed by Seldin DW & Giebisch G, Raven Press, New York, 1992, pp. 1249-1290
 
2) Ito S:Kidney and hypertension:Role of the juxtaglomerular apparatus. Tohoku J Exp Med 181:411-429, 1997
PubMed
3) 伊藤貞嘉:病態高血圧学. 阿部圭志, 伊藤貞嘉監修, メディカルレビュー社, 大阪, 1998
 
4) Keeton TK, Campbell WB:The pharmacologic alteration of renin release. Pharmacol Rev 31:81-227, 1981
 
5) Clark AF., Sharp MGF, Morley SD et al:Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa norphology. J Biol Chem 272:18185-18190, 1997
 
6) Blaien EH, Davis JO, Prewitt RL:Evidence for a renal vascular receptor in control of renin release. Am J Physiol 220:1593-1597, 1971
 
7) Fray JCS, Lush DJ, Park CS:Interrelationship of blood flow, juxtaglomerular cell, and hypertension; Role of physical equilibrium and Ca. Am J Physiol 251:R643-R662, 1986
 
8) Churchill PC:Second messengers in renin release. Am J Physiol 249:F175-F184, 1985
 
9) Salomonsson M, Skott O, Persson AEG:Influence of intraluminal arterial pressure on renin release. Acta Physiol Scand 141:285-286, 1991
 
10) Bock HA, Hermle M, Brunner FP, Thiel G:Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int 41:275-280, 1992
PubMed
11) Juncos LA, Garvin J, Carretero OA et al:Flow modulates myogenic responses in isolated microperfused rabbit afferent arterioles via endothelium-derived nitrirc oxide. J Clin In vest 95:2741-2748, 1995
 
12) Goormaghtigh N:Facts in favor of an endocrine function of the renal arterioles. J Pathol 57:392-393, 1945
 
13) Vander AJ:Control of renin release. Physiol Rev 47:359-382, 1967
PubMed
14) Ito S, Carretero OA:Role of the macula densa in renin release Hypertension 7 (Suppl I):1-49-1-54, 1985
 
15) Skott O, Briggs JP:Derect demonstration of macula densa-mediated renin secretion Science 237:1618-1620, 1987
 
16) Bell PD, Lapointe J-Y, Cardinal J:Direct measurement of basolateral membrance potentials from cells of the macula densa. Am. J Physiol 257:F463-F468, 1989
 
17) Obermuller N, Kunchaparty S, Ellison DH. et al:Expression of the Na-K-2C1 cotransporter by macula densa and thick ascending limb cells of rat and rabbit nephron. J Clin Invest 98:635-640, 1996
 
18) Lorenz JN, Weihprecht II, Schnermann J et al:Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Physiol 260:F486-F493, 1991
 
19) Morgan T, Barrett G, Zhang Y et al:The role of macula densa in renin synthesis. Clin Exp Pharmacol Physiol 18:123-126, 1991
PubMed
20) Dibona GF, Kopp UC:Neural control of renal function. Physiol Rev 77:75-197, 1997
PubMed
21) Nagamine Y, Reich E.:Gene expression and cAMP. Proc Natl Acad Sci USA 82:4604, 1985
 
22) Zhang Y, Morgan T, Read G:The role of the renal nerve in renin synthesis. Clin Exp Pharmacol Physiol 19:827-831, 1992
 
23) Bonvalet J-P, Pradelles P, Farman N:Segmental synthesis and actions of postaglandins along the nephron. Am J Physiol 253:F377-F378, 1987
 
24) Ito S, Carretero OA, Abe K et al:Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int 35:1138-1144, 1989
PubMed
25) Ilarris RC, McKanna JA, Akai Y et al:Cycloxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504-2510, 1994
 
26) Morhan S, Langenbach R, Loftin CD et al:Prostaglandin synthase 2 gene distruption causes severe renal pathology in the mouse. Cell 83:473-482, 1995
 
27) Schnermann J:Juxtaglomerular cell complex the regulation of renal salt excretion. Am Physiol 274:R263-R279, 1998
PubMed
28) Yang T, Singh I, Pham H et al:Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 274:F481-F489, 1998
PubMed
29) Harding P, Sigmon DH, Alfie M E et al:Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension 29:297-302, 1997
PubMed
30) Ito S:Nitric oxide in the kidney. Current Opinion in Nephrol Hypertens 4:23-30, 1995
 
31) Greenberg SG, He X-R, Schnermann JB et al:Effect of nitric oxide on renin secretion. I. Studies in isolated juxtaglomerular granular cells. Am J Physiol 268:F948-F952, 1995
PubMed
32) Schricker K, Kurtz A:Liberators of NO exert a dual effect on renin secretion from isolated mouse renal juxtaglomerular cells. Am J Physiol 265:F180-F186, 1993
PubMed
33) Wilcox CS, Deng X, Doll AH et al:Nitric oxide mediates renal vasodilation during erythropoietininduced polycythemia. Kidney Int 44:430-435, 1993
PubMed
34) Mundel P, Bachmann S, Bader M et al:Expression of nitric oxide synthase in kidney macula densa cells. Kidney Int 42:1017-1019, 1992
PubMed
35) He X-R, Greenberg SG, Briggs JP et al:Effect of nitric oxide on renin secretion II. Studies in the perfused juxtaglomerular apparatus. Am J Physiol 268:F953-F959, 1995
PubMed
36) Singh I, Grams M, Wang W-H et al:Coordinate regulation of renal expression of nitric oxide synthase, renin, and angiotensinogen mRNA by dietary salt. Am J Physiol 270:F1027-F1037, 1996
PubMed
37) Bosse H-M Bohm R, Resch S et al:Parallel regulation of constitutive NO synthase and renin at JGA of rat kidney under various stimuli. Am J Physiol 269:F793-F805, 1995
PubMed
38) Tojo A, Madsen KM, Wilcox CS:Expression of immunoreactive nitric oxide synthase isoforms in rat kidney. Effect of dietary salt and losartan. Jpn Heart J 36:389-398, 1995
PubMed
39) Salvemini D, Seibert K, Massgerrer JL et al:Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 93:1940-1947, 1994
 
40) Itoh S, Carretero OA, Murray RD:Possible role of adenosine in the macula densa mechanism of renin release in rabbits. J Clin Invest 76:1412-1417, 1985
PubMed
41) Weihprechet H, Lorenz JN, Schnermann J et al:Effect of adenosine 1-receptor blockade on renin release from rabbit isolated perfused juxtaglomerular apparatus. J Clin Invest 85:1622-1628, 1990
 
42) Matsusaka K, Nishimura H, Utsunomiya H et al:Chimeric mice carrying regional targeted deletion of the angiotensin type 1A receptor gene. Evidence against the role for local angiotensin in the in vivo feedback regulation of renin synthesis in juxtaglomerular cells. J Clin Invest 98:1867-1877, 1996
 
43) Sands JM, Kokko JP, Jacobson HR:Internal heterogeneity:Vascular and tubular. In:The Kidney, Physiology and Pathophysiology, ed by Seldin DW, Giebisch O, Raven Press, New York, 1992, pp. 1087-1156
 
44) Nushiro N, Ito S, Carretero OA:Renin release from micro-dissected superficial, midcortical, and juxtamedullary afferent arterioles in rabbits. Kidney Int 38:426-431, 1990
 
P.106 掲載の参考文献
1) Griendling KK, Murphy TJ, Alexander RW:Molecular biology of the renin-angiotensin system. Circulation 87:1817-1828, 1993
 
2) Tamura K, Umemura S, Fykamizu A et al:Recent advances in the study of renin and angiotensinogen genes:from molecules to the whole body. Hypertens Res 18:7-18, 1995
 
3) Fukamizu A, Takahashi S, Seo MS et al:Structure and expression of the human angiotensinogen gene. Identification of a unique and highly active promoter. J Biol Chem 265:7576-7582, 1990
PubMed
4) Tamura K, Tanimoto K, Takahashi S et al:Structure and expression of the mouse angiotensinogen gene. Jpn Heart J 33:113-124, 1992
PubMed
5) Tamura K, Tanimoto K, Ishii M et al:Molecular mechanism of transcriptional activation of angiotensinogen gene by proximal promoter. J Clin Invest 93:1370-1379, 1994
PubMed
6) Yanai K, Nibu Y, Murakalni K et al:A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. J Biol Chem 271:15981-15986, 1996
 
7) Nibu Y, Tanimoto K, Takahashi H et al:A cell type-dependent enhancer core element is located in exon 5 of the human angiotensinogen gene. Biochem Biophys Res Commun 205:1102-1108, 1994
 
8) Tamura K, Tanimoto K, Ishii M et al:Proximal and core DNA elements are required for efficient angiotensiongen promoter activation during adipogenic differentiation. J Biol Chem 268:15024-15032, 1993
 
9) Tamura K, Umemura S, Iwamoto T et al:Molecular mechanism of adipogenic activation of the angiotensinogen gene. Hypertension 23:364-368, 1994
PubMed
10) Campbell DJ, Habener JF:Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 78:31-39, 1986
 
11) Dzau VJ, Ingelfillger JR, Pratt RE:Regulation of tissue renin and angiotensinogen gene expression. J Cardiovasc Pharmacol (Suppl 10):S11-S16, 1986
 
12) Yongue BG, Angulo JA, McEwen BS et al:Brain and liver angiotensinogen messenger RNA in genetic hypertensive and normotensive rats. Hypertension 17:485-491, 1991
PubMed
13) Kageyama R, Ohkubo H, Nakanishi S:Induction of rat liver angiotensinogen mRNA following acute inflammation. Biochem Biophys Res Commun 129:826-832, 1985
PubMed
14) Schunkert H, Ingelfinger JR, Dzau VJ:Evolving concepts of the intrarenal renin-angiotensin system in health and disease:contributions of molecular biology. Renal Physiol Biochem 14:146-154, 1991
PubMed
15) Baker KM, Chernin MI, Wixson S K et al.:Renin-angiotensin system involvement in pressure-over-load cardiac hypertrophy in rats. Am J Physiol 269:H324-H332, 1990
 
16) Sadoshima J, Xu Y, Slayter HS et al:Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vivo. Cell 75:977-984, 1993
 
17) Rakugi H, Jacob HJ, Krieger JE et al:Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 87:283-290, 1993
PubMed
18) Clauser E, Gaillard I., Wei L et al:Regulation of angiotensinogen gene. Am J Hypertens 2:403-410, 1989
PubMed
19) Fukamizu A, Seo MS, Hatae T et al:Tissue-specific expression of the human renin gene in transgenic mouse. Biochem Biophys Res Commun 165:826-832, 1989
PubMed
20) Takahashi S, Fukamizu A, Hasegawa T et al:Expression of the human angiotensinogen gene in transgenic mice and cultured cells. Biohem Biophys Commun 180:1103-1109, 1991
PubMed
21) Fukamizu A, Sugimura K, Takimoto E et al:Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268:31334-31337, 1994
 
22) Kokubu T, Hiwada K, Murakami E et al:ES-8891, an orally active renin inhibitor of human renin. Hypertension 15:909-913, 1990
PubMed
23) Tanimoto K, Sugiyama F, Goto Y et al:Angiotensinogen-deficient mice with hypotension. J Biol Chem 269:31334-31337, 1994
PubMed
P.113 掲載の参考文献
1) Griendling KK, Murphy TJ, Alexander RW:Molecular biology of the renin-angiotensin system. Circulation 87:1816-1828, 1993
PubMed
2) Tamura K, Umemura S, Fukamizu A et al:Recent advances in the study of renin and angiotensinogen genes:from molecules to the whole body. Hypertens Res 18:7-18, 1995
 
3) Soubrier F, Alhenc-Gelas F, Hubert C et al:Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc:Natl Acad Sci USA 85:9386-9390, 1988
PubMed
4) 田村功一, 深水昭吉, 村上和雄:レニン-アンジオテンシン系の生化学. 最新内科学大系15-副腎疾患, 水・電界質異常 (山村雄一, 吉利和監修). 中山書店, 東京, 1993, pp.253-266
 
5) Wei L, Alhenc-Gelas F, Corvol P et al:The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266:9002-9008, 1991
PubMed
6) Hubert C, Houot A-M, Corvol P et al:Structure of the angiotensin I-converting enzyme gene. J Biol Chem 266:15377-15383, 1991
 
7) Howard TE, Shai S-Y, Langford KG et al:Transcription of testicular angiotensin-converting enzyme (ACE) is initiated within the 12th intron of the somatic ACE gene. Mol Cell Biol 10:4294-4302, 1990
PubMed
8) Thekkumkara TJ, Livingston W, Kumar RS et al:Use of alternative polyadenylation sites for tissue-specific transcription of two angiotensin-converting enzyme mRNAs. Nucleic Acids Res 20:683-687, 1992
PubMed
9) Howard T, Balogh R, Overbeek P et al:Sperm-specific expression of angiotensin-converting enzyme (ACE) is mediated by a 91-base-pair promoter containing a CRE-like element. Mol Cell Biol 13:18-27, 1993
PubMed
10) 田村功一, 梅村敏:レニン-アンジオテンシン系の遺伝子制御. 医学のあゆみ 169:437-442, 1994
Medical*Online
11) Langford KG, Shai S-Y, Howard TE et al:Transgenic mice demonstrate a testis-specific promoter for angiotensin-converting enzyme. J Biol Chem 266:15559-15562, 1991
PubMed
12) Shiota N, Miyazaki M, Okunishi H:Increase of angiotensin converting enzyme expression in the hypertensive aorta. Hypertension 20:168-174, 1992
PubMed
13) Schunkert H, Dzau VJ, Tang SS et al:Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload ventricular hypertrophy:effects on coronary resistance, contractility, and relaxation. J Clin Invest 86:1913-1920, 1990
PubMed
14) Iwai N, Shimoike H, Kinoshita M:Cardiac renin-angiotensin system in the hypertrophied heart. Circulation 92:2690-2696, 1995
PubMed
15) Shiota N, Okunishi H, Fukamizu A et al:Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett 323:239-242, 1993
PubMed
16) 檜垣實男, 荻原俊男:アンジオテンシン変換酵素. メディカル用語ライブラリー. 高血圧:分子メカニズムから病態・診断・治療まで. 藤田敏郎編集, 羊土社, 東京, 1995, pp. 24-25
 
17) Rigat B, Hubert C, Alhenc-Gelas F et al:An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
PubMed
18) Danser AHJ, Schalekamp MADH, Bax WA et al:Angiotensin-converting enzyme in the human heart:effect of the deletion/insertion polymorphism. Circulation 92:1387-1388, 1995
 
19) Inoue, I, Nakajima T, Williams CS et al:A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786-1797, 1997
PubMed
20) Sato N, Katsuya T, Rakugi H et al:Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japaneses. Hypertension 30:321-325, 1997
PubMed
21) Ishigami T, Umemura S, Tamura K et al:5'upstream core promoter region of angiotensinogen gene and essential hypertension. Hypertension 30:1325-1330, 1997
PubMed
22) Ishigami T, Iwamoto T, Tamura K et al:Angiotensin I converting enzyme gene polymorphism and essential hypertension in Japan. Am J Hypertens 8:95-97, 1995
PubMed
23):平林高之, 岡本洋, 北畠顕:ACE遺伝子多型性. 腎と透析 39:87-91, 1995
 
24) Lindpaintner K, Pfeffer MA, Kreutz R et al:A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 332:706-711, 1995
PubMed
25) Watanabe Y, Ishigami T, Kawano Y et al:Angiotensin-converting enzyme gene I/D polymorphism and carotid plaques in Japanese. Hypertension 30:569-573, 1997
 
26) Hibi K, Ishigami T, Kimura K et al:Angiotensin converting enzyme gene polymorphism adds risk for the severity of coronary atherosclerosis in smokers. Hypertension 30:574-579, 1997
PubMed
27) 深水昭吉, 村上和雄:レニン-アンジオテンシン情報伝達系の血圧制御とtransgenic 動物. 最新医学 51:821-828, 1996
Medical*Online
28) Krege JH, John SWM, Langenbach LL et al:Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375:146-148, 1995
 
29) Tanimoto K, Sugiyama F, Goto Y et al:Angiotensinogen-deficient mice with hypotension. J Biol Chem 269:31334-31337, 1994
PubMed
30) Kim HS, Krege JH, Kluckman KD et al:Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92:2735-2739, 1995
PubMed
31) Niimura F, Labosky PA, Kakuchi J et al:Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 96:2947-2954, 1995
PubMed
32) Carpenter C, Honkanen AA, Mashimo H et al:Renal abnormalities in mutant mice. Nature 380:292, 1996
PubMed
33) Esther CR, Howard TE, Marino EM et al:Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74:953-965, 1996
PubMed
34) Esther CR, Marino EM, Howard TE et al:The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 99:2375-2385, 1997
PubMed
P.121 掲載の参考文献
1) 日和田邦男:レニン-アンジオテンシン. nano GIGA 2:1576-1583, 1993
 
2) Ferrario CM, Chappell MC, Tallant EA et al:Counterregulatory actions of angiotensin-(1-7) . Hypertension 30:535-541, 1997
PubMed
3) Schiavone MT, Santos RAS, Brosnihan KB et al:Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA 85:4095-4098, 1988
 
4) Santos RAS, Campagnole-Santos MJ, Braracho NCV et al:Characterization of a new angiotensin antagonist selective for angiotensin-(1-7):evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 35:293-298, 1994
 
5) Fontes MAP, Silva LCS, Campagnole-Santos MJ et al:Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors. Brain Res 665:175-180, 1994
 
6) Oliveira DR, Santos RAS, Santos GFP et al:Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension 27:1284-1290, 1996
 
7) Moriguchi A, Tallant, EA, Matsumura K et al:Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 25:1260-1265, 1995
PubMed
8) Holy Z, Braszko J, Kupryszewski G et al:Angiotensin II derived peptides devoid of phenylalanine in position 8 have full psychotropic activity of the parent hormone. J Physiol Pharmacol 43:183-192, 1992
PubMed
9) Ferrario CM, Brosnihan KB, Diz DI et al:Angiotensin-(1-7):a new hormone of the angiotensin system. Hypertension 18 (Suppl III):III-S126-III-S133, 1991 III-126-III133
 
10) Benter IF, Diz, DI, Ferrario CM:Cardiovascular actions of angiotensin-(1-7) . Peptides 14:679-684, 1993
PubMed
11) Hilchey SD, Bell-Quilley CP:Association between the natriuretic action of angiotensin-(1-7) and selective stimulation of renal prostaglandin I2 release. Hypertension 25:1238-1244, 1995
PubMed
12) Benter IF, Ferrario CM, Morris M et al:Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 269:H313-H319, 1995
PubMed
13) Porsti I, Bara AT, Busse R et al:Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium:implications for a novel angiotensin receptor. Br J Pharmacol 111:652-654, 1994
PubMed
14) Brosnihan KB, Li P, Ferrario CM:Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27:523-528, 1996
PubMed
15) Li P, Chappell MC, Ferrario MC et al:Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29:394-400, 1997
 
16) DelliPizzi AM, Hilchey SD, Bell-Quillery CP:Natriuretic action of angiotensin-(1-7) . Br J Pharmacol 111:1-3, 1994
 
17) Santos RAS, Silva ACS, Magaldi A J et al:Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension 27:875-884, 1996
 
18) Garcia NH, Garvin JL:Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 5:1133-1138, 1994
 
19) Freeman EJ, Chisolm GM, Ferrario C M et al:Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28:104-108, 1996
PubMed
20) Nakamoto H, Ferrario CM, Fuller SB et al:Angiotensin-(1-7) and nitric oxide interaction in renobvascular hypertension. Hypertension 25:796-802, 1995
PubMed
21) Mahon JM, Carr RD, Nicol AK et al:Angiotensin-(1-7) is an antagonist at the type I angiotensin II receptor. J Hypertens 12:1377-1382, 1994
PubMed
22) Benter IF, Diz DI, Ferrario CM:Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 26:1138-1144, 1995
PubMed
23) Paula RD, Lima CV, Khosla MC et al:Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26:1154-1159, 1995
PubMed
24) Nossaman BD, Feng CJ, Kaye AD et al:Analysis of responses to angiotensin IV:effects of PD-123319 and Dup-753 in the pulmonary circulation of the rat. Am J Physiol 268:L302-L308, 1995
 
25) Cheng DY, DeWitt BJ, Dent EL et al:Analysis of response to angiotensin IV in the pulmonary vascular bed of the cat. Eur J Pharmacol 261:223-227, 1994
PubMed
26) Gardiner SM et al:Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol 110:159-162, 1993
PubMed
27) Garrison EA, Kadowitz PJ:Analysis of responses to angiotensin I-(3-10) in the hindlimb vascular bed of the cat. Am J Physiol 270:H1172-H1177, 1996
PubMed
28) Yoshida M, Kikukawa M, Hisa H et al:Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3-8). Br J Pharmacol 117:885-890, 1996
PubMed
29) Li Q, Zhang L, Pfaffendorf M et al:Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br J Pharmacol 116:2963-2970, 1995
 
30) Swanson GN, Hanesworth JM, Sardinia MF et al:Discovery of a distinct binding site for angiotensin II (3-8), putative angiotensin IV receptor. Regul Pept 40:409-419, 1992
PubMed
31) Kramar EA, Harding JW, Wright JW:Angiotensin II and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept 68:131-138, 1997
PubMed
32) Kerins DM, Hao Q, Vaughan DE:Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the heptapeptide angiotensin IV. J Clin Invest 96:2515-2520, 1995
 
33) Moeller I, Paxinos G, Mendelsohn FA et al:Distribution of AT4 receptors in the Macaca fascicularis brain. Brain Res 712:307-324, 1996
PubMed
34) Greenland K, Wyse B, Sernia C:Identification and characterization of angiotensin IV binding sites in rat neurone and astrocyte cell cultures. J Neuroen-docrinol 8:687-693, 1996
 
35) Wright JW, Miller-Wing AV, Shaffer MJ et al:Angiotensin II (3-8) (ANG IV) hippocampal binding:potential role in the facilitation of memory. Brain Res Bull 32:497-502, 1993
PubMed
36) Delorenzi A, Locatelli F, Romano A et al:Angiotensin II (3-8) induces long-term memory improvement in the crab Chasmagnathus. Neurosci Lett 226:143-146, 1997
PubMed
37) Wright JW, Clemaens JA, Panetta JA et al:Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res 717:1-11, 1996
 
38) Braszko JJ, Kulakowska A, Wisniewski K:Angiotensin II and its 3-7 fragment improve recognition but not saptial memory in rats. Brain Res Bull 37:627-631, 1995
PubMed
39) Miller-Wig AV, Hanesworth JM, Sardinia Mf et al:Central angiotensin IV binding sites:distribution and specificity in guinea pig brain. J Pharmacol Exp Ther 266:1718-1726, 1993
 
40) Roberts KA, Krebs LT, Kramar EA et al:Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection fo angiotensin II and IV in rats. Brain Res 682:13-21, 1995
 
41) Pawlikowski M Kunert-Redek J:Angiotensin IV stimulates the proliferation of rat anterior pituitary cells in vitro. Biochem Biophys Res Commun 232:292-293, 1997
 
42) Moeller I, Small DH, Reed G et al:Angiotensin IV inhibits neurite outgrowth in cultured embryonic chicken sympathetic neurones. Brain Res 725:61-66, 1996
PubMed
43) Baker KM, Aceto JF:Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 259:H610-H618, 1990
PubMed
44) Hanesworht J M. Sardinia MF, Krebs LT, et al:Elucidation of a specific binding site for angiotensin II (3-8), angiotensin IV, in mammalian heart membranes. J Pharmacol Exp Ther 266:1036-1042, 1993
 
45) Hall KL, Venkateswaran S Hanesworth JM et al:Characterization of a functional angiotensin IV receptor on coronary microvascular endothelial cells. Regul Pept 58:107-115, 1995
PubMed
46) Dulin N, Madhun Z T, Chang C H et al:Angiotensin IV receptors and signaling in opossum kidney cells. Am J Physiol 269:F644-F652, 1995.
PubMed
47) Bernier S G Servdnt g, Boudreau M et al:Characterization of a binding site for angiotensin IV on bovine aortic endothelial cells. Eur J Pharmacol 291:191-200, 1995
PubMed
48) Wyse B, Greenland, K, Sernia C:Specific binding sites for (3-8) angiotensin in C6 glioma cells. Brain Res 681:41-46, 1995
PubMed
49) Czekalski S, Chansel D, Vandermeersch S et al:Evidence for angiotensin IV receptors in human collecting duct cells. Kidney Int 50:1125-1131, 1996
PubMed
50) Riva L, Galzin AM:Pharmacological characterization of a specific binding site for angiotensin IV in cultured porcine aortic endothelial cells. Eur J Pharmacol 305:193-199, 1996
PubMed
P.133 掲載の参考文献
1) Timmermams PBMWM, Wong PC, Chiu AT et al:Angiotensin II receptors and angiotensin II receptor antagonist. Pharmacol Rev 45:205-251, 1993
PubMed
2) Inagami T, Guo D-F, Kitami Y:Molecular biology of angiotensin II receptors:Overview. J Hypertens 12 (Suppl 10):S83-S94, 1994
 
3) Sasaki K, Yamano Y, Bardhan S et al:Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type 1 receptor. Nature 351:230-232, 1991
PubMed
4) Iwai N, Yamano Y, Chaki S et al:Rat angiotensin receptor:cDNA sequence and regulation of gene expression. Biochem Biophys Res Commun 177:299-304, 1991
PubMed
5) Murphy TJ, Alexander RW, Griendling KK et al:Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233-236, 1991
PubMed
6) Iwai N, Inagami T:Identification of two subtypes in the rat type 1 angiotensin II receptor. FEBS Lett 298:257-260, 1992
 
7) Sandberg K, Ji H, Clark A et al:Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem 267:9455-9458, 1992
PubMed
8) Kakar SS, Sellers JC, Devor DC et al:Angiotensin II type-1a receptor subtype cDNAs:differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 183:1090-1096, 1992
PubMed
9) Elton TS, Stephan CC, Taylor GR et al:Isolation of two distinct type 1 angiotensin II receptor genes. Biochem Biophys Res Commun 184:1067-1072, 1992
 
10) Yoshida H, Kakinuma J, Guo D-F et al:Analysis of the evolution of angiotensin II type 2 receptor gene in mammals (mouse, rat, bovine and human). Biochem Biophys Res Commun 186:1042-1049, 1992
 
11) Sasamura H, Hein L, Krieger JE et al:Cloning characterization and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Commun 185:253-259, 1992
PubMed
12) Takayanagi R, Ohnaka K, Sakai Y et al:Molecular cloning sequnece analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. Biochem Biophys Res Commun 183:910-916, 1992
 
13) Tissir F, Riviere M, Guo D-F et al:Localization of the genes encoding the three rat angiotensin II receptors, Agtrla, Agtrlb, Agtr2 and human Agtr2 receptors, respectively to rat chromosome 17q 12, 2q 24 and X34, and human Xq 22. Crytogenet Cell Genet 71:77-80, 1995
 
14) Du Y, Guo D-F, Inagami T et al:Regulation of Ang II-receptor subtype and its gene expression in adrenal gland. Am J Physiol 271:H440-H446, 1996
PubMed
15) Sandberg, K:Structural analysis and regulation of angiotensin receptor. Trends Endocrinol Metab Clin North Am 5:28-35, 1994
 
16) Kambayashi Y, Bardhan S, Takahashi T et al:Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 168:24543-24546, 1993
 
17) Mukoyama M, Nakajima M, Horiuchi M et al:Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven transmembrane receptors. J Biol Chem 268:24539-24542, 1993
PubMed
18) Kang J, Posner P, Sumners C:Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein. Am J Physiol 267:C1389-C1397, 1994
PubMed
19) Zang J, Pratt R E:The AT2 receptor selectively associates with Giiα2 and Giiα3 in the rat fetus. J Biol Chem 271:15026-15033, 1996
 
20) Curnow KM, Pascoe L, White PC et al:Genetic analysis of the human type 1 angiotensin II receptor. Mol Endocrinol 6:1113-1118, 1992
PubMed
21) Guo D-F, Furuta H, Mizukoshi M, Inagami, T.:The genomic organization of human angiotensin II type 1 receptor. Biochem Biophys Res Commun 200:313319, 1994
 
22) Takeuchi K, Alexander W, Nakamura Y et al:Molecular structure and transcriptional function of the rat vascular AT1A angiotensin receptor gene. Circ Res 73:612-621, 1993
 
23) Guo D-F, Inagami T:The genomic organization of the rat angiotensin receptor AT1B. Biochem Biophys Acta 1218:91-94, 1994
PubMed
24) 1chiki T, Inagami T:Expression, genomic organization and transcription of the mouse angiotensin II type 2 receptor gene. Circ Res 76:693-700, 1995
 
25) Murasawa S, Matsubara H, Urakami M et al:Regulatory elements that mediate expresseion of the gane for the angiotensin II type 1A receptor for the rat. J Biol Chem 268:26996-27003, 1993
 
26) Guo D-F, Uno S, Ishihata A et al:Identification of cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promotor. Circ Res 77:249-257, 1995
 
27) Guo, D-F, Inagami T:Epidermis growth factor enhances human angiotensin II receptor type1 receptor. Hypertension 23 (Suppl):S1032-S1035, 1994
 
28) Makita Y, Iwai N, Inagami T et al:Two distinct pathways in the down regulation of type-1 angiotensin II receptor gene in rat glomerular mesangial cells. Biochem Biophys Res Commun 185:142-146, 1992
 
29) Kitami Y, Okura T, Marumoto K et al:Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Biochem Biophys Res Commun 188:446-452, 1992
PubMed
30) Iwai N, Inagami T, Ohmichi N:Differential regulation of rat AT1A and AT1B receptor mRNA. Biochem Biophys Res Commun 188:298-303, 1992
PubMed
31) Cheng HF, Beckner BN, Burns DK:Angiotensin II upregulates Type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 95:2012-2019, 1995
 
32) Horiuchi M, Koike G, Yamada T et al:The growth-dependent expression of angiotensin II type 2 receptor is regulated by transcription factors interferon regulatory factor-1 and-2. J Biol Chem 270:20225-20230, 1995
PubMed
33) Ichiki T, Kambayashi Y, Inagami T:Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells. Circ Res 77:1070-1076, 1995
PubMed
34) KambayashiY, Nagata K, Ichiki T et al:Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptors in vasular smooth muscle cells. Eur J Biochem 239:558-565, 1996
 
35) Harris RC, Inagami T:Molecular biology and pharmacology of angiotensin receptor subtypes. In:ed by "Hypertension, Pathophysiology, Diagnosis and Management. 2nd ed Laragh JH ed by Brenner BM Raven Press, Ltd, New York, 1995, pp. 1721-1738
 
36) Iwai N, Inagami T:Regulation of the expression of the rat angiotensin II receptor mRNA. Biochem Biophys Res Commun 182:1094-1099, 1992
PubMed
37) Suzuki J, Matsubara H, Uraki M et al:Rat angiotensin II (Type 1A) receptor mRNA regulation and subtype expressed in myocardial growth ahd hypertrophy. Circ Res 73:439-447, 1993
 
38) Paxton WG, Runge M, Haraist C et al:Immunohistochemical localization of rat angiotensin II AT1 receptor. Am J Physiol 264:F989-F995, 1993
 
39) Viswanathan N, Tsutsumi K, Correa FMA et al:Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun 179:1361-1367, 1991
 
40) Tang H, Shirai H, Inagami T:Inhibition of protein kinase C prevents rapid desensitization of type 1IB angiotensin II (AT1B) receptors. Circ Res 77:239-248, 1995
 
41) Thomas WG, Baker KM, Motel TJ et al:Angiotensin II receptor endocytosis involves two distinct regions of the cytoplasmic tail. J Biol Chem 270:22153-22159, 1995
PubMed
42) Abdellatf MM, Neubauer CF, Lederer WJ et al:Angiotensin-induced desensitization of the phospholipid pathway in cardiac cells occur at the level of the receptor. Circ Res 69:800-809, 1991
PubMed
43) Huntady L, Bor Marta Balla T et al:Identification of a cytoplasmic Ser-Thr-Leu motif that determines agonist induced internalization of the AT1v angiotensin receptor. J Biol Chem 269:31378-31382, 1994
 
44) Hunyady L, Baukal A, Balla T et al:Independence of type 1 angiotensin II receptor endocytosis from G-protein coupling and signal transduction. J Biol Chem 269:24798-24804, 1994
 
45) Yamano Y, Ohyama K, Chaki S et al:Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site-derected mutagenesis. Biochem Biophys Res Commun 187:1426-1431, 1992
 
46) Noda K, Yasser S, Karnik SS:Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem 270:28511-28514, 1995
 
47) YamanoY, Ohyama K, KikyoM et al:Mutagenesis and the molecular modeling of the rat angiotensins II receptor (AT1) . J Biol Chem 270:14024-14030, 1995
 
48) Feng YH, Noda K, Saad Y et al:The docking of Arg8 of Ang II with Asp2sl of AT1 receptor is essential for full agonism. J Biol Chem 270:12846-12850, 1995
 
49) Hunyady L, Balla T, Catt KJ:The ligand binding site of the angiotensin AT1 receptor. TiPs 17:135-140, 1996
PubMed
50) Schambye HT, HjorthS A, Bergsma D Jet al:Differentiation beween binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc Natl Acad Sci USA 91:7045-7050, 1994
 
51) Perlman S, Schambye HT, Rivero RA et al:Non-peptide angiotensin agonist. J Biol Chem 270:1493-1496, 1995
PubMed
52) Inoue Y, Nakamura N, Inagami T:A review of mutagenesis studies of angiotensin II type 1 receptor, the three dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertension 15:703-714, 1997
 
53) Bioreau C, Monnot C, Davies E et al:Mutation of Asp74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G-Protein coupling. Proc Natl Acad Sci USA 90:5133-5137, 1993
 
54) Ohyama K, Yamano Y, Chaki S et al:Domains for G-protein coupling in angiotensin II receptor type 1:Studies by site directed mutagenesis. Biochem Biophys Res Commun 189:677-683, 1992
 
55) Hunyady L, Bor M, Baukal et al:A conserved NPLFY sequence contributes to agonist binding and signal transduction but is not an internalization signal for the type 1 angiotensin II receptor. J Biol Chem 270:16602-16609, 1995
 
56) Laporte SA, Cervant G, Richard DE et al:The tyrosine within the NPXnY motif of the human angiotensin II type 1 receptor is involved in mediating signal transduction but not essential for internalization. Mol Pharmacol 49:89-95, 1996.
 
57) Marie J, Maigret B, Joseph M-P et al:Tyr292 in the seventh transmembrane domain of the AT1A angiotensin II receptor is essential for its coupling to phospholipase C. J Biol Chem 269:20815-20818, 1994
PubMed
58) Balmforth AJ, Lee AJ, Warburton P et al:The conformational changes responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J Biol Chem 272:4245-4251, 1997
 
59) Opperman M, Freedman NJ, Alexander RN et al.:Phosphorylation of the type 1A angiotensin II receptor by G-protein-coupled receptor kinases and protein kinase C. J Biol Chem 271:13266-13272, 1996
 
60) Shirai H, Takahashi K, Katada T et al:Mapping of G protein coupling sites of the angiotensin II type 1 receptor. Hypertension 25:(part 2):726-730, 1995
 
61) Sano T, Ohyama, K, Yamano Y et al:A domain for G protein coupling in carboxyl-terminal tail of rat angiotensin II receptor type 1A. J Biol Chem 272:23631-23636, 1997
 
62) Wang C, Jayadev S, Escobedo JA:Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use of receptor Chimerics. J Biol Chem 270:16677-16682, 1995
PubMed
63) Greindling KK, Murphy TJ, Alexander RW:Molecular biology of renin-angiotensin system. Circulation 87:1816-1828, 1993
 
64) Bieson T, Luttrell LM, Hawaes BE et al:Mitogenic signaling via G-protein-coupled receptors. Endocrine Rev 17:698-714, 1996
 
65) Berk BC, Corson MA:Angiotensin II signal transduction in vascular smooth muscle:Role of tyrosine kinase. Circ Res 80:607-616, 1997
PubMed
66) Marrero, MB, Paxton WB, Duff J L et al:Angiotensin II stimulates tyrosine phosphorylation of phospholipase C-γ1 in vascular smooth muscle cells. J Biol Chem 269:10935-10939, 1994
 
67) Tsuda T, Kawahara Y, Shii K et al:Vasoconstrictor-induced protein tyrosine phosphorylation in cultured rat vascular smooth muscle cells. FEBS Lett 285:44-48, 1992
 
68) Duff JL, Berk BC, Corson MA:Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinase in cultured vascular smooth muscle cells. Biochem Biophys Res Comun 188:257-264, 1992
 
69) Morrero MB, Schieffer B, Paxton W:Direct stimulation of JAK/STAT pathway by the angiotensin II AT1 receptor. Nature 375:247-250, 1995
 
70) Bhat GJ, Thekkumkara TJ, Thomas WG et al:Angiotensin II stimulates sis-inducing factor-like DNA binding activity. J Biol Chem 269:31443-31449, 1994
 
71) 1shida M, Marrero MB, Schiffer B et al:Angiotensin II activates pp60c-Src in vascular smooth muscle cells. Circ Res 77:1053-1059, 1995
 
72) Showkatali M, Sayaskit PP, Dirksen LB et al:Dependence on the motif YIPP for the physical association of Jak 2 kinase with the intracellular carboxy tail of the angiotensin II ATI receptor. J Biol Chem 272:23382-23388, 1997
 
73) Eguchi S, Matsumoto T, Motley ED et al:Identification of essential signaling casade for mitogenactivated protein kinase activation by angiotensin II in cultured vascular smooth muscle cells. Possible requirement of Gq-mediated p21 ras activation coupled to Ca2+/calmodulin sensitive tyrosine kinase. J Biol Chem 271:14169-14175, 1996
 
74) Schieffer B, Paxton WG, Chai Q et al:Angiotensin II controls p21ras activity via pp60. J Biol Chem 271:10329-10333, 1996
PubMed
75) Sadoshima J, IzumoS:The heterotrimeric Gq protein-coupled angiotensin II receptor activates p21ras via the tyrosine kinase-Shc-Grb2-Sos pathway in cardiac myocytes. EMBO J 15:775-787, 1996
PubMed
76) Linseman DA, Benjamin CW, Jones DA:Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 270:12563-12568, 1995
 
77) Eguchi S, Numaguchi K, Matsumoto T et al:Calcium-dependent multiple tyrosine kinase interaction mediates the angiotensin II-induced MAP kinase activation in vascular smooth muscle cells. J Biol Chem, in press
 
78) Arai H, Escobedo JA:Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism. Mol Pharmacol 50:522-528, 1996.
PubMed
79) Takahashi T, Kawahara Y, Okuda M:Angiotensin II stimulates mitogen-activated protein kinases and protein synthesis by a ras-independent pathway in vascular smooth muscle cells. J Biol Chem 272:16018-16022, 1997
 
80) Yamazaki T, Komuro I, Kudoh S et al:Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J Clin In vest 96:438-446, 1995
 
81) Sadoshima J, QuiZ, Morgan J et al:Angiotensin II and other hypertrophic stimuli mediated by G-protein-coupled receptors activate tyrosine kinase, mitogen activated protein kinase, and 90-KD S6 kinase in cardiac myocytes in vitro:a potential role of 70k S6 Kinase. Circ Res 76:1-15, 1995
 
82) Shorb H, Peeler TC, Madigan NN et al:Angiotensin II-induced protein tyrosine phosphorylation in neonatal cardiac fibroblasts. J Biol Chem 269:19626-19632, 1994
 
83) Villareal FJ, Kim NN, Ungab GD et al:Identification of functional angiotensin II receptors in rat cardiac fibroblasts. Circulation 88:2849-2861, 1993
 
84) Suzuki J, Matsubara H, Urakami M et al:Rat angiotensin II (Type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 73:439-447, 1993
PubMed
85) Asano K, Dutcher D, Port JD et al:Selective down regulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 95:1193-1200, 1997
PubMed
86) Kurabayashi M, Yazaki Y:Down regulation of angiotensin II receptor type 1 in heart failure. A process of adaptation or deterioration? Circulation 95:1104-1107, 1997
PubMed
87) Vallos LA, LolliF, Sun J et al:Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93:12490-12495, 1996
 
88) Yamada T, Horiuchi M, Dzau VJ:Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93:156-160, 1996
PubMed
89) Huang Y-C, Richards EM, Sumners C:Mitogen activated protein Kinase in rat brain neuronal cultures are activated by angiotensin type I receptors and inhibited by the type 2 receptor. J Biol Chem 271:15635-15641, 1996
 
90) Bottari SP, King IN, Reichlin S:The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun 183:206-211, 1992
PubMed
91) Tsuzuki S, Matoba T, Eguchi S et al:Angiotensin II type 2 receptor inhibits cell proliferation and tyrosine phosphatase. Hypertension 28:916-918, 1996
PubMed
92) Nahmias C, Cazaubon SM, Briend-Sutren, MM:Angiotensin II AT2 receptors are functionally coupled to protein tyrosine dephosphorylation in NIE-115 neuroblastoma cells. Biochem J 306:87-92, 1995
 
93) Takahashi, K, Bardhan S, Kambayashi Y:Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor AT2. Biochem Biophy Res Commun 196:313-319, 1994
 
94) Lokita AJ, Cooper C, Gaa, ST et al:Angiotensin II stimulates the release of phospholipid-derived second messengers through multiple receptor subtypes in heart cells. J Biol Chem 269:4832-4838, 1994
 
95) Kohout TA, and Rogers TB:Angiotensin II activates the Na+/HCO3-symport through a phosphoinositide-independent mechanism in cardiac cells. J Biol Chem 270:20432-20438, 1995
 
96) Buisson B, Laflamme L,Bottari SP et al:A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells. J Biol Chem 270:1670-1674 1995
 
97) Siragy HM, Carey RM:The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin In vest 100:264-269, 1997
 
98) Sugaya T, Nishimatsu S, Tanimoto K et al:Angiotensin II type 1a receptor deficient mice with hypotension and hyperreninemia. J Biol Chem 270:18719-18722, 1995
PubMed
99) Ito M, Oliverio MI, Mannon PJ et al:Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92:3521-3525, 1995
PubMed
100) Niimura F, Labosky C, Kakuchi J et al:Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 96:2947-2954, 1995
 
101) KimH-S, Krege HH, Kluckman KD:Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92:2735-2739, 1995
 
102) Tanimoto K, Sugiyama F, Goto Y et al:Angiotensinogen-deficient mice with hypotension. J Biol Chem 269:31334-31337, 1994
PubMed
103) Matsusaka T, Nishimura H, Utsunomiya H et al:Chimeric mice carrying regional targeted deletion of the angiotensin type 1A receptor gene. J Clin Invest 98:1867-1877, 1996
 
104) Ichiki T, Labosky PA, Shiota C et al:Effect on blood pressure and reduced exploratory behavior in mice lacking angiotensin II receptor Nature 377:748-750, 1995
 
P.142 掲載の参考文献
1) 国府達郎:レニン・アンジオテンシン・アルドステロン系の分泌調節とその異常 (その1)-レニン-アンジオテンシン系を中心として-代謝 (臨床増刊):102-116, 1974
 
2) Goodfriend T:Angiotensinases. In:The Renin-angiotensin system, ed by Robertoson, PJI, Nicholls, MG, Gower Medical Publishing, London, 1993 pp-11.1-11. 5
 
3) Ferrario CM, Chappell MC, Tallant EA et al:Counterregulatory actions of angiotensin-(1-7) . Hypertension 30:535-541, 1997
PubMed
4) Kerins DM, Hao Q, Vaughan DE:Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the heptapeptide angiotensin IV. J Clin Invest 96:2515-2520, 1995
 
5) Wright JW, Clemaens JA, Panetta JA et al:Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res 717:1-11, 1996
 
6) McDonald JK:An overview of protease specificity and catalytic mechanisms:aspects related to nomenclature and classification. Histochem J 74:247-261, 1982
 
7) Kugler P:Aminopeptidase A is angiotensinase A:II. Biochemical studies on aminopeptidase A and M in rat kidney homogenate. Histochemistry 74:247-261, 1982
 
8) Goodfriend TL, Peach MJ:Angiotensin III:(desaspartic acid)-angiotensin II. Circ Res 36&37 (Suppl I):1-38-1-48, 1975
 
9) Harding JW, Felix D:The effects of the aminopeptidase inhibitors amastatin and bestatin on angiotensin-evoked neuronal activity in rat brain. Brain Res 424:299-304, 1987
PubMed
10) Peach MJ:Renin-angiotensin system:biochemistry and mechanisms of action. Physiol Rev 57:313-379, 1977
PubMed
11) Mizutani S, Taira H, Kurauchi O et al:Effect of microsomal leucine aminopeptidase from human placenta (microsomal P-LAP) on pressor response to infused angiotensin II (A-II) in rat. Exp Clin Endocrinol 90:206-212, 1987
 
12) Wright JW, Jensen LL, Cushing LL et al:Leucine aminopeptidase M-induced reductions in blood pressure in spontaneously hypertensive rats. Hypertension 13:910-915, 1989
PubMed
13) McDonald JK, Zeitman BB, Reilly TJ et al:New observation on the substrate specificity of cathepsin C (dipeptidyl aminopeptidase I):including the degradation of β-corticotropin and other peptide hormones. J Biol Chem 244:2693-2709, 1969
 
14) Lee C-M, Snyder S S:Dipeptidyl-aminopeptidase III of rat brain. J Biol Chem 257:12043-12050, 1982
 
15) Hui K-S:A novel dipeptidyl aminopeptidase in rat brain membranes:its isolation, purification, and characterization. J Biol Chem 263:6613-6618, 1988
PubMed
16) ErdoS EG, Skidgel RA:Neutoral endopeptidase 24. 11 (enkephalinase) and related regulators of peptide hormoned. FASEB J 3:145-151, 1989
 
17) Yamamoto K, Chappell MC, Brosnihan K B:In vivo metabolism of angiotensin I by neutral endopeptidase (3. 4. 24. 11) in spontaneously hypertensive rats. Hypertension 19:692-696, 1992
 
18) Odya CE, Marinkovic DC, Hammon KJ et al:Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 253:5927-5931, 1978
 
19) Kokubu T, Hiwada K, Ueda, E et al:Plasma angiotensinase activity in liver disease. Biochem Med 1:54-61, 1967
 
20) Healy DD, Wilk S:Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II. Brain Res 606:295-303, 1993.
 
21) Ferrario CM, Milsted A, Santos RAS.:Renin, converting enzyme, and angiotensin peptide:a review. In:A focus on The Clinical Effect of A Long-acting ACE Inhibitor/Hypertension, ed. by Kean, W. F., Raven Press, New York, 1990 pp.1-20
 
22) Unger T, Badoer E, Ganten D et al:Brain angiotensin pathways and pharmacology. Circulation 77 (Suppl I):I-40-I-54, 1988
 
23) Yroyanovskaya M, Song L, Jayaraman G et al:Expression of aminopeptidase A an angiotensinase, in glomerular mesangial cells. Hypertension 27:518-522, 1996
 
24) Thaiss F, Wolf G, Assad N et al:Angiotensinase A gene expression and enzyme activity in isolated glomeruli of diabetic rats. Diabetologia 39:275-280, 1996
PubMed
25) Wolf G, Thaiss F, Scherberich JE et al:Glomerular angiotensinase A in the rat:increase of enzyme activity following renal ablation. Kidney Int 38:862-868, 1990
PubMed
26) Neudeck H, Schuster C, Hildebrandt R et al:Histochemical evaluation of placental angiotensinase A in preeclampsia:enzyme activity i villous trophoblast indicates an enhanced likelihood of gestational proteinuric hypertension. Placenta 17:155-163, 1996
PubMed
27) Nozaki Y, Sato N, Iida T et al:Prolyl endopeptidase purified from granulomatous inflammation in mice. J Cell Biochem 49:296-303, 1992
PubMed
P.152 掲載の参考文献
1) Panthier JJ, Foote S, Chambreud B et al:Complete amino acid sequence and maturation of the mouse submaxillary gland renin precursor. Nature 298:90-92, 1982
 
2) Masuda T, Imai T, Fukushi T et al:Molecular cloning of complementary DNA to mouse submandibular gland renin mRNA. Biomed Res 3:541-545, 1982
 
3) Imai T, Miyazaki H, Hirose S et al:Cloning and sequence analysis of cDNA for human renin precursor. Pro Nalt Acad Sci USA 80:7405-7409, 1983
 
4) Murakami K:Primary and tertiary structure of human renin. J Hypertension 2:285-287, 1984
 
5) Murakami K, Hirose S, Miyazaki H et al:Complementary DNA sequences of renin. State-of-the-art review. Hypertension 6:195-1100, 1984
 
6) Miyazaki H, Fukamizu A, Hirose S et al:Structure of the human renin gene. Proc Natl Acad Sci USA 81:5999-6003, 1984
PubMed
7) Poorman RA, Palermo DP, Post LE et al:Isolation and characterization of native human renin derive from Chinese hamster ovary cells. Proteins:Structure Function and Genetics 1:139-145, 1986
 
8) Murakami K, Imai T, Takamatsu H et al:Expression of human prorenin in Escherizchia-coli and Chinese hamster ovary cells-activation of proenzyme and isolation of renin. J Hypertension (Suppl) 4:S388-S390, 1986
 
9) Miyazaki H, Fukamizu A, Hirose S et al:Structure of the human renin gene. Proc Nalt Acad Sci USA 181:5999-6003, 1984
 
10) Murakami K, Hirose S, Miyazaki H et al:Complementary DNA sequences of renin. State-of-the-art review. Hypertension 6:195-1100, 1984
 
11) Fukamizu A, Takahashi S, Seo MS et al:Structure and expression of the human angiotensinogen gene. Identification of a unique and highly active promoter. J Biol Chem 265:7576-7582, 1990
PubMed
12) Fukamizu A, Uehara S, Sugimura K et al:Cell type-specific expression of the human renin gene. J Biol Regulators and Homeostatic Agents 5:112-116, 1991
 
13) Seo MS, Fukamizu A, Nomura T et al:The human renin gene in transgenic mice. J Cardiovascular Pharmacol 16:S8-S1O, 1990
 
14) Fukamizu A, Hatae T, Kon Y et al:Human renin in transgenic mouse kidney is localized to juxtaglomerular cells. Biochem J 278:601-603, 1991
PubMed
15) Fukamizu A, Seo MS, Hatae T et al:Tissue-specific expression of the human renin gene in transgenic mice. Biochem Biophys Res Commun 165:826-832, 1989
PubMed
16) Fukamizu A, Takahashi S, Murakami K:Expression of the human angiotensinogen gene in human cell lines. J Cardiovasc Pharmacol 16:S11-S13, 1980
 
17) Takahashi S, Fukamizu A, Hasegawa T et al:Expression of the human angiotensinogen gene in transgenic mice and transfected cells. Biochem Biophys Res Commun 180:1103-1109, 1991
PubMed
18) Fukamizu A, Sugimura K, Takimoto E et al:Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268:11617-11621, 1993
 
19) 杉山文博, 深水昭吉:つくば高血圧マウス, Biomedica 8:1140-1164, 1993
 
20) 塩田直考, 深水昭吉, 杉山文博ほか:トランスジェニク動物とレニン・アンギオテンシン系. Molecular Medicine 30:1406-1413, 1993
 
21) Fukamizu A, Takimoto E, Sugimura K et al:Dependence of angiotensin production in transgenic mice carrying either the human renin or human angiotensinogen genes on species-specific kinetics of the renin-angiotensin system. Drug Res 43:222-225, 1993
PubMed
22) Hatae T, Takimoto E, Murakami K et al:Comparative studies on species-specific reactivity between renin and angiotensinogen. Molecular and Cellular Biochemistry 131:43-47, 1994
PubMed
23) Sugiyama F, Haraoka S, Watanabe T et al:Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab Invest 76:835-842, 1997
PubMed
24) Takimoto E, J, Sugiyama F et al:Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 274:995-998, 1996
 
25) Tanimoto E, Sugiyama F, Goto Y et al:Angiotensinogen-deficient mice with hypotension. J Biol Chem Communication 269:31334-31337, 1994
 
26) Sugaya T, Nishimatu S, Tanimoto K et al:Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270:18719-18722, 1995
 
27) 1chiki T, Labosky PA, Shiota C et al:Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748-750, 1995
 
P.163 掲載の参考文献
1) Ganten D, Marquez-Julio A, Grangen P et al:Renin in dog brain. Am J Physiol 221:1733-1737, 1971
 
2) Hirose S, Ohsawa T, Inagami T:Brain renin from bovine anterior pituitary:isolation and properties. J Biol Chem 257:6316-6321, 1982
PubMed
3) Dzau V:Significance of the vascular renin-angiotensin pathway. Hypertension 8:553-559, 1986
PubMed
4) Okamura T, Miyazaki M, Inagami T et al:Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats. Hypertension 8:560-565, 1986
PubMed
5) Miyazaki M, Okunishi H, Okamura T et al:Elevated vascular angiotensin converting enzyme in chronic two-kidney, one clip hypertension in the dog. J Hypertens 5:155-160, 1987
PubMed
6) Miyazaki M, Kawamoto T, Okunishi H:Vascular affinity of trandolapril. J Hypertens 8:S63-S67, 1995
 
7) Okamura T, Clemens, DL, Inagami T:Renin, angiotensin and angiotensin-converting enzyme in neuroblastoma cells:evidence for intracellular formation of angiotensins. Proc Natl Acad Sci USA 78:6940-6943, 1981
PubMed
8) Tang SS, Stevenson L, Dzau V:Endothelial renin-angiotensin pathway. Adrenergic regulation of angiotensin seretion. Cir Res 66:103-108, 1990
 
9) Okunishi H, Miyazaki M, Toda N:Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 2:277-284, 1984
 
10) Okunishi H, Kawamoto, Kurobe Y et al:Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin. Exp Pharmacol Physiol 18:649-659, 1991
PubMed
11) Shiota N, Miyazaki M, Okunishi H:Increase of anglotensin converting enzyme gene expression in the hypertensive aorta. Hypertension 20:168-174, 1992
 
12) Miyazaki M, Okamura T, Toda N:Role of vascular angiotensin converting enzyme in hypertension. J Hypertens 6:S13-S15, 1988
 
13) Jin D, Takai S, Shiota N et al:Roles of vascular angiotensin converting enzyme and chymase in tow-kidney, one clip hypertensive hamsters. J Hypertens 16:657-664, 1998
 
14) Wintroub BU, Klickstein LB, Dzau VJ et al:Granulocyte-angiotensin system. Identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochem 23:227-232, 1984
 
15) Arakawa K, Maruta H:Ability of kallikrein to generate angiotensin II-like pressor substance and aproposed`kinin-tensin enzyme system'. Nature 288:705-706, 1980
 
16) Schiller PW, Demassieux S, Boucher R:Substrate specificity of tonin from rat submaxillary gland. Circ Res 39:629-632, 1976
PubMed
17) Reilly CF, Tewksbury DA, Schechter NM et al:Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 257:8619-8622, 1982
PubMed
18) Urata H, Kinoshita A, Misono KS et al:Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265:22348-22357, 1990
 
19) Takai S, Shiota N, Sakaguchi M et al:Characterization of chymase from human vascular tissues. Clin Chim Acta 265:13-20, 1997
PubMed
20) Caughey GH, Zerweck EH, Vanderslice P:Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem 266:12956-12963, 1991
PubMed
21) Urata H, Kinoshita A, Perez DM et al:Cloning of the gene and cDNA for human heart chymase. Biol Chem 266:17173-17179, 1991
PubMed
22) MERCATOR Study Group:Dose the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study. Circulation 86:100-110, 1992
 
23) Shiota N, Okunishi H, Fukamizu A et al:Activation of tow angiotensin-generating systems in the balloon-injured artery. FEBS Lett 323:239-242, 1993
 
24) Shiota N, Fukamizu A, Takai S et al:Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens 15:431-440, 1997
 
25) Jin D, Takai S, Shiota N et al:Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J Hypertens 16:657-664, 1998
PubMed
P.172 掲載の参考文献
1) Bickerton RK, uckley JP:Evidence for a central mechanism in angiotensin induced hypertension. J Proc Soo Exp Biol Med 106:834-836, 1961
 
2) Ganten D, Merquez-Julio A, Granger P et al:Renin in dog brain. Am J Physiol 221:1733-1737, 1971
 
3) Johren O, Imboden H, Hauser W et al:Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 757:218-227, 1997
PubMed
4) Bunnemann B, Fuxe K, Ganten D:Extrarenal renin systems:the brain In:The Renin-Angiotensin System:Biochemistry, Physiology, Pathophysiology, Therapeutics, ed by JIS Robertson and MG Nichols-Gower Medical Publishers, London, 1993, vol. 1, ch. 41, pp. 41, 1-41, 17
 
5) Zini S, Fournie-Zaluski M-C, Chauvel E et al:Idenification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors:predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci 93:11968-11973, 1996
 
6) Lon S, Szczepanska-Sadowska E, Szczypaczewska M:Evidence that centrally released arginine vasopressin is involved in central pressor action of angiotensin II. Am J Physiol 270:H167-H173, 1996
PubMed
7) Fitts D A, Thunhorst RL:Rapid elicitation of salt appetite by an intravenous infusion of angiotensin II in rats. Am J Physiol 270:R1092-R1098, 1996
PubMed
8) Eriksson S, Andersson B, Gunnarsson U, Rundgren M:Hypertension and thirst outlasting renal vasoconstriction as effect of a brief elevation of systemic angiotensin II in sheep. Acta Physiol Scand 150:181-188, 1994
PubMed
9) Hiooka Y, Head GA, Potts PD et al:Medullary neurons activated by angiotensin II in the conscious rabbit. Hypertension 27:287-296, 1996
 
10) Lippoldt A, Bunnemann B, Ueki A et al:On the plasticity of the cerebellar renin-angiotensin system-localization of components and effects of mechanical perturbation. Brain Res 668:144-159, 1994
PubMed
11) Zhuo J, Allen AM, Alcorn D et al:The distribution of angiotensin II receptors. In:Hypertension, Pathophysiology, Diagnosis and Management, second edition, ed by (Laragh JH, Brenner BM,) Raven press, New York, 1995, pp.1739-1762
 
12) Hein L, Barsh GS, Pratt RE et al:Behavioral and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 377:744-747, 1995
PubMed
13) 1chiki T, Labosky PA, Shiota C et al:Effects on blood pressure and exploratory behavior of mice lacking angiotensin II type-2 receptor. Nature 377:748-750, 1995
 
14) Brooks V L:Chronic infusion of angiotensin II resets baroreflex control of heart rate by an arterial pressure-independent mechanism. Hypertension 26:420-424, 1995
PubMed
15) Heesch CM, Crandall ME, Turbek JA:Converting enzyme inhibitors cause pressure-independent resetting of baroreflex control of sympathetic outflow. Am J Physiol 270:R728-R737, 1996
PubMed
16) Hirooka Y, Dampney RAL:Endogenous angiotensin within the rostral ventrolateral medulla facilitates the somatosympathetic reflex. J Hypertens 13:747-754, 1995
 
17) Niederberger M, Aubert J-F, Nussberger J et al:Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist. J Hypertens 13:439-445, 1995
PubMed
18) Kumagai H, Averill DB, Ferrario CM:Renal nerve activity in rats with spontaneous hypertension:effect of converting enzyme inhibitor. Am J Physiol 263:R109-R115, 1992
PubMed
19) Denton D:The hunger for salt:an anthropological, physiological and medical analysis. Springer-Verlag, Berlin, p. 650
 
20) May CN, McAllen RM:Baroreceptor-independent renal nerve inhibition by intracerebroventricular angiotensin II in conscious sheep. Am J Physiol 273:R560-R567, 1997
PubMed
21) Rohmeiss P, Beyer C, Hocher B et al:Osmotically induced natriuresis and blood pressure response involves angiotensin AT (1) receptors in the subfornical organ. J Hypertens 13:1399-1404, 1995
PubMed
22) Rohmeiss P, Beyer C, Nagy E et al:NaCl injections in brain induce natriuresis and blood pressure responses Sensitive to ANG II AT1 receptors. Am J Physiol 269:F282-288, 1995
PubMed
23) Huang BS, Leenen FHH:Sympathoexcitatory and pressor responses to increased brain sodium and ouabain are mediated via brain ANG II. Am J Physiol 270:H275-H280, 1996
 
24) Lou Y-K, Liu DT, Whitworth JA et al:Renin mRNA, quantified by ploymerase chain reaction, in renal hypertensive rat tissues. Hypertension 26:656-664, 1995
 
25) Nishimura M, Takahashi H, Nanbu A et al:Sodium intake regulates renin gene expression differently in the hypothalamus and kidney of rats. Hypertens 15:509-516, 1997
PubMed
26) Osborn JL, Camara AKS:Renal neurogenic mediation of intracerebroventricular angiotensin II hypertension in rats raised on high sodium chloride diet. Hypertension 30:331-336, 1997
 
27) Teruya H, Muratani H, Takishita S et al:Brain angiotensin II contributes to the development of hypertension in Dah1-Iwai salt sensitive rats. J Hypertens 13:883-890, 1995
 
28) Bahner U, Geiger H, Palkovits M et al:Angiotensin II-induced hypertension:effects on central and peripheral atrial natriuretic peptide. Hypertens Res 18:279-284, 1995
PubMed
29) Geiger H, Bahner U, Puschel A et al:A trial natriuretic factor in brain areas of Dah1 salt-sensitive and salt-resistant rats. Hypertens Res 16:71-77, 1993
 
30) Unger T, Badoer E, Ganten D et al:Brain angiotensin:pathways and pharmacology. Circulation 77 (Suppl I):S140-S154, 1988
 
31) Bunting MW, Widdop RE:Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats. Br J Pharmacol 116:3181-3190, 1995
PubMed
32) Saiki Y, Watanabe T, Tan N et al:Role of central ANG II receptors in stress-induced cardiovascular and hyperthermic responses in rats. Am J Physiol 41:R26-R33, 1997
 
33) Sim MK, Qiu XS:Effect of of des-Asp angiotensin I on the contractile action of angiotensin II and angiotensin III. Eur J Pharmacol 28:175-178, 1995
 
34) Harding JW, Jensen LL, Hanesworth JM et al:Release of angiotensins in paraventricular nucleus of rat in response to physiological and chemical stimuli. Am J Physiol 262:F17-F23, 1992
PubMed
35) HardingJW, Imboden H, Felix D:Is angiotensin III the centrally active form of angiotensin? Experimentia 42:706, 1986
 
36) Papouchado ML, Vatta MS, Escalada A et al:Angiotensin III modulates noradrenaline uptake and release in the rat hypothalamus. J Auton Pharmacol 15:1-8, 1995
PubMed
37) Wright JW, Harding JW:Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Behav Rev 18:21-53, 1994
 
38) Wright JW, Krebs LT, Stobb JW et al:The angiotensin IV system:functional implications. Frontiers Nueroendocrinol 16:23-52, 1995
 
39) Moriguchi A, Tallant EA, Matshumura K et al:Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 25:1260-1265, 1995
 
P.179 掲載の参考文献
1) Erdos EG:Angiotensin I converting enzyme. Cir Res 36:247-255, 1975
 
2) Abe K, Irokawa N, Yasujima M et al:The kalli krein-kinin system and prostaglandins in the kidney. Circ Res 43:254-260, 1978
 
3) Regoli D, Pheng LH, Allogho SN et al:Receptors for kinins:form classical pharmacology to molecular biology. Immunopharmacology 33:16-122, 1996
 
4) McEachern AE, Shelton ER, Bhakta S et al:Expession cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 88:7742-7728, 1991
 
5) Menke JG, Borowski JA, Bieriol KK et al:Expression cloning of a human B1 bradykinin receptor. J Biol Chem 269:21583-21586, 1994
 
6) Chai KX, Chen LM, Chao J et al:Kallistantin:a novel human serine protease inhibitor. Molecular cloning, tissue, distribution, and expression in Escherichia coli J Biol Chem 268:24498-24505, 1993
PubMed
7) Omata K, Carreterro OA, Itoh S et al:Active and inactive kallikrein in rabbit connecting tubules and urine during low and norrpal sodium intake. Kidney Int 24:714-718, 1983
 
8) Chen L-M, Song Q, Chao L et al:Cellular localization of tissue kallikrein and kallistantin mRNA in human kidney. Kidney Int 48:690-697, 1995
PubMed
9) Moncada S:Nitric oxide:physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142, 1991
PubMed
10) Wang J, Xiong W, Yang Z et al:Human tissue kallikrein induces hypotension in transgenic mouse. Hypertension 23:236-243, 1994
 
11) Chen L-M, Ma J-X, Liang Y-M et al:Tissue kallikrein-binding Protein reduces blood pressure in transgenic mice. J Biol Chem 271:27590-27594, 1996
PubMed
12) Borkowski JA, Ransom, RW, Seabrook GR et al:Targetted disruption of a B2 bradkinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270:13706-13710, 1995
 
13) Alfe ME, Sigmon DH, Pomposiello SI et al:Effect of high salt intake in mice lacking bradykinin-B2 receptors. Hypertension 29 [part II]:483-487, 1997
 
14) Madeddu P, Varoni MV, Palomba D, et al:Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96:3570-3578, 1997
PubMed
15) Yang X-P, Liu Y-H, Scicli G et al:Role of kinin in the cardioprotective effect of preconditioning. Study of myocardial ischemia/reperfusion injury in B2 receptor knockout mice and kininogen-deficient rats. Hypertension 30:735-740, 1997
PubMed
16) Majima M, Yoshida O, Mihara H et al:High sensitivity to salt in kininogen-deficient rats. Hypertension 22:705-714, 1993
PubMed
17) El-Dahr SS, Yosipiv IV, Muchant DG et al:Salt intake modulates the developemental expression of renal kallikrein and bradykinin B2 receptors. Am J Physiol 270:F425-F431, 1996
 
18) Takeuchi K, Abe K, Maeyema K et al:Simultaneous measurements of cytosolic free caclium level and prostaglandin synthesis reveals a correlation between them in perfused monolayer of cultured rat vascular smooth muscle cells:effects of bradykinin and angiotensin II. Tohoku J Exp Med 165:183-192, 1991
 
19) Schlondorf D:Renal prostaglandin systheis. Site of production and specific actions of prostaglandins. Am J Med 81:1-11, 1986
 
20) Omata K, Abe K, Tsunoda K et al:Role of endogenous angiotensin II and prostaglandins in the antihypertensive mechanism of angiotensin converting enzyme inhibitors in hypertension. Clin Exp Hypertens A9:556-574, 1987
 
21) Seino M, Abe K, Irokawa N et al:Effects of furosimide on urinary kallikrein excretion in patients with essential hypertension. Tohoku J Exp Med 124:197-203, 1978
 
P.186 掲載の参考文献
1) 上原誉志夫:プロスタグランジンと関連物質. 医学のあゆみ:169:467-471. 1994
 
2) Arima S, Ren Y, Juncos L A et al:Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles. Kid Int 45:650-658, 1994
 
3) Uehara Y, Numabe A, Kawabata Y et al:Rapid smooth muscle cell growth and endogenous prostaglandin system in spontaneously hypertensive rats. Am J Hypertens 4:806-814. 1991
PubMed
4) Herschman H R:Analysis of the secretory phospholipase A2 that mediates prostaglandin production in mast cells. J Biol Chem:272 (21) 13591-13596, 1997
PubMed
5) Nagoshi H, Uehara Y, Kanai F et al:Prostaglandin D2 inhibits inducible nitric oxide synthase expression in rat vascular smooth muscle cells. Cir Res 82 204-209, 1988
 
6) Nagata T, Uehara Y, Numabe A et al:Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats. Am J Physiol 263 1331-H1338, 1992
 
7) Papayianni Serhan, C N, Brady H R:Lipoxin A4 and B4 inhibit leukotriene-stimulated interaction of human neutrophils and endothelial cells. J Immunol 156 2264-2272, 1996
PubMed
8) Mayadas T N, Mendrick D L Brady H R et al:Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kid Int 49:1342-1349, 1996
 
9) Kisch E S, Jaffe A, Knoll E et al:Role of the lipoxygenase pathway in angiotensin II-induced vascoconstriction in the human placenta. Hypertension 29:796-801, 1997
 
10) Whe Y, Nadler J. L, Gonzales N et al:Mechanisms of ANG II-induced mitogenic response:role of 12-lipoxygenase and biphasic MAP kinase. Am J Physiol 271:C1212-1220, 1996
 
11) Natarajan R, Gonzales N, lanting L et al:Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy. Hypertension 23:142-147, 1994
 
12) Natarajan R, Guuu J L, Rossi J et al:Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Pro Nat Aca Sci USA 90:4947-4951, 1993
 
13) 西川哲司, 沼部敦司, 金子洋ほか:Dahl 食塩感受性高血圧ラットの腎障害に及ぼすプロスタサイクリン誘導体 OP-2507 の長期投与の影響. 猫協医学会雑誌 10:303-312, 1995
 
14) Hirawa N, Uehara Y, Kawabata Y et al:Mechanistic analysis of renal protection by angiotensin-converting enzyme inhibitor in Dahl salt-sensitive rats. J Hypertens 12:909-918, 1994
PubMed
P.196 掲載の参考文献
1) 伊藤裕, 菅真一, 小川佳宏ほか:脳内ナトリウム利尿ペプチドとその受容体-中枢性血圧・体液調節における意義-. 神経研究の進歩 37:517-530, 1993
 
2) 伊藤裕, 中尾一和:高血圧発症のメカニズムー最近の話題, 血管壁レニン・アンジオテンシン系. 内科 75:130-134, 1995
 
3) 伊藤裕, 中尾一和:血管の再構築. 実験医学 13:126-134, 1995
 
4) 伊藤裕, 中尾一和:内皮由来ペプチド性血管作動性物質と血管のリモデリング. 分子動脈硬化学森崎信尋ほか編, メディカルレビュー社, 大阪, 1995, pp. 155-171
 
5) 伊藤裕, 中尾一和:ナトリウム利尿ペプチドファミリー. 現代の神経内分泌学, 吉田尚監修, メディカルサイエンスインターナショナル, 東京, 1996, pp. 63-74
 
6) 伊藤裕, 中尾一和:高血圧と血管リモデリングの分子機構. 最新医学 51:1606-1617, 1996
Medical*Online
7) 伊藤裕, 中尾一和:局所分泌系-血管内皮を中心に. 最新内科学体系2 (別冊) 科学としての内科学, 井村裕夫, 尾形悦郎, 高久史麿, 垂井清一郎編, 中山書店, 東京, 1996, pp. 213-226
 
8) 伊藤裕, 中尾一和:循環調節因子と血管リモデリング. Molecular Medicine (別冊) 分子医学の新しい流れ:62-67, 1997
 
9) 伊藤裕, 中尾一和:ナトリウム利尿ペプチド系. 日本臨牀 55:41-54, 1997
 
P.201 掲載の参考文献
1) Yanagisawa M, Kurihara H, Kimura S et al:A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988
PubMed
2) Inoue A, Yanagisawa M, Kimura S et al:Three structually and pharmacologically distinct isopeptides predicted by three separate genes. J Proc Natl Acad Sci USA 86:2863-2867, 1989
 
3) Emori T, Hirata Y, Ohta K et al:Secretory mechanism of immunoreactive in cultured bovine endothelial cells. Biochem Biophys Res Commun 160:93-100, 1989
PubMed
4) Imai T, Hirata Y, Emori T. et al:Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19:753-757, 1992
 
5) Resink TJ, Hahn AWA, Scott-Burden T et al:Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun 168:1303-1310, 1990
 
6) Hanehira T, Kohno M, Yoshikawa J:Endothelin production in cultured vascular smooth muscle cells-modulation by the atrial, brain, and C-typenatriuretic peptide system. Metabolism 46:487-493, 1997
 
7) Kohno M, Yokokawa K, Horio T et al:A trial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res 70:241-247, 1992
 
8) Kohno M, Yasunari K, Yokokawa K et al:Inhibition by atrial and brain natriuretic peptides ofendothelin-1 secretion after stirnulation with angiotensin II and thronlbin of cultured human endothelial cells. J Clin Invest 87:1999-2004, 1991
 
9) Dohi Y, Hahn AWA, Boulanger CM et al:Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 19:131-137, 1992
 
10) Sung C-P, Arleth AJ, Storer BL, et al:Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 271:429-437, 1994
PubMed
11) Clavell AL, Mattingly MT, Stevens TL et al:Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 97:1286-1292, 1996
PubMed
12) Ito H, Hirata Y, Adachi S et al:Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92:398-403, 1993
PubMed
13) Ishiye M, Ynenyra K, Uematsu T et al:Angiotensin AT1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload:involvement of endothelin. Eur J Pharmacol 280:11-17, 1995
 
14) Kohno M, Horio T, Ikeda M et al:Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int 42:860-866, 1992
PubMed
15) Bakris GL, Re RN:Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 264 (Renal Fluid Electrolyte Physiol 33) F937-F942, 1993
 
P.206 掲載の参考文献
1) 江口暁, 平田結喜緒:レニンアンジオテンシン系と内皮細胞障害. 現代医療 29:39-43, 1997
 
2) 平田結喜緒:一酸化窒素 (NO) とNO 合成酵素 (NOS) . 日本内分泌学会雑誌 73:1-9, 1997
 
3) Boulanger CM, Caputo L, Levy BI:Endothelial AT1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. Hypertension 26:752-757, 1995
PubMed
4) Saito S, Hirata Y, Emori T et al:Angiotensin II activates endothelial constitutive nitric oxide synthase via AT1 receptors. Hypertension Res 19:201, 1996
 
5) Hahn AWA, Jonas U, Buhler FR et al:Activation of human peripheral monocyto by angiotensin II. FEBS Lett 347:178, 1994
 
6) Kim JA, Berliner JA, Nadler JL:Angiotensin II increases monocyto binding to endothelial cells. Biochem Biophys Res Comm 226:862, 1996
 
7) 平田結喜緒:NO その後の展開. 最新医学 52:934-941, 1997
 
8) Molloy CJ, Taylor DS, Weber H:Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat vascular smooth muscle cells. J Biol Chem 268:7338-7345, 1993
 
9) 江口暁, 稲上正:アンジオテンシンII受容体の情報伝達と発現調節. アンジオテンシンII受容体拮抗薬のすべて, 荻原俊男ほか:先端医学社, 東京, 1997, pp.54-60
 
10) Eguchi S, Matsumoto T, Motley ED et al:Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. J Biol Chem 271:14169-14175, 1996
 
11) Eguchi S, Numaguchi K, Iwasaki H et:al Calcium-dependent EGF receaptor transactivation mediates the angiotensin II-induced MAP kinase activation in vascular smooth muscle cells. J Biol Chem 1998in press
 
12) Yu, S-M, Hung L-M, Lin C-C et al:cGMP-elevating agents supperess proliferation of vascular smooth muscle cells by inhibiting activation of epidermal growth factor signaling pathway. Circulation 95:1269-1277, 1997
PubMed
13) Dhaunsi GS, Matthews C, Kaur K et al:NO increases protein tyrosine phosphatase activity in smooth muscle cells:relationship to antimitogenesis. Am J Physiol 272:H1342-H1349, 1997
PubMed
14) Ishida A, Sasaguri T, Kosaka, C et al:Induction of the cyclin-dependent kinase inhibitor p21Sdi/Cip1/Walf by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 272:10050-10057, 1997
 
15) Dubey RK, Jackson EK, Luscher TF et al:Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cells. J Clin Invest 96:141-149, 1995
PubMed
16) Pollman MJ, Yamada T, Horiuchi M et al:Vasoactive substances regulate vascular smooth muscle cell apoptosis. Circ Res 79:748-756, 1996
PubMed
P.212 掲載の参考文献
1) Tigerstedt R, Bergman PG:Niere und Keislauf. Skand Arch Physiol 8:223-271, 1898
 
2) Kitamura K, Kangawa K, Kawamoto M et al:Adrenomedullin:a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553-560, 1993
PubMed
3) Kitamura K, Eto T:Adrenomedullin-physiological regulator of the cardiovascular system or biochemical curiosity? Curr Opin Nephrol Hypertens 6:80-87, 1997
 
4) 加藤丈司, 北村和雄, 松井英三郎ほか:本態性高血圧症 (EHT) および悪性高血圧症 (MHT) における血中アドレノメデュリン (AM) の臨床的意義.:Jpn Cir J 61 (suppl I):S323, 1997
 
5) Fukuhara M, Tsuchihashi T, Abe I et al:Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. Am J Physiol 269:R1289-R1293, 1995
PubMed
6) Khan AI, Kato J, Ishiyama Y et al:Effect of chronically infused adrenomedullin in two-kidney, one-clip hypertensive rats. Eur J Pharmacol 333:187-1901997
 
7) Shimokubo T, Sakata J, Kitamura K et al:Adrenomedullin:changes in circulating and cardiac tissue concentration in Dahl salt-sensitive rats on a high-salt diet. Clin Exp Hypertens 18:949-961, 1996
PubMed
8) Ishiyama Y, Kitamura K, Kato J et al:Changes in cardiac adrenomedullin concentration in renovascular hypertensive rats. Hypertens Res 20:113-117, 1997
PubMed
9) Tsuruda T, Kato J, Kitamura K, et al:Adrenomedullin:a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes Hypertension 31:505-510, 1998
 
10) Schelling P, Fischer H and Ganten D:Angiotensin and cell growth:a link to cardiovascular hypertrophy? J Hypertens 9:3-15, 1991
PubMed
11) Rajagopalan S, Kurz S, Munzel T et al:Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97:1916-1923, 1996
 
12) Ishihara T, Kato J, Kitamura K et al:Production of adrenomedullin in human vascular endothelial cells. Life Sci 60:1763-1769, 1997
PubMed
13) Kano H, Kohno M, Yasunari K et al:Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens 14:209-213, 1996
 
P.218 掲載の参考文献
1) Goldblatt H, Lynch J, Hanazal, R F et al:Studies on experimental hypertension. 1. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59:347-379, 1934
 
2) Postel-Vinay N:The discovery of the renin-angiotensin system. In:A Century of arterial Hypertension, West Sussex, England, 1996, pp. 67-78
 
3) 荻原俊男, 三上洋, 熊原雄一:実験的高血圧. 川俣順一, 松下宏編:疾患モデル動物ハンドブック. 医歯薬出版, 東京, 1979, pp. 210-216
 
4) 鈴木洋通:腎性高血圧. 日本臨牀 (増刊) 「高血圧」50:738-745, 1992.
 
5) Thurston H:Experimental models of hypertension. In:Textbook of Hypertension. ed.dy:Swales J. D. Blackwell Scientific Publications. Oxford, England, 1994, pp. 477-538
 
6) 檜垣實男, 荻原俊男:レニン・アンジオテンシン系と血圧調節. 日内分泌会誌 69:575-587, 1993
Medical*Online
P.224 掲載の参考文献
1) Black IB:Stages of neurotransmitter development in autonomic neurons. Science 215:1198-1204, 1982
PubMed
2) McCarty R, Cierpital MA, Murphy CA et al:Maternal involvement in the development of cardiovascular phenotype. Experientia 48:315-322, 1992
 
3) Harrap SB, Doyle AE:Renal haemodynamics and total body sodium in immature spontaneously hypertensive and Wistar-Kyoto rats. J Hypertents 4:S249-S252, 1986
PubMed
4) Beierwaltes WH, Arendshorst WJ, Klemmer PJ:Electrolyte and water balance in young spontaneously hypertensive rats. Hypertension 4:908-915, 1982
PubMed
5) Cierpital MA, McCarty R:Hypertension in SHR rats:contribution of maternal environment. Am J Physiol 253:H980-H984, 1987
 
6) Sinaiko A, Mirkin BL:Ontogenesis of the renin-angiotensin system in spontaneously hypertensive and normal Wistar rats. Circ Res 34:693-696, 1974
PubMed
7) Matsushima Y, Kawamura M, Akabane S et al:Increases in renal angiotensin II content and tubular angiotensin II receptors in prehypertensive spontaneously hypertensive rats. J Hypertens 6:791-796, 1988
PubMed
8) Henrich WL, Levi M:Ontogeny of renal renin release in spontaneously hypertensive rat and Wistar-Kyoto rat. Am J Physiol 260:F530-F535, 1991
PubMed
9) Nagaoka A, Kakihara M, Fujiwara K et al:Reduced ability to excrete sodium and water in young spontaneously hypertensive rats. In:Hypertensive Mechanisms, ed. by, Rascher. W, Clugh. D, and Ganten, D, Schattauer Verlag, Stuttgart-New York, 1982, pp. 249-251
 
10) Kirby, RF, Johnson AK:Regulation of sodium and body fluid homeostasis during development:implications for the pathogenesis of hypertension. Experientia 48:345-351, 1992
PubMed
11) Smith PG, Poston CW, Mills E:Ontogeny of neural and non-neural contributions to arterial blood pressure in spontaneously hypertensive rats. Hypertension 6:54-60, 1984
PubMed
12) McCarty R, Kirby RF, Cierpial MA et al:Accelerated development of cardiac sympathetic responses in spontaneously hypertensive (SHR) rats. Behav Neural Biol 48:321-333, 1987
PubMed
13) Kirby RF, Johnson AK:Effects of sympathetic activation on plasma renin activity in the developing rat. J Pharmacol Exp Ther 253:152-157, 1990
 
14) Slotkin TA, Whitmore WL, Orband-Miller L et al:Beta adrenergic control of macromolecule synthesis in neonatal rat heart, kidney, and lung:relationship to sympathetic neuronal developement. J Pharmac. Exp Theor 243:101-109, 1987
 
15) Wu JN, Berecek KH:Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor. Hypertension 22:139-146, 1993
PubMed
16) Rapp JP, Deng AY:Detection and positional cloning of blood pressure quantitative trait loci:Is it possible? Identifying the genes for genetic hypertension. Hypertension 25:1121-1128, 1995
PubMed
17) Rapp JP, Wang S-M, Dene H:A genetic polymorphism in the renin gene of Dahl rats cosegregates with blood pressure. Science 243:542-544, 1989
PubMed
18) Kurz TW, Simonet L, Kabra PM et al:Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure. J Clin Invest 85:1328-1332, 1990
 
19) Pravenec M, Simonet L, Kren V et al:The rat renin gene:assignment to chromosome 13 and linkage to the regulation of blood pressure. Genomics 9:466-472, 1991
 
20) Lindpaintner K, Takahashi S, Ganten D:Structural alterations of the renin gene in stroke-prone spontaneously hypertensive rats:examination of geno-type-phenotype correlations. J Hypertens 8:763-773, 1990
 
21) Samani NJ, Gauguier D, Vincent M et al:Analysis of quantitative trait loci for blood pressure on rat chromosomes 2 and 13. Hypertension 28:1118, 1996
PubMed
22) Alam KY, Wang Y, Dene H et al:Renin gene nucleotide sequence of coding and regulatory regions in Dahl rats. Clin Exp Hypertens 15:599-614, 1993
PubMed
23) Rapp JP, Dene H, Deng AY:Seven renin alleles in rats and their effects on blood pressure. J Hypertens 12:349-355, 1994
PubMed
24) St Lezin EM, Pravenec M, Wong AL et al:Effects of renin gene transfer on blood pressure and renin gene expression in a congenic strain of Dahl salt-resistant rats. J Clin In vest 97:522-527, 1996
 
25) Jiang J, Stec DE, Drummond H et al:Transfer of a salt-resistant renin allele raises blood pressure in Dahl salt-sensitive rats. Hypertension 29:619-627, 1997
PubMed
26) Zhang OY, Dene H, Deng AY et al:Interval mapping and congenic strains for a blood pressure QTL on rat chromosome 13. Mamm Genome 8:636-641, 1997
 
27) Hilbert P, Lindpaintner K, Beckmann JS et al:Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. Nature 353:521-529, 1991
PubMed
28) Jacob HJ, Lindpaintner K, Lincoln SE et al:Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 67:213-224, 1991
PubMed
29) Deng Y, Rapp JP:Cosegregation of blood pressure with angiotensin converting enzyme and atrial natriuretic peptide receptor genes using Dahl salt-sensitive rats. Nat Genet 1:267-272, 1992
 
30) Nara Y, Nabika T, Ikeda K et al:Blood pressure cosegregates with a microsatellite of angiotensin I converting enzyme (ACE) in F2 generation from across between original normotensive Wistar-Kyoto rat (WKY) and stroke-prone hypertensive rat (SHRSP) . Biochenz Biophys Res Commun 181:941-946, 1991
 
31) Julier C, Delepine M, Keavney B et al:Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. Hum Mol Genet 6:2077-2085, 1997
 
32) Dukhanina OI, Dene H, Deng AY. et al:Linkage map and congenic strains to localize blood pressure QTL on rat chromosome 10. Mamm Genome 8:229-235, 1997
PubMed
33) Jeunemaitre X, Soubrier F, Kotelevtsev YV et al:Molecular basis of human hypertension:role of angiotensinogen. Cell 71:169-180, 1992
PubMed
34) Lodwick D, Kaiser MA, Harris J et al:Analysis of the role of angiotensinogen in Spontaneous hypertension. Hypertension 25:1245-1251, 1995
PubMed
35) Hubner N, Kreutz R, Takahashi S et al:Unlike human hypertension, blood pressure in a hereditary hypertensive rat strain shows no linkage to the angiotensinogen locus. Hypertension 23:797-801, 1994
 
36) Deng AY, Dene H, Pravenec M et al:Genetic mapping of two new blood pressure quantitative trait loci in the rat by genotyping endothelin system genes. J Clin Invest 93:2701-2709, 1994
 
37) Hubner N, Kreutz R, Takahashi S et al:Altered angiotensinogen amino acid sequence and plasma angiotensin II levels in genetically hypertensive rats. A study on cause and effects. Hypertension 26:279-284, 1995
 
38) Deng AY, Rapp Jp:Evaluation of the angiotensin II receptor AT1B gene as a candidate gene for blood pressure. J Hypertens 12:1001-1006, 1994
PubMed
39) Koike G, Winer ES, Horiuchi M et al:Cloning, characterization, and genetic mapping of the rat type 2 angiotensin II receptor gene. Hypertension 26 (part 1):998-1002, 1995
 
40) Lu D, Raizada K, Iyer S et al:Losartan versus gene therapy:chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 30 (part 1):363-370, 1997
 
P.246 掲載の参考文献
1) Rapp JP, Wang SM, Dene H:A genetic polymorphism in the renin gene of Dahl rats cosegregates with blood pressure. Science 243:542-544, 1989
PubMed
2) Kurtz TW, Simonet L, Kabra PM et al:Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure. J Clin Invest 85:1328-1332, 1990
PubMed
3) Pravenec M, Simonet L, Kren V et al:The rat renin gene:assignment to chromosome 13 and linkage to the regulation of blood pressure. Genomics 9:466-472, 1991
 
4) Rapp JP, Dene H, Deng AY:Seven renin alleles in rats and their effects on blood pressure. J Hypertens 12:349-355, 1994
PubMed
5) Morris BJ, Griffiths LR:Frequency in hypertensives of alleles for a RFLP associated with the renin gene. Biochem Biophys Res Commun 150:219-224, 1988
PubMed
6) Naftilan AJ, Williams R, Burt D et al:A lack of genetic linkage of renin gene restriction fragment length polymorphisms with human hypertension. Hypertension 14:614-618, 1989
 
7) Soubrier F, Jeunemaitre X, Rigat B et al:Similar frequencies of renin gene restriction fragment length polymorphisms in hypertensive and normotensive subjects. Hypertension 16:712-717, 1990
PubMed
8) Chiang FT, Hsu KL, Tseng CD et al:Association of the renin gene polymorphism with essential hypertension in a Chinese population. Clin Genet 51:370-374, 1997
 
9) Villard E, Lalau JD, van Hooft IS et al:A mutant renin gene in familial elevation of prorenin. J Biol Chem 269:30307-30312, 1994
PubMed
10) Mercure C, Thibault G, Lussier Cacan S et al:Molecular analysis of human prorenin prosegment variants in vitro and in vivo. J Biol Chem 270:16355-16359, 1995
PubMed
11) Walker WG, Whelton PK, Saito H et al:Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1:287-291, 1979
PubMed
12) Jeunemaitre X, Soubrier F, Kotelevtsev YV et al:Molecular basis of human hypertension:role of angiotensinogen. Cell 71:169-180, 1992
PubMed
13) Kamitani A, Rakugi H, Higaki J et al:Association analysis of a polymorphism of the angiotensinogengene with essential hypertension in Japanese. J Hum Hypertens 8:521-524, 1994
 
14) Barley J, Blackwood A, Sagnella G et al:Angiotensinogen Met235→Thr polymorphism in a London normotensive and hypertensive black and white population. J Hum Hypertens 8:639-640, 1994
 
15) Yanai K, Nibu Y, Murakami K et al:A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. J Biol Chem 271:15981-15986, 1996
 
16) Yanai K, Saito T, Hirota K et al:Molecular variation of human angiotensinogen core promoter element located between TATA box and transcription initiation site affects its transcriptional activity. J Biol Chem 48:30558-30562 1997
PubMed
17) Sato N, Katsuya T, Rakugi H et al:Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension. Hypertension 30:321-325, 1997
PubMed
18) Inoue I, Nakajima T, Williams CS et al:A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786-1797, 1997
PubMed
19) Jeunemaitre X, Inoue I, Williams C et al:Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 60:1448-1460, 1997
PubMed
20) Katsuya T, Koike G, Yee TW et al:Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 345:1600-1603, 1995
PubMed
21) Kamitani A, Rakugi H, Higaki J et al:Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis. Hypertension 25:950-953, 1995.
PubMed
22) Ishanov A, Okamoto H, Yoneya K et al:Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 133:184-189, 1997
PubMed
23) Russ AP, Maerz W, Ruzicka V et al:Rapid detection of the hypertension-associated Met235→Thr allele of the human angiotensinogen gene. Hum Mol Genet 2:609-610, 1993
 
24) Moskowitz DW:Hypertension, thermotolerance, and the"African gene":an hypothesis. Clin Exp Hypertens 18:1-19, 1996
PubMed
25) Rigat B, Hubert C, Alhenc Gelas F et al:An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
PubMed
26) Hilbert P, Lindpaintner K, Beckmann JS et al:Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats [see comments]. Nature 353:521-529, 1991
 
27) Jacob HJ, Lindpaintner K, Lincoln SE et al:Genetic mapping of a gelle causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 67:213-224, 1991
 
28) Kreutz R, Hubner N, Ganten D et al:Genetic linkage of the ACE gene to plasma angiotensinconverting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension. Circulation 92:2381-2384, 1995
 
29) Zee RY, Lou YK, Griffiths LR et al:Association of apolymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 184:9-15, 1992
 
30) Higashimori K, Zhao Y, Higaki J et al:Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. Biochem Biophys Res Commun 191:399-404, 1993
PubMed
31) Jeunemaitre X, Lifton RP, Hunt SC et al:Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1:72-75, 1992
PubMed
32) Krege JH, Kim HS, Moyer JS et al:Angiotensinconverting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29:150-157, 1997
PubMed
33) Cambien F, Poirier O, Lecerf L et al:Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644, 1992
PubMed
34) Mattu RK, Needham EW, Galton DJ et al:A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation 91:270-274, 1995
PubMed
35) Cambien F, Costerousse O, Tiret L et al:Plasma level and gene polymorphism of angiotensinconverting enzyme in relation to myocardial infarction. Circulation 90:669-676, 1994.
PubMed
36) Tiret L, Rigat B, Visvikis S et al:Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51:197-205, 1992
PubMed
37) McKenzie CA, Julier C, Forrester T et al:Segregation and linkage analysis of serum angiotensin Iconverting enzyme levels:evidence for two quantitative-trait loci. Am J Hum Genet 57:1426-1435, 1995
PubMed
38) Villard E, Tiret L, Visvikis S et al:Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am/Hum Genet 58:1268-1278, 1996
PubMed
39) Lachurie ML, Azizi M, Guyene TT et al:Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subj ects. Circulation 91:2933-2942, 1995
PubMed
40) Cidl K, Strelcova L, Znojil V et al:Angiotensin Iconverting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Exp Hematol 24:790-794, 1996
PubMed
41) Williams TA, Villard E, Prigent Y et al:A genetic study of angiotensin I-converting enzyme levels inhuman semen. Mol Cell Endocrinol 107:215-219, 1995
 
42) Katsuya T, Horiuchi M, Chen YD et al:Relations between deletion polymorphism of the angiotensin converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia. Arterioscler Thromb Vasc Biol 15:779-782, 1995
PubMed
43) Celermajer DS, Sorensen KE, Barley J et al:Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors. A therosclerosis 111:121-126, 1994
PubMed
44) Samani NJ, Thompson JR, O:Toole L et al:A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712, 1996
 
45) Lindpaintner K, Pfeffer MA, Kreutz R et al:A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease [see comments]. N Engl J Med 332:706-711, 1995
 
46) Jeunemaitre X, Ledru F, Battaglia S et al:Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease:the CORGENE study. Hum Genet 99:66-73, 1997
PubMed
47) Agerholm Larsen B, Nordestgaard BG, Steffensen Ret al:ACE gene polymorphism; ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 951 2358-2367, 1997
 
48) Ohishi M, Fujii K, Minamino T et al:A potent risk factor for restenosis. Nature Genet 5:324-325, 1993
PubMed
49) Amant C, Bauters C, Bodart J C et al:Dallele of the angiotenin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 96:56-60, 1997
 
50) Schunkert H, Hense HW, Holmer SR et al:Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 330:1634-1638, 1994
PubMed
51) Ohishi M, Rakugi H, Ogihara T:Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 331:1097-1098, 1994
PubMed
52) Lindpaintner K, Lee M, Larson MG et al:Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med 334:1023-1028, 1996
PubMed
53) MarianAJ, Yu QT, Workman R et al:Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342:1085-1086, 1993
 
54) Raynolds MV, Bristow MR, Bush EW et al:Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated car-diomyopathy. Lancet 342:1073-1075, 1993
PubMed
55) Harden PN, Geddes C, Rowe PA et al:Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 345:1540-1542, 1995
PubMed
56) Dudley CR, Keavney B, Stratton Im et al:UK. Prospective Diabetes Study. XV:Relationship ofrenin-angiotensin system gene polymorphisms withmicroalbuminuria in NIDDM. Kidney Int 48:1907-1911, 1995
 
57) Kario K, Kanai N, Saito K et al:Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation 93:1630-1633, 1996
PubMed
58) Catto A, Carter AM, Barrett JH et al:Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Strolee 27:435-440, 1996
PubMed
59) Odawara M, Matsunuma A, Yamashita K:A pitfall in the association study of ACE gene polymorphism. Diabetes Care 19:543-544, 1996
 
60) Schachter F, Faure Delanef L, Guenot F et al.:Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6:29-32, 1994
PubMed
61) Gemmill RM, and Drabkin HA; Report of the Second International Workshop on Human Chromosome 3 mapping. Cytogenet Cell Genet 57:162-166, 1991
PubMed
62) Rolfs A, Weber RI, Regitz ZV et al:Genetic polymorphisms of the angiotensin II type 1 (AT1) receptor gene. Eur Heart J 15:108-112, 1994
 
63) Bonnardeaux A, Davies E, Jeunemaitre X et al:Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24:63-69, 1994
PubMed
64) Wang WY, Zee RY, Morris BJ:Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Clin Genet 51:31-34, 1997
PubMed
65) Benetos A, Topouchian J, Ricard S et al:Influence of angiotensin II type 1 receptor polymorphism onaortic stiffness in never-treated hypertensive patients. Hypertension 26:44-47, 1995
PubMed
66) Deng AY, Rapp JP:Evaluation of the angiotensin II receptor AT1B gene as a candidate gene for blood pressure. J Hypertens 12:1001-1006, 1994
PubMed
67) Dubay C, Vincent M, Samani NJ et al:Genetic determinants of diastolic and pulse pressure map to different loci in Lyon hypertensive rats. Nat Genet 3:354-357, 1993
PubMed
68) Amant C, Hamon M, Bauters C et al:The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction. J Am Coll Cardiol 29:486-490, 1997
PubMed
69) Takami S, Katsuya T, Rakugi H et al:Angiotensin II gene polymorphism is associated with increase of left vebtricular mass but not with hypertension. Am J Hypertens 11:316-321, 1998.
 
70) Haywood GA, Gullestad L, Katsuya T et al:AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 95:1201-1206, 1997
PubMed
71) Katsuya T, Horiuchi M, Minami S et al:Genomic organization and polymorphism of human angiotensin II type 2 receptor:no evidence for its gene mutation in two families of human premature ovarian failure syndrome. Mol Cell Endocrinol 127:221-228, 1997
PubMed
72) Ichiki T, Labosky PA, Shiota C et al:Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748-750, 1995
PubMed
P.256 掲載の参考文献
1) Saruta T, Kondo K:Endocrine factors in essential hypertension. Jpn J Med 21:152-154, 1982
PubMed
2) Julius S:Interaction between renin and the autonomic nervous system in hypertension. Am Heart J 116:611-616, 1988
PubMed
3) Johnson JA, Davis JO, Witty RT:Effects of catecholamines and renal nerve stimulation on renin release in the monfiltering kidney. Cir Res 29:646-653, 1971
 
4) Tuck ML, Stern T et al:AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 95:1201-1206, 1997
 
5) Dzau V J:Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 (Suppl 1) S1-S4-S1-S13, 1988
 
6) Lyall F, Dornan ES, McQueen J et al:Angiotensin II increases protooncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensinII AT1 receptor. J Hypertens 10:1463-1469, 1992
 
7) Hollenberg NK:Abnormal renal sodium handling in essential hypertension. Am J Med 81:412-418, 198
 
8) Kawabe H, Furukawa T, Takenaka T et al:Importance of the renin-angiotensin system in sodium regulation in essential hypertension. Am J Hypertens 4:119-125, 1991
PubMed
9) 奥野哲二, 猿田享男, 近藤和興ほか:高血圧自然発症 rat (SHR) の高血圧発症における脳内 renin-angiotensin 系の役割. 高血圧 6:1, 1993
 
10) Fink GD, Bruner CA, Mangiapane ML:Area postrema is critical for angiotensin-induced hypertension in rats. Hypertension 9:355-361, 1987
PubMed
11) Finkielman S, Fiscker-Ferraro C, Diaz A et al:A pressor substance in the cerebrospinal fluid of normotensive and hypertensive patients. Proc Nat Acad Sci USA 69:3341-3344, 1972
 
12) 大西俊正, 藤島智, 田中一男ほか:高血圧 1:42, 1978
 
13) Jeunemaitre X, Soubrier F, Kotelevtsev YV et al:Molecular basis of human hypertension:Role of angiotensinogen. Cell 71:169-180, 1992
PubMed
14) Ward K, Hata, A, Jeunemaitre X et al:A molecular variant of angiotensinogen associatel with preeclampsia. Natzare Genetics 4:59-61, 1993
PubMed
15) Rigat B, Hubert C, Alhenc-Gelas F et al:An insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86; 1343-1346, 1990
PubMed
16) Cambien F, Poirier, O, Lecerf L et al:Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644, 1992
PubMed
17) Bonnardeaux A, Davies E, Jeunemaitre X et al:AngiotensinII type1 receptor gene polymorphisms in human essential hypertension. Hypertension 24:63-69, 1994
 
P.268 掲載の参考文献
1) Robertson P, Klidjian P, Harding L:Hypertension due to a renin-secreting renal tumor. Am J Med 43:963-966, 1967
 
2) Anderson P, Macaulay L, Do Y:Extrarenal renin-secreting tumors:Insights into hypertension and ovarian renin porduction. Medicine (Baltimor) 68:257-268, 1989
 
3) Baruch D, Corvol P, Alphence-Gelas F:Diagnosis and treatment of renin-secreting tumors. Report of three cases. Hypertension 6:760-766, 1984
 
4) Corvol P, Pinet F, Galen F et al:Seven lessons from seven renin secreting tumors. Kidney Int 34:S38-S44, 1988
 
5) Ram C:Renovascular hypertension. Curr Opin Nephrol Hypertens 6:575-579, 1997
PubMed
6) Harris R:The macular densa:recent developments. J Hypertens. 14:815-822, 1996
 
7) Briggs J, Schnermann J:Whys and wherefores of juxtaglomerular apparatus function. Kidney Int 49:1724-1726, 1996
PubMed
8) Ichihara A, Suzuki H, Murakami M et al:Interactions between angiotensin II and norepinephrine on renin release by juxtaglomerular cells. Eur J Endocrinol 133:569-577, 1995
PubMed
9) Abboud F:Personal communication. 1998
PubMed
10) Reid L, Chiu Y:Nitric oxide and the control of renin secretion:Fundam Clin Pharmacol 9:309-323, 1995
 
11) Hall J, Guyton A, Brands M:Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In:Hypertension:Pathophysiology Diagnosi, and Management Vol. Vol. 1.ed by BM Brenner Laragh JH, Brenner BM, Raven Press, New York, 1995, pp. 1451-1475
 
12) Geyskes G, Oei H, Puylaert C:Renovasuclar hypertension identified by captopril-induced changes in the renogram. Hypertension 9:451-456, 1987
PubMed
13) Yu S, Withworth J, Kincaid-Smith P:Malignant hypertension:etiology and outcome. Clin Exp Hyertens 8:1211-1230, 1986
 
14) Kincaid-Smith P:Malignant hypertension:Mechanisms and management. Pharmac Ther 9:245-269, 1980
 
15) Consortium TiPKD:Polycystic kidney disease:The complete structure of the PKDI gene and its protein. Cell 81:289-198, 1995
 
16) Parfrey P, Barrett B:Hypertension in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens 4:460-464, 1995
PubMed
17) Chapman A, Johnson A, Gabow P at el:The renin-angiotensin-aldosterone system and autosmal dominant polycystic kidney disease. N Engl J med 323:1091-1096, 1990
 
18) Chapman A, Gabow P, Schrier R:Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease. Ann Intern Med 115:769-773, 1991
PubMed
19) Shimkets R, Warnock D, Bositis C et al:Liddle's syndrome:Heritable human hypertension caused by mutations in the b subunit of the epihtelial sodium channel. Cell 79:407-414, 1994
 
20) Gordon R:Heterogeneous hypertension. Nature Genet 11:6-9, 1995
PubMed
21) Lifton P:Genetic determinants of human hypertension. Proc Natl Acad Sci USA 92:8545-8551, 1995
 
22) Edwards C, Stewart P, Burt D et al:Localization of 11 beta-hydroxysteroid dehydrogenase:tissue specific protector of the mineralocorticoid receptor. Lancet (ii):986-989, 1988
 
23) Ulick S, Levine L, Gunczler P et al:A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortiso. J Clin Endocrinol Metab 49:757-764, 1979
 
24) Mune T, Rogerson F, Nikkita H et al:Human hypertension caused by mutations in the kidney of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 10:394-399, 1995
 
25) Mune T, White P:Apparent mineralocorticoid excess:genotype is correlated with biochemical phenotype. Hypertension 27 1193-1199, 1996
PubMed
26) Epstein M, Espiner E, Donald R et al:Liquorice toxicity and the renin-angiotensin axis in man. Br Med J 1:209-213, 1977
PubMed
27) Stewart P, Wallace A, Valentino R et al:Mineralocorticoid activity of liquorice:11 beta-hydroxyteroid dehydrogenase deficiency comes of age. Lancet (II):821-824, 1987
 
28) Lifton RP, Dluhy RG, Powcrs M et al.:Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 2:66-74, 1992
 
29) Gordon R:Primary aldosteronism. J Endocrinol Invest 18:495-511, 1995
PubMed
30) Saruta T:Mechanism of glucocorticoid-induced hypertension. Hypertens, Res 7:1-8, 1996
 
31) Saruta T, Suzuki H, Handa M et al:Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 62:275-279, 1986
 
32) Shibata H, Suzuki H, Maruyama T et al:Gene expression of angiotensin II receptor in blood cells of Cushing's syndrome. Hypertension 26:1003-1010, 1997
 
33) Sato A, Suzuki H, Murakami M et al:Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 23:25-30, 1994
PubMed
34) Hall J, Guyton A, Brands M:Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In:Hypertension:Pathophysiology, Diagnosis and Management. Vol 1. 2. ed y Laragh JHB, Brenner BM, Raven Press New York,:1995, 1451-1475, 1995
 
35) Mitchell K, Navar G:Intrarenal actions of angiotensin II in the pathogenesis of experimental hypertension. In:Hypertension:. Pathophysiology Diagnosis and Management. Vol. 2, Laragh JH, Brenner BM:Raven Press, New York. 1995, pp-1437-1449
 
36) Brenner BM, Meyer T, Hostetter T:Dietary protein intake and the progressive nature of kidney disease:the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
PubMed
37) Maschio G, Alberti D, Janin G et al:Effect of the angiotensin converting-enzyme inhibitor benaze pril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
 
38) Kasiske B, Kalil R, Ma J et al:Effect of antihypertensive therapy on the kidney in pateints with diabetes:ameta-regression analysis. Ann Intern Med 118:129-138. 1993
 
39) Schmidt S, Ritz E:Genetics of the renin-angiotensin system and renal disease:a progress report. Curr Opin Nephrol Hypertens 6:146-151, 1997
PubMed
40) Ishigami T, Umemura S, Tamura K et al:Essential hypertension and 5:upstream core promoter region of human angiotensinogen gene. Hypertension 30:1325-1350, 1997
PubMed
41) Sato N, Katsuya T, Rakugi H et al:Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese, Hypertension. 30:321-325, 1997
PubMed
42) Chapmann P, Van Zyl P:Successful use of captopril in the treatment of scleroderm renal crisis. Clin Ne hrol 26:106-108, 1986
 
P.277 掲載の参考文献
1) Urata H, Boehm KD, Phillip A et al:Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart J Clin Invest 91:1269-1281, 1993
 
2) Yamazaki T, Komuro I, Kudoh S et al:Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J Clin Invest 96:438-446, 1995
PubMed
3) Booz GW, Baker KM:Role of type 1 and type 2 angitotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 28:635-640, 1996
 
4) Brilla CG, Janicki JS, Weber KT:Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 83:1771-1779, 1991.
PubMed
5) Motz W, Strauer BE:Left ventricular function and collagen content after regression of hypertensive hypertrophy. Hypertension 13:43-56, 1989
PubMed
6) Brilla CG, Matsutara LS, Weber KT:Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Moll Cell Cardiol 251563-575, 1993
 
7) Diez J, Laviades C, Mayor G et al:Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 91:1450-1456, 1995
PubMed
8) Kerins DM, Hao Q, Vaughan DE:Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin In vest 96:2515-2520, 1995.
 
9) Rajagopalan S, Kurz S, Munzel T et al:Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vascular tone. J Clin Jn vest 97:1916-1923, 1996.
 
10) John Manucini GB, Henry GC, Macaya C et al:Angiotensin-converting enzyme inhibition with quinapril irnproves endothelial vasolnotor dysfunction in patients with coronary artery disease:the TREND (Trial on Revesing ENdothelial Dysfunction) Study. Circulation 94:258-265, 1996
 
11) Schwartzcopff B, Mortz W, Frenzel H et al:Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 88:993-1003, 1993
 
12) Anand IS, Ferrari R, Kalra GS et al:Edema of cardiac origin. Circulation 80:299-305, 1989
 
13) Dzau VJ, Colucci WS, Hollenberg NK et al:Relation of renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63:645-651, 1981
 
14) Bertram P, Robert S, Felipe A, Martinez et al:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752, 1997
 
P.286 掲載の参考文献
1) Urata H, Bernadine H, Robert W S et al:Angiotensin II-forming pathway in normal and failing human heart. Circ Res 66:883-890, 1990
 
2) Murakami M, Matsuda H, Hayashi K et al:Effects of angiotensin II generated by an ACE-independent pathway on renal hemodynamics. 29th annual meeting of American Society of Nephrology, 1996 J Anz Soc Nephrol 7:1585, 1996
 
3) Hirakata M, Kaname S, Chung UG et al:Tyrosine kinase dependent expression of TGF beta induced by stretch in mesangial cells. Kidney Int. 51:1028, 1997
PubMed
4) Qing LI, Muragaki Y, Ueno H et al:Stretch-induced proliferation of cultured vascular smooth muscle cells and a possible involvement of local renin-angiotensin system and platelet-derived growth factor (PDGF). Hypertens Res 20:217, 1997
 
5) Wolf G, Haberstroh U, Neilson EG:Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 95:107-140, 1992
 
6) Itoh H, Mukoyama M, Pratt RE:Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91:2268-2274, 1993
PubMed
7) Kagami S, Border WA, Miller DE, et al:Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
 
8) Baricos WH, Cortez SL, EL Dahr SS et al:ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47:1039-1047, 1995
PubMed
9) Wu LL, Cox A, Roe CJ et al:Transforming growth factor-β1 an renal injury following subtotal nephreoctomy in the rat:role of the renin-angiotensin system. Kidney Int 51:1553-1567, 1997
 
10) Fujiwara K, Hayashi K, Kanno Y et al:Renal protective effects of efonidipine hydrochloride in subtotally nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens, 1997, in press
 
11) Shihab FS, Bennett WM, Tanner AM et al:Anglotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52:660-673, 1997
 
12) Choi KC, Kim NH, An MR et al:Alterations of intrarenal renin-angiotensin and nitric oxide system in streptozotocin-induced diabetic rats. Kidney Int 52 (Suppl. 60):S7-S11, 1997
 
13) Taguma Y et al:Effect of captopril on heavy proteinuria in azotemic diabetes. New Engl J Med 313:1617, 1985
PubMed
14) Lewis EJ et al:The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. New Engl J Med 329:1456, 1993
PubMed
15) Maschio G et al:Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. New Engl J Med 334:939, 1996
PubMed
16) The GISEN Group:Randomized placebo-controlled trial of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857, 1997
PubMed
17) Okada H, Suzuki H, Kanno Y et al:Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 26:564-569, 1995
PubMed
P.292 掲載の参考文献
1) Swales JD:Molecular biology and biochemistry of the renin-angiotensin system. In:Textboofe Of Hypertension. Blackwell Scientific Publications, Oxford, 1994, pp. 214-232
 
2) Levy M:Pathophysiology of ascites formation. The kidney in liver disease. Williams & Wilkins, Baltimore, 1988, pp. 209-237
 
3) Brunkhorst R, Wrenger E, Malcharzik C et al:Renal effects of atrial natriuretic peptide in cirrhotic rats with and without captopril pretreatment. Nephron 64:275-281, 1993
PubMed
4) Badalamenti S, Graziani G, Salerno F et al:Hepatorenal syndrome. New perspectives in pathogenesis and treatment. Arch Intern Medicine 153:1957-1967, 1993
 
5) Moore K, Wendon J, Frazer M et al:Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327:1774-1778, 1992
PubMed
6) Matsumoto A, Ogura K, Hirata Y et al:Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 123:110-113, 1995
PubMed
7) Ishizuka H, Konno K, Naganuma H et al:Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR)
PubMed
P.296 掲載の参考文献
1) Christlieb A R:Plasma renin activity and hypertension Diabetes 25:969-974, 1976
PubMed
2) Tuck M Sambhi P, Levin L:Hypoeninemic hypoaldosteronism in diabetes mellitus:studies of the autonomic nervous system:s control of renin release. Diabetes 28:237-241, 1979
 
3) Christlieb AR, Munichoodappa C, Braaten JT:Decreased response of plasma renin activity to orthostatic hypotension. Diabetes 23:835-840, 1974
PubMed
4) KatayamaS Lee JB:Hypertension in experimental diabetes mellitus. Renin-prostaglandin interaction. Hypertension 7:554-561, 1985
PubMed
5) Brands MW, Harrison DL, Keen HL et al:Insulin-induced hypertension in rats depends on an intact renin-angiotensin system. Hypertension 29:1014-1019, 1997
 
6) DeLevia A, Christlieb AR, Melby JC et al:Big renin and biosynthetic defect of aldosterone in diabetes mellitus. N Engl J Med 295:639-643, 1976
PubMed
7) Luetscher JA, Kraemer FB, Wilson DM et al:Increased plasma inactive renin in diabetes mellitus. N Engl J Med 312:1412-1427, 1985
PubMed
8) Toop MJ, Dallinger KJC, Jennings PE et al:Angiotensin-converting enzyme (ACE):relationship to insulin-dependent diabetes and microangiopathy. Diabetic Med 3:455-457, 1986
 
9) Sechi LA, Griffin CA, Schambelan M:The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 43:1180-1184, 1994
PubMed
10) Jaffa AA, Rust PF, Mayfield RK:Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes 44:156-160, 1995
PubMed
11) Komers R, Cooper M:Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration:role of kinins. Am J Physiol 268:F588-F594, 1995
PubMed
12) Vora JP, OyamaT, Thompson MM et al:Interactions of the kallikrein-kinin and renin-angiotensin system in experimental diabetes. Diabetes 46:107-112, 1997
 
13) Anderson S, Jung FF, Ingelfinger JR:Renal reninangiotensin system in diabetes:functional, immunohistochemical and molecular biological correlations. Am J Physiol 265:F477-F486, 1993
PubMed
14) Lewis EJ, Hunsicker G, Bain RP et al:The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
 
15) Marre M, Bernadet P, Gallois Y et al:Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
PubMed
16) Tamow L, Cambien F, Rossing P et al:Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and dibetic nephropathy and prolife rative retinopathy in IDDM patients. Diabetes 44;489-494, 1995
 
17) Marre M, Jeunemaitre X, Gallois Y et al:Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest. 99:1585-1595, 1997
 
18) Mizuiri S, Hemmi H, Inoue A et al:Angiotensinconverting enzyme polymorphism and development of diabetic nephropathy in non-insulin-dependent diabetes mellitus. Nephron 70:455-459, 1995
PubMed
19) Ohno T, Kawazu S, Tomono S:Association of the polymorphism of the angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism 45:218-222, 1996
PubMed
20) Yoshida H, Kuriyama S, Atsumi Y et al:Angiotensin I converting enzyme gene polymorphism in non-insulin-dependent diabetes mellitus. Kidney Int 50:657-664, 1996
PubMed
21) Parving HH Jacobson P, Tamow L et al:Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme:observational follow up study. Br Med J 313:591-594, 1996
 
22) Forgaty DG, Harron JC, Hughes AE et al:The association of an angiotensinogen gene variant with diabetic nephropathy (Abstract) . J Am Soc Nephrol 6:449, 1995
 
23) Doria A, Onuma T, Gearin G et al:Angiotensinogen polymorphism M235T, hypertension and nephropathy in insulindependent diabetes. Hypertension 27:1134-1139, 1996.
PubMed
24) Tamow L, Cambien F, Rossing P et al:Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Diabetes 45:367-369, 1996
 
25) Tamow L, Cambien F, Rossing P et al:Angiotensin type 1receptor genepolymorphism and diabetic microangiopathy. Nephrol Dial Transplant 11:1019-1023, 1996
 
P.302 掲載の参考文献
1) Bartter FC, Pronove P, Gill JR et al:Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med 33:811-828. 1962
PubMed
2) Gitelman HJ, Graham JB, Welt LG:A new familiar disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Phys 79:221-235, 1966
 
3) Stein JH:The pathogenetic spectrum of Bartter's syndrome. Kidney Int 28:85-93, 1985
PubMed
4) Gill JR, Bartter FC:Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Hnle as a proximal cause of Bartter's syndrome. Am J Med 65:766-772, 1978
 
5) Bettinelli A, Bianchetti MG, Girardin E et al:Use of calcium excretion values to distinguish two forms of primary renal kalosis:Bartter and Pedeatr 120:38-43, 1992
PubMed
6) Bettinelli A, Bianchetti MG, Borella P et al:Genetic heterogeneity in tubular hypomagnesemia-hypokalemia with hypocalcuris. Kidney Int 47:547-551, 1995
PubMed
7) Simon DB, Nelson-Williams C, Bia MJ et al:GItelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nature Genet 12:24-30, 1996
 
8) Simon DB, Karet FE, Hamdan JM et al:Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nature Genet 13183-188, 1996
 
9) Simon DB, Karet FE, Rodriguez-Soriano J et al:Genetic heterogeneity of Bartter's syndrome revealed by mutatiions in the K+channel, ROMK. Nature Genet 14:152-156, 1996
 
10) Simon DB, Bindra RS, Mansfield TA et al:Mutation in the chloride channel gene, CLCNKB, cause Bartter's syndrome typeIII. Nature Genet 17:171-178, 1997
 
11) International Collaborative Study Group for Bartterlike Syndromes:Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome:evidence for genetic heterogeneity. Hum Mol Genet 6:17-26, 1997
 
12) Mastroianni N, Bettinelli A, Bianchetti M et al:Novel molecular variants of the Na-Cl cotransporter gene are responsible for Gitelman syndrome. Am J Hum Genet 59:1019-1026, 1996
PubMed
13) Goodman AD, Vabnucci AH, Hartroft PM:Pathogenesis of Bartter's syndrome. N Engl J Med 129:1435-1439, 1969
 
14) Fujita T, Sakaguchi H, Shibagaki M et al:The pathogenesis of Bartter's syndrome. Am J Med 63:467-474, 1977
PubMed
15) White MG:Bartter's syndrome. Arch Intrern Med 129:41-47, 1972
PubMed
16) Fichman MP, Telfer N, Zia P et al:Role of prostaglandins in the pathogenesis of Bartter's syndrome. Am J Med 60:785-797, 1976
PubMed
17) Fuj ita T, Ando K, Sato Y et al:Independent roles of prostaglandin and the renin-angiotensin system in abnormal vascular reactivity in Bartter's syndrome. Am J Med 73:71-76, 1982
 
18) Calo L, D:Angelo A, Cantaro S et al:Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. Nephron 72:570-573, 1996
PubMed
19) Calo LD et al:Increased urinary NO2-/NO3-and cyclic guanosine monophosphate levels in patients with Bartter's syndrome:relationship to vascular reactivity. Am J Kidney:Dis 27:784-789, 1996
 
20) Yoshida H, Kakuchi J, Yoshikawa N et al:Angiotensin II typel receptor gene abnormality in a patient with Bartter's syndrome. Kidney Int 46:1505-1509, 1994
 
P.308 掲載の参考文献
1) Gordon R, Doran F, Thomas M et al:Solitary kidney and ageing as causes of low renin and aldosterone concentrations:relevance to "lowrenin" essential hypertension. Clin Sci Mol Med 3:S177-S180, 1976
 
2) Bauer JH, Brooks CS:Volume studies in men with mild to moderate hypertension. Am J Cardiol 44:1163-1170, 1979
PubMed
3) Beretta-Piccoli C, Weidemalm P:Circulatory volume in essential hypertension. Relationship with age, blood pressure, exchangeable sodium, aldosterone and catecholamines. Miner Electrolyte Metab 10:292-300, 1984
PubMed
4) de Wardener HE, MacGregor GA:Dahl's hypothesis that a saluretic substance may be responsible role for a sustained rise in arterial pressure:Its possible role in essential hypertension. Kidney Int 18:1-9, 1980
 
5) Ishibashi K, Oshima T, Matsuura H et al:Effects of age and sex on sodium chloride sensitivity:association with plasma renin activity. Clin Nephrol 42:376-380, 1994
PubMed
6) Oshima T, Matsuura H, Kido K et al:Intralymphocytic sodium and free calcium concentration in relation to salt sensitivity in patients with essential hypertension. Jpn Circ J 51:1184-1190, 1987
PubMed
7) Matsuura H, Shingu, T, Inoue I et al:Significance of intracellular cations and calcium-regulating hormones on salt sensitvity in patients with essential hypertension. Contrib Nephrol 90:11-18, 1991
 
8) Guyton AC:Kidneys and fluids in pressure regulation. Small volume but large pressure change. Hypertension 19:12-18, 1992
 
9) Shoback DM, Williams, GH, Moore TJ et al:Defect in sodium-mediated tissue responsiveness to angiotensin II in essential hypertension. J. Clin Invest 72:2115-2124, 1983
 
10) Ozono R, Matsuura H, Oshima T et al:Modulation of target tissue response to angiotensin II and sodium sensitivity in Japanese patients with essential hypertension. Hypertens Res 19:141-145, 1996
 
P.315 掲載の参考文献
1) Tigerstedt R, Bergman PG:Niere und Kreislauf. Skand Arch Physiol 8:223-270, 1898
 
2) Bright R:Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hosp Rep 1:388, 1836
 
3) 塩之入洋, 南澤康介, 植田真一郎ほか:高血圧診断と治療シリーズ-その9, レニン・アンジオテンシン系-. 横浜医学48:697-702, 1997
 
4) Goldblatt H, Lynch J, HanzaI RE et al:Studies on experimantal hypertention. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59:347, 1934
 
5) Young HH, Hugh Young.:A surgeon:s autobiography. New York, Harcourt, Brace and Co., 1940, p. 193
 
6) Page I H, Helmer OM:A crystalline pressor substance, angiotonin, resulting from the reaction between renin and reninactivator. J Exp Med 71:29-42, 1940 (Proc Soc Clin Invest 12:17, 1939)
 
7) Braun-Menendez E, Fasciolo JC, Leloir IF et al.:The substance causing renal hypertension. J Physiol 98:283-298, 1940 (La substancia hypertensora de la sangre del rinon isquemiado. Rev Soc Argent Biol 15:420-425, 1939.)
 
8) Skeggs, LTJr, Marsh WH, Kahn Jr et al:The existence of two forms of hypertension. J Exp Med 99:275-282, 1954 (The purification of hypertension I. Exp Med 100:363-370, 1954)
 
9) Braun-Menendez E, and Page IH:Suggested revision of nomenclature-angiotellsin. Science 127:242, 1958
PubMed
10) Skeggs LTJr, Kahn JR, Shumway NP:The preparation and function of hypertension converting enzyme. J Exp Med 103:259-299, 1956.
 
11) Yang HYT, Erdos EG, Levin Y:A dipeptidyi carboxypeptidase that converts angiotensin land inactivates bradykinin. Biochem Biophys Acta 214:374-376, 1970.
 
12) Soubrier F, Alhenc-Gelas F, Hubert C et al:Two putative centers in human angiotension-converting enzyme revealed by molecular cloning. 1) roc Natl Acad Sci USA 185:9386-9390, 1988
 
13) Cushman D, Cheung H, Sabo E et al:Design of potent competitive inhibitors of angiotensinconverting enzyme carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16:15484-5491, 1977
 
14) Timmermans PBMWN, Wong P C, Chiu A T. et al.:Angiotensin II and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251, 1993
PubMed
15) Inagami T:Recent progress in molecular and cell biological studies of angiotensin receptors. Curr Opin Nephro Hypertens 4:47-54, 1995
 
16) 塩之入洋, 成瀬雅彦, . 高崎泉:ACE阻害薬の分類と作用機序. 医学のあゆみ 174:753-760, 1995
Medical*Online
17) 塩之入洋, 植田真一郎, 高崎泉ほか:アンジオテンシンII受容体拮抗薬はACE阻害薬を凌ぐか? Medical Practice 14:77-88, 1997
Medical*Online
18) 塩之入洋, 高崎泉:高血圧診断と治療シリーズ-その 3, 高血圧の診断と二次性高血圧の手掛かり-横浜医学 48:317-320, 1997
 
19) Shionoiri H, Eggena P, Barrett JD et al:An increase in high-molecular weight renin substrate associated with estrogenic hypertension. Biochem Med 29:14-22, 1983
PubMed
20) Shionoiri H, Takasaki I, Ishikawa Y et al:Measurement of plasma active renin by solid phase radioimmunoassay using monoclonal antibodies. Am J Med Sci 300:138-143, 1990
PubMed
21) Sugimoto K, Shionoiri H, Minamisawa K et al:Measurement of plasma total renin by the antihuman renin monoclonal antibodies. Am Med Sci 302:342-346, 1991
PubMed
22) Shionoiri H, Hirawa N, Ueda S et al:Renin gene expression in the adrenal and kidney of patients with primary aldosterromism. J Clin Endocrinol Metab 74:103-107, 1992
PubMed
P.322 掲載の参考文献
1) Ishigami T, Umemura S, Iwamoto T et al:Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. Circulation 91:951-954, 1995
PubMed
2) Gordon MS, Chin WW, Shupnik MA:Regulation of angiotensinogen gene expression by estrogen. J Hypertens 10:361-366, 1992
PubMed
3) August P, Lenz T, Ales KI et al:Longitudinal study of the renin-angiotensin-aldosterone in hypertensive pregnant women:Deviations related to the development of superimposed preeclampsia. Am J Obstet Gynecol 163:1612-1621, 1990
 
4) Wilson M, Morganti AA, Zervoudakis I et al:Blood pressure, the renin-aldosterone system and sex steroid throughout normal pregnancy. Am J Med 68:97-104, 1980
PubMed
5) Hanssens M, Keirse MJ, Spitz B et al:Angiotensin II levels in hypertensive and normotensive pregnancies. Br J Obstet Gynaecol 98:155, 1991
PubMed
6) Weir RJ, Brown JJ, Fraser R et al:Plasma renin, renin substrate, angiotensin II and aldosterone in hypertensive disease of pregnancy. Lancet i:291-294, 1973
PubMed
7) Bay WH, Ferris TF:Factors controlling plasma renin and aldosterone during Pregnancy. Hypertension 1:410-415, 1979
PubMed
8) Warren AY, Craven DS, Symonds EM:Production of active and inactive renin by cultured explants from the human female genital tract. Br. J Obstet Gynaecol 89:628-632, 1982
 
9) Poisner AM, Wood GW, Poisner R et al:Renin and inactive renin in human amnion at term pregnancy. Proc Soc Exp Biol Med 169:4-6, 1982
PubMed
10) Derkx FH, Alberda AT, de Jung FH et al:Source of plasma prorenin in early and late pregnancy:Observation in a patient with primary ovarian failure. J Clin Endocrinol Metab 65:349-354, 1987
 
11) Stevens KJ, Paintin DB, Few JD:Aldosterne is secreted intermittently during Pregnancy. Br J Obstet Gynecol 96:80-87, 1989
 
12) Brown RD, Strott CA, Liddle GW:Plasma deoxycorticosterone in normal and abnormal pregnancy. J Clin Endocrinol Metab 35:736-742, 1972
PubMed
13) Winkel CA, Milewitch L, Parker CR et al:Conversion of plasma progesterone to deoxycorticosterone in men, nonpregnant and pregnant women, and adrenalectomized subjects. J Clin Invest 66:803-812, 1980
 
14) Chesley LC, Wynn RM, Silverman NI:Renal effects of angiotensin II infusions in normotensive preg nant and non pregnant women. Circ Res 13:232-238, 1963
 
15) Brown MA, Sinosich MJ, Saunders DM et al:Potassium regulation and progesterone-aldosterone interrelationships. Am J Obstet Gynecol 155:349-353, 1986
PubMed
16) Abdul-Karim R, Assali NS:Pressor response to angiotensin in pregnant and non-pregnant women. Am J Obstet Gynecol 82:246-251, 1961
 
17) Lumbers ER:Peripheral vascular reactivity to angiotensin and noradrenaline in pregnant and non-pregnant women. Aust J Exp Biol Med Sci 48:493-500, 1970
PubMed
18) Matsuura S, Naden RP, Gant NFJr et al:Effect of volume expression on pressor responses to angiotensin II in pregnant ewes. Am J Physiol 240:H908-H913, 1981
 
19) Rosenfeld CR, Naden RP:Uterine and nonuterine vascular responses to angiotensin II in ovine pregnancy. Am J Physiol 257:H17-H24, 1989
PubMed
20) Assali NS, Brinkmann CRIII:Disorders of maternal circulatory and respiratory adjustments. In:Pathophysiology Of gestational disorders, vol 1. ed by Assali NS, Academic Press, New York, 1972
 
21) Ferris TF, Gorden P:Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 44:359-365, 1968
 
22) Franklin GO, Dowd AJ, Caldwell BV et al:The effect of angiotensin II intravenous infusion on plasma renin activity and prostaglandins A, E, and Flevels in the uterine vein of the pregnant monkey. Prostaglandins 6:271-280, 1974
 
23) Gant NF, Daley GL, Chand S et al:A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 52:2682-2689, 1973
PubMed
24) Baker PN, and Pipkin BF, Symonds EM:Comparative study of platelet angiotensin II binding and the angiotensin II sensitivity test as predictors of pregnancy-induced hypertension. Clin Sci 83:89-95, 1992
 
25) Common complications of pregnancy In:Appleton and Lange, Norwalk, CT, 20th ed. by Williams Obstetrics, Cunningham FG, MacDonald PC, Gant NF et al. 1997, pp. 693-774
 
26) Gavras H, Brunner HR, Laragh JH:Renin and aldosterone and the pathogenesis of hypertensive vascular damage. Prog Cardiovasc Dis 17:39-49, 1974
PubMed
27) Mckay DG:Disseminated Intravascular Coagulation. New York, Harper & Row, 1965
 
28) Raab W, Schroeder G, Wagner R et al:Vascular reactivity and electrolytes in normal and toxemic pregnancy. J Clin Endocrinol 16:1196-1216, 1956
 
29) Talledo OE, Chesley LC, Zuspan FP:Angiotensin and norepinephrine infusions during Pregnancy:Alterations in plasma epinephrine (E) and norepinephrine (NE) . J Clin Endocrinol Metab 33:929-933, 1971
 
30) Gant NF, Chand S, Worley RJ et al:A clinical test useful for predicting the development of acute hypertension in pregnancy. Am J Obstet Gynecol 120:1-7, 1974
PubMed
31) O'Brien WR Predicting preeclampsia. Obstet Gynecol 76:445-452 1990
 
32) Inoue I, Rohrwasser A, Helin C et al:A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system. J Biol Chem 270:11430-11436, 1995
 
33) Gant NF, Jimenez JM, Whalley PJ et al:A prospective study of angiotensin II pressor responsiveness in pregnancies complicated by chronic essential hypertension. Am J Obstet Gynecol 127:369-375, 1977
PubMed
34) Matsumoto T, Sagawa N, Mukoyama M et al:Type 2 angiotensin II receptor is expressed in human myometrium and uterine leiomyoma and is down-regulated during pregnancy. J Clin Endocrinol Metab 81:4366-4372, 1996
PubMed
35) MacKanjee HR, Shaul PW, Magness RR et al:Angiotensin II vascular smooth-muscle receptors are not down-regulated in near-term pregnant sheep. Am J Obstet Gynecol 165:1641-1648, 1991
 
36) Magness RR, Cox K, Rosenfeld CR et al:Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. Am J Obstet Gynecol 171:668-679, 1994
PubMed
37) Cunningham FG, Fernandez CO, Hernandez C:Blindness associated with preeclampsia and eclampsia. Am J Obstet Gynecol 172:1291-1298, 1995
PubMed
38) Everett RB, Worley RJ, MacDonald PC et al:Effect of prostaglandin synthetase inhibitors on pressor response to angiotensin II in human pregnancy. J Clin Endocrinol Metab 46:1007-1010, 1978
PubMed
39) Walsh SW:Preeclampsia:An imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol 152:335-340, 1985
PubMed
40) Spitz B, Magness RR, Cox SM et al:Low-dose aspirin, 1. Effect on angiotensin II pressor responses and blood prostaglandin concentrations in pregnant women sensitive to angiotensin II. Am J Obstet Gynecol 159:1035-1043, 1988
PubMed
41) Editorial:Are ACE inhibitors safe in pregnancy? Lancet ii:482-483, 482-483, 1989
 
42) Kreft Jais C, Plouin PF, Tchobroutsky C et al:Angiotensin-converting enzyme inhibitors during pregnancy:A survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol 95:420-422, 1988
PubMed
43) Aiko A, Itoh M, Okamura H et al:Effect of a low calcium intake on the vascular sensitivity to angiotensin II in normotensivepregnant rats. Artery 19:199-210, 1992
 
P.330 掲載の参考文献
1) Ondetti MA, Rubin B, Cushman DW:Design of specific inhibitors of angiotensin converting enzyme:new class of orally active antihypertensive agents. Science 196:441-444, 1977
PubMed
2) Deodhar SD, Haas E, Goldblatt H:Production of antirenin to homologous renin and its effect on experimental renal hypertension. J Exp Med 119:425-432, 1964
PubMed
3) Dzau VJ, Kopelman RI, Barger AC et al:Reninspecific antibody for study of cardiovascular homeostasis. Science 207:1091-1093, 1980
PubMed
4) Wood JM, Heusser C, Gulati N et al:monoclonal antibodies against humnan renin:blood pressure effects in the marmoset. Hypertension 8:600-605, 1986
 
5) Evin G, Devin J, Castro B et al:Synthesis of peptides related to the prosegment of mouse sub-maxillary gland renin precursor:an approach to renin inhibitors. Proc Natl Acad Sci USA 81:48-52 1984
 
6) Cumin F, Evin G, Fehrentz JA et al:Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem 260:9154-9157, 1985
PubMed
7) 日和田邦男:レニン阻害薬の開発. 高血圧の基礎から臨床まで-1992 年第12回高血圧シンポジウム-. 尾前照雄監修, 診断と治療社, 東京, 1993, pp. 20-39
 
8) Gross F, Lazar J, Orth H:Inhibition of reninangiotensinogen reaction by pepstatin. Science 175:656, 1972
PubMed
9) Kokubu T, Ueda E, Fujimato S et al:Peptide inhibitors of the renin angiotensin system. Nature 217:456-457, 1968
 
10) Burton J, Cody RJ, Herd JA et al:Specific inhibition of renin by an angiotensinogen analog:syudies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA 77:5476-5479, 1980
PubMed
11) Kokubu T, Hiwada K, Nagae A et al:Statincontaining dipeptide and tripeptide inhibitors of human renin. Hypertension 8 (Suppl II):II-1-II-5, 1986
 
12) Hiwada K, Kokubu T, Murakami E et al:A highly potent and long-acting oral inhibitor of human renin. Hypertension 11:708-712, 1988
 
13) Randdatz P, Minck K-0, Rippmann F et al:Nonpeptide renin inhibitors containing 2(((3-pheny1propy1)phosphory1)oxy)alkanoic acid moieties as P2-P3 replacements J Med Chem 37:486-497, 1994
 
14) Smith ABIII, Akaishi R, Jones DR et al:Design and synthesis of nonpeptide peptidomimetic inhibitors of renin. Biopolymers 37:29-53, 1995
 
15) Yang L, Weber AE, Greenlee WJ et al:Macrocyclic renin inhibitors:synthesis of a subnanomolar, orally active cysteine derived inhibitor. Tetrahedron Lett 34:7035-7038, 1993
 
16) Gante J, Krug M, Lauterbach G et al:Synthesis and biological activity of a potent renin inhibitor of the azapeptide type. Liebigs. Ann Chem 1231-1233, 1994
 
17) Tong L, Pav S, Lamarre D et al:Crystallographic studies on the binding modes of P2-P3 butanediamide renin inhibitors. J Biol Chem 270:29520-29524, 1995
PubMed
18) Kleinert HD, Rosenberg SH, Baker WR. et al:Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science 257:1940-1943, 1992
PubMed
19) Kleinert H D, Stein HH, Boyd S et al:Discovery of a well-absorbed efficious renin inhibitor, A-74273. Hypertension 20:768-775, 1992
 
20) Delabays A, Nussberger J, Porchet M et al:Hemodynamics and humoral effects of a new renin inhibitor enalkiren in normal humans. Hypertension 13:941-947, 1989
PubMed
21) Nussberger J, Delabays A, de Gasparo M et al:Hemodyanamic and biochemical consequences of renin inhibition by infusion of GCP 38560 A in normal volunteers. Hypertension 13:948-953, 1989
 
22) Camenzind E, Nussberger J, Juillerat L et al:Effect of the renin response during renin inhibition:oral Ro 425892 in normal humans. J Cardiovasc Pharmacol 18:299-307, 1991
PubMed
23) Menard J, Boger R S, Moyes DM et al:Dose-dependent effects of the renin inhibitor zankiren HCI after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 91:330-338, 1995
 
24) Jeunemaitre X, Menard J, Nussberger J et al:Plasma angiotensin, renin and blood pressure during acute renin inhibition by GCP 38560A in hypertensive patients. Am J Hypertens 2:819-827, 1989
 
25) Bursztyn M, Gavras I, Tifft C P et al:Renin inhibition with A-64662:effect in blood pressure and hormonal response in man. J Hypertens 7 (Suppl):S306-S307, 1989
 
26) van Passen P, de Zeeuw D, de Jong PE:Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. J Cardiovasc Pharmacol 26:39-45, 1995
 
27) Himmelmann A, Bergbrant A, Svensson A et al:Remikiren (Ro 42-5892) an orally active renin inhibitior in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am J Hypertens 9:517-522, 1996
 
28) Kitami, Y, Hiwada K, Murakami E et al:The effect of the renin inhibitor ES-10050n the expression of the kidney renin gene in sodium-depleted marmosets. J Hypertens 8:1143-1146, 1990
 
29) Ii Y, Murakami E, Hiwada K:Effect of renin inhibitor. ES-8891, on renal renin secretion and storage in the marmoset:comparison with captopril. J Hypertens 9:1119-1125, 1991
PubMed
30) de Gasparo M, Cumin F, Nussberger J et al:Pharmacolongical investigation of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol 27:587-596, 1989
PubMed
31) Murakami E, Kokubu T, Ii Y et al:Effects of repeated oral administration of renin inhibitor ES-88910n the renin-angiotensin system in human subjects. Hypertens Res 15:41-44, 1992
 
32) Kiowski W, Linder L, Kleinbloesem C et al:Blood pressure control by the renin-angiotensin system in normotensive subjects:assessment by angiotensin converting enzyme and renin inhibition. Circulation 85:1-8, 1992
PubMed
33) Webb DJ, Manhem PJ, Ball SG et al:A study of the renin inhibitor H-142 in man. J Hypertens 3:653-658, 1985
 
34) Weber MA, Neutel JM, Essinger J et al:Assessment of renin dependency of hypertention with a dipeptide renin inhibitor. Circulation 81:1768-1774, 1990
 
35) Boger RS, Glassman, HN, Cavanaugh JH et al:Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor in essential hypertension. Hypertension 1:835-840, 1990
PubMed
36) van den Meiracker AH, Admiraal PJJ, Man in:t Veld, AJ et al.:Prolonged blood pressure reduction by orally active renin inhibitor Ro 42-5892 in essential hypertension. BMJ 301:205-210, 1990
 
37) Kobrin, I., Viskoper, R. J., Laszt, A. et al.:Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens. 6:349-356, 1993
PubMed
38) Viskoper RJ, Charlton V, Laszt A et al:Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42-5892. J Hum Hypertens:133-136, 1994
 
39) van den Meiracker AH, Admiraal PJJ, Derkx FHM et al:Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J Hypertens 11:831-838, 1993
 
P.348 掲載の参考文献
1) Schunkert H, Jackson B, Tang SS et al:Angiotensin II-induced growth responses in isolated adult rat hearts. Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 76:489-497, 1995
 
2) Campbell-Boswell M, Robertson ALJr:Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 35:265-276, 1991
 
3) Dzau V J, Gibbons GH, Pratt RE:Molecular mechanisms of vascular renin angiotensin system in myointimal hyperplasia. Hypertension 18 (Suppl II):1100-1105, 1991
 
4) Schelling P, Fischer, H, Ganten D:Angiotensin and cell growth:a link to cardiovascular hypertrophy? J Hypertens 9:3-15, 1991
PubMed
5) Bao G, Gohlke, P, Unger T:Role of brady kinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 20 (Suppl 9):S96-S99, 1992
 
6) Johnston CI, McGrath BP, Millar JA et al:Longterm effects of captopril (SQ 14, 225) on blood pressure and hormone levels in essential hypertension. Lancet ii:493-495, 1979
PubMed
7) Ogihara T, Maruyama A, Hata T et al:Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacol Ther 30:328-335, 1981
 
8) Salvetti A, Arzilli F:Chronic dose-response curve of enalapril in essential hypertensives. An Italian multicenter study.Am J Hypertens 2:352-354, 1989
PubMed
9) Fogari R, Zoppi A, Tettamanti F et al:Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors:adouble-blind, randomized, cross-over study. J Cardiovasc Pharmacol 19:670-673, 1992
 
10) Nicholls MG, Gilchrist NL:Sulindac and cough induced by converting enzyme inhibitors. Lancet i:872, 1987
PubMed
11) Chobanian AV, Haudenschild CC, Nickerson C et al:Trandolapril inhibits atherogenesis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 20:473-477, 1992
PubMed
12) Schuh JR, Blehm DJ, Frierdich GE et al:Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91:1453-1458, 1993
PubMed
13) 石光俊彦, 小川吉一, 塚田高樹ほか:高血圧ラットにおける各種降圧薬の標的障害抑制効果の比較. Ther Res 17:2637-2642, 1996
 
14) Dahlof B, Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5:95-110, 1992
PubMed
15) Neaton JD, Grimm RHJr, Prineas RJ et al:Treatment of Mild Hypertension Study. Final results. JAMA 270:713-724, 1993
PubMed
16) Ludwig M, Stumpe KO, Heagerty AM et al:Vascular wall thickness in hypertension:the Perindopril Regression Of vascular Thickening European Community Trial (PROTECT) . Am J Cardiol 76:50E-54E, 1995
PubMed
17) The PHYLLIS Project Group:Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS):A protocol for noninvasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. J Hypertens 11 (Suppl 5):S314-S315, 1993
 
18) The Medical Research Council working party:MRC trial of treatment of mild hypertension:Principal results. Br Med J 291:97-104, 1985
 
19) Multiple Risk Factor Intervention Trial research group:Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. . Am J Cardiol 55:1-15, 1985
 
20) Hypertension Detection and Follow-Up Program Cooperative Group:The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline:the HDFP experience. Circulation 70:996-1003, 1984
 
21) Holme I, Helgeland A, Hjermann I et al:Treatment of mild hypertension with diuretics. The importance of ECG abnormalities in the Oslo Study and in MRFIT. IAMA 251:1298-1299, 1984
 
22) Ferrari P, Weidmann P:Insulin, insulin sensitivity and hypertension. J Hypertens 8:491-500, 1990
PubMed
23) Magrini F, Shimizu M, Roberts N et al:Angiotensin converting enzyme inhibition and coronary blood flow. Circulation 75 (Suppl I):1168-1173, 1987
 
24) Daly, P, Rouleau JL, Cousineau D et al:Acute effects of captopril in hypertensive patients with stable angina. Postgrad Med/2 (Suppl 1):S54-S58, 1986
 
25) Strozzi C, Cocco G, Portaluppi F et al:Ergometric evaluation of the effects of captopril in hypertensive patients with stable angina. Curr Ther Res 41:301-304, 1987
 
26) Katz RJ, Levy WS, Buff L et al:Prevention of nitrate tolerance with angiotensin convertingenzyme inhibitors. Circulation 83:1271-1277, 1991
 
27) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. N Engl J Med 327:669-677, 1992
 
28) The SOLVD investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
PubMed
29) Cohn J N, Johnson G, Zieche S et al:A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
 
30) Kober L, Torp-Pedersen C, Carlsen JE et al:A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670-1676, 1995
PubMed
31) Frei A, Muller-Brand J:Cerebral blood flow and antihypertensive treatment with enalapril. J Hypertens 4:365-368, 1986
PubMed
32) Minematsu K, Yamaguchi T, Tsuchiya M et al:Effect of angiotensin converting enzyme inhibitor (captopril) on cerebral blood flow in hypertensive patients without a history of stroke. Clin Exp Hypertens A9:551-557, 1987
 
33) Hajdu MA, Heistad DD, Ghoneim S et al:Effects of antihypertensive treatment on composition of cerebral arteries. J Hypertension 18 (Suppl II):II15-II21, 1991
 
34) Ogiku N, Sumikawa H, Hashimoto Y et al:Prophylactic effect of imidapril on stroke in stroke-prone spontaneously hypertensive rats. Strolee 24:245-52, 1993
PubMed
35) The GLANT study group:A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension. The GLANT study. Hypertens Res 18:235-244, 1995
 
36) Hostetter TH, Olson JL, Rennke HG et al:Hyperfiltration in remnant nephrons. A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
PubMed
37) Brenner BM, Meyer TW, Hostetter TH:Dietary protein intake and the progressive nature of kidney disease. The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
PubMed
38) Anderson S, Rennke HG, Brenner BM:Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
 
39) Ishimitsu T, Yagi H, Ohkubo M:Different effects between antihypertensive drugs on nephrotic-range proteinuria in renovascular hypertension. Am J Nephrol 14:60-63, 1994
PubMed
40) Maschio G, Alberti D, Janin G et al:Effects of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
PubMed
41) Ferder L, Daccordi H, Martello M et al:Angiotensin converting enzyme inhibitors versus calciumantagonists in the treatment of diabetic hyper tensive patients. Hypertension 19 (Suppl II):II237-II242, 1992
 
42) Zucchelli P, Zuccala A, Borghi M et al:Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
PubMed
43) 高木信嘉, 石井當男:腎障害を伴う高血圧患者の降圧療法. 日本臨床増刊号50 (高血圧下巻):192-197, 1992
 
44) Croog SH, Levine S, Testa MA et al:The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657-1664, 1986
 
45) Kaada B, Woie L:Effects of an angiotensin converting enzyme (ACE) inhibitor on plasma endorphin level. Gen Pharmacol 21:693-695, 1990
PubMed
46) Melzig MF, Heder G:Dexamethasone induced enhanced enkephalin degradation by angiotensinconverting enzyme (ACE) of endothelial cells. Pharmazie 50:139-141, 1995
PubMed
47) Fletcher AE, Bulpitt CJ, Chase DM et al:Quality of life with three antihypertensive treatments:cilazapril, atenolol, nifedipine. Hypertension 19:499-507, 1992
 
48) Omvik P, Thaulow E, Herland OB:Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients:a multicentre study. J Hypertens 11:103-113, 1993
 
49) Pordy RC:Cilazapril with adjunctive hydrochlorothiazide-analysis of safety and efficacy in hypertensive patients not responding to cilazapril alone. Cardio logy 86:41-48, 1995
PubMed
50) Lacourciere Y, Gagne C:Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypetension. J Hum Hypertens 7:149-152, 1993
 
51) Clarke PF, Kendall R, Hornby R et al:Captopril and hydrochlorothiazide-a safe antihypertensive for use in general practice? J Clin Pharm Ther 16:361-366, 1991
PubMed
52) Ishimitsu T, Yagi S, Ebihara A et al:Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. Jpn Heart J, in press
 
53) Tobian L, Brunner HR, Cohn JN et al:Modern strategies to Prevent coronary sequelae and stroke in hypertensive patients differ from JNC V consensus guidelines. Am H Hypertens 7:859-872, 1994
 
54) Eggertsen R, Svensson A, Dahlof B et al:Additive effect of isradipine in combination with captopril in hypertensive patients. Am J Med 86 (4A):124-126, 1989
PubMed
55) Ferrier C, Ferrari P, Weidmann P et al:Antihypertensive therapy with Ca2+antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Oiabetes Care 14:911-914, 1991
PubMed
56) Epstein, M.:The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure:focus on fixed-dose combination antihypertensive therapy. Ren, Fail 18:813-832, 1996
PubMed
57) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 153:154-183, 1993
PubMed
P.361 掲載の参考文献
1) Theroux P, Ross, JJr, Franklin D, et al:Regional myocardial function in the conscious dog during acute coronary occlusion and responses to morphine, propranolol, nitroglycerin, and lidocaine. Circulation 53:302-314, 1976
 
2) Sasayama S, Franklin D, Ross JJr et al:Dynamic changes in left ventricular wall thickness and their use in analyzing cardiac function in the conscious dog. A m J Cardiol 38:870-879, 1976
 
3) Sasayama S, Gallagher KP, Kemper WS et al:Regional left ventricular wall thickness early and late after coronary occlusion in the conscious dog. Am J Physiol 240:H293-H299, 1981
PubMed
4) Pfeffer JM, Pfeffer MA, Fletcher PJ et al:Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 260:H1406-H1414, 1991
PubMed
5) Dzau VJ, Re R:Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 89:493-498, 1994
PubMed
6) Sadoshima J, Izumo S:Signal transduction path-ways of angiotensin II induced c-foc gene expression in cardiac myocytes in vitro. Roles of phospholipid derived second messengers. Circ Res 73:423, 1993
 
7) Pfeffer JM, Pfeffer MA, Braunwald E:Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57:84-95, 1985
 
8) Pfeffer MA, Braunwald E, Moye LA et al for the SAVE Investigators:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction; Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327:669-677, 1992
 
9) The CONSENSUS Trial Study Group; Effects of enalapril on mortality in severe congestive heart failure:Results of the Cooperative North Scan dinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med 316:1429-1435, 1987
 
10) Cohn JN, Johnson G, Ziesche S et al:A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
PubMed
11) The SOLVD Investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
PubMed
12) Kober L, Torp-Pederson C, Carlsen JE et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group:Aclinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670-1676, 1995
 
13) The AIRE Study Investigators:Effects of remipril on mortality and morbidity of survivals of acute myocardial infarction with clinical evidence of cardiac failure. Lancet 342:821-828, 1993
 
14) The SOLVD Investigators:Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992
PubMed
15) Greenberg B, Quinones, MA, Koilpillai C et al for the SOLVD Investigators:Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction; Results of the SOLVD echocardiography substudy. Circulation 91:2573-2581, 1995
 
16) Konstam MA, Rousseau MF, Kronenberg MW et al for the SOLVD Investigators:Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 86:431-438, 1992
 
17) Konstam MA, Kronenberg MW, Rousseau M F et al for the SOLVD Investigators:Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 88:2277-2283, 1993
 
18) Pouleur H, Rousseau MF, van Eyll C et al for the SOLVD Investigators:Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. Circulation 88:481-491, 1993
 
19) Hayashida W, ven Eyll C, Rousseau MF et al for the SOLVD Investigators:Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction; Modification by long-term enalapril treatment. J Am Coll Cardiol 22:1403-1410, 1993.
 
20) Yusuf S, Pepine C J, Garces C et al:Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340:1173-1178, 1992
PubMed
21) Sutton M S J, Pfeffer M A, Moye L A, et al:Determinants of left ventricular thrombus post-infarction are extent and location of wall motion abnormality and left ventricular cavity shape. Circulation 92 (Suppl.1):(Suppl):1-48391, 1995
 
22) Sutton M S J, Pfeffer M A PIappert T, et al:Echocardiographic estimate of infarct size predicts adverse cardiac events and left ventricular remodeling in survivors of acute myocardial infarction. Circulation 92 (Suppl. 1):(Suppl):1-483591, 1995
 
23) Urena P E, Lamas G A, Mitchell G et al for the SAVE Investigators:Ejection fraction by redionuclide ventriculography vs. contrast left ventriculogram:Atale of two techniques. Circulation 92 (Suppl. 1):(Suppl):1-48392, 1995
 
24) Loh E, Sutton MSJ, Wun CC et al for the SAVE Investigators:Ventricular dysfunction predicts cerebrovascular and arterial thromboembolic events following myocardial infarction. Circulation 92 (Suppl 1):(Suppl):1-483483, 1995
 
25) Swedberg K, Held P, Kjekshus J et al for the CONSENSUS II Study Group:Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction; Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327:678-684, 1992
 
26) ISIS-4 Fourth International Study of Infarct Survival Collaborative Group:ISIS-4; A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345:669-685, 1995
 
27) Gruppo Italiano per lo Studio della Sopravvivenza nell:Infarto Miocardico:GISSI-3; Effects of lisinopril and transdermal nitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115-1122, 1994
PubMed
28) Aceto JF, Baker KM:[Sar1]angiotensin II receptor-mediated stimulation of protein synthesis in. chick heart cells. Am J Physiol 258:1-1806-H813, 1990
 
29) Weber KT, Brilla CG:Pathological hypertrophy and cardiac interstitium:fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849-1865, 1991
PubMed
30) Cohn JN:The prevention of heart failure-a new agenda. N Engl J Med 327:725-727, 1992.
PubMed
31) Doroshow J H, Locker G Y, Ifrim I et al:Prevention of doxorubicin cardiac toxicity in the mouse by N-acetyl-cysteine. J Clin Invest 68:1053-1064, 1981
 
32) Devi PU, Prasanna PGS:Radioprotective effect of combinations of WR-2721 and mercaptopropionylglycine on mouse bone marrow chromosomes. Radial Res 124:165-170, 1990
 
33) Forman HJ, Rotman EI, Fisher AB:Roles of selenium and sulfur-countaining amino acids in protection against oxygen toxicity. Lab Invest 49:148-153, 1983
 
34) Suzuki H, Matsumori A, Matoba Y et al:Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. J Clin Invest 91:2727-2733, 1993
PubMed
35) Gilst WH, Graeff PA, Wesseling H et al:Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors:acomparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol 8:722-728, 1986
 
36) Pi X, Chen X:Captopril and ramiprilat protect against free radical injury in isolated working rat hearts. J Mol Cell Cardiol 21:1261-1271, 1989
PubMed
37) Mitsos S E Askew T E, Fantone J C et al:Protective effects of N-2-mercapto propionyl glycine against myocardial reperfusion injury after neutro-phil depletion in the dog:evidence for the role of intracellular-derived free radicals. Circulation 73:1077-1086, 1986
 
38) Mehta JL, Nicolini FA, Lawson DL:Sulfhydryl group angiotensin converting-enzyme inhibitors and superoxide radical formation. J Cardiovasc Pharmacol 16:847-849, 1990
PubMed
39) Foy SG, Crozier I G, Turner JG et al:Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study) . Am J Cardiol 73:1180-1186, 1994
PubMed
40) Borghi C, Ambrosioni E, Magnani B for SMILE Investigators:Effects of early ace-inhibition on long-term survival in patients with acute anterior myocardial infarction. Circulation 90:1-18, 1994
 
41) Hochman JS, Srichai MB, Picard M et al for the CAPTIN Investigators:Very early ACE inhibition reduces progressive left ventricular dilation when tPA fails to establish early reperfusion during acute anterior Inyocardial infarction. Circulation 90:1-19, 1994
 
42) Barr CS, Lang CC, Hanson J et al:Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76:1259-1265, 1995
 
43) Zannad F:Aldosterone and heart failure. Eur Heart J 16 (Suppl N):98-102, 1995
 
44) Staessen J, Lijnen P, Fagard R et al:Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91:457-465, 1981
PubMed
45) Urata H, Healy BH, Stewart R et al:Angiotensin II forming pathways in normal and failing human hearts. Circ Res 66:883-890, 1990
 
46) Pitt B:ACE inhibitor co-therapy in patients with heart failure:rationale for the Randomized AL dactone Evaluation Study (RALES) . Eur Heart J 16 (Suppl. N):107-110, 1995
 
47) The RALES Investigators:Effectiveness of spir-onolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]) . Am J Cardiol 78:902-907, 1996
 
48) Stafford RS, Saglam D, Blumenthal D:Low rates of angiotensin-converting enzyme inhibitor use in congestive heart failure. Circulation 94 (Suppl I):194, 1996
 
49) Philbin EF:Current community practices in heart failure:understanding the under utilization of angiotensin-converting enzyme inhibitors. J AM Coll Cardiol 29 (Suppl A):325, 1997
 
50) Asano K, Dutcher DL, Port JD. et al:Selective down regulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 95:1193-1200, 1997
PubMed
51) Haywood GA, Gullestad L, Katsuya T et al:AT1 and AT2 antiotensin receptor gene expression in human heart failure. Circulation 95:1201-1206, 1997
 
52) Pitt B, Dickstein K, Benedict CR et al for the RAAS Investigator:The randomized angiotensin receptor antagonist-ACE inhibitor study (RAAS)-Pilot Study. Circulation 94 (Suppl I):428, 1996
 
53) Azizi M, Guyene TT, Chatellier G et al:Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29:634-640, 1997
PubMed
54) Shen YT, Lynch JJ, Wiedmann RT et al:Angiotensin II receptor antagonist enhances the effects of angiotensin converting enzyme inhibitor in conscious pigs with congestive heart failure. J Am Coll Cardiol 29 (Suppl A):244, 1997
 
55) Pitt B, Segal R, Martinez FA et al on behalf of ELITE Study Investigators:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) . Lancet 349:747-752, 1997
 
56) Klinger G, Jaramillo N, Ikram H et al:Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. J Am Coll Cardiol 29 (Suppl A):205, 1997
 
57) Ross R:Polypeptide growth factors and atherosclerosis. Trends. Cardiovas Med 1:277, 1991
 
58) Powell JS, Clozel J-P, Muller RK et al:Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186, 1989.
PubMed
59) Nolly H, Scicli A G, Scicli G et al:Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein. Circ Res 56:816, 1985
PubMed
60) Farhy RDI Carretero OA, Ho K-L et al:Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72:1202, 1993
 
61) Furukawa Y, Matsumori A, Hirozane T et al:Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 93:333, 1996
 
P.370 掲載の参考文献
1) Brenner BM:Nephron adaptation to renal injury or ablation. Am J Physiol 249:F324-F337, 1985
 
2) Fujiwara Y, Kitamura E, Ueda N et al:Mechanism of action of angiotensin II on isolated glomeruli. Kidney Int 36:985-991, 1989 Fujiwara Y, Kitamura E, Ochi S et al:Isotopic measurements of glomerular intracapillary volume as a quantitative index for mesangial cell contractility. Contrib Nephrol 95:12-21, 1991
 
3) Fujiwara Y, Ochi S, Takama T et al:Mesangial proliferation and membrane phospholipid metabolism. Acta Med Biol 39:93-101, 1991
 
4) Wolf G, Heberstroh U, Nelson EG:Angiotensin II stimulates the proliferation and biosynthesis of type i collagen in cultured murine mesangial cells. Am J Pathol 140:95-107, 1992
 
5) Ray EP, Aguilera G, Kopp JB et al:Angiotensin II receptor mediated proliferation of cultured human fetal mesangial cells. Kidney Int 40:764-771, 1991
 
6) Barkis GL, Re RN:Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 264:F937-F942, 1993
 
7) Kashgarian M, Sterzel RB:The pathobiology of the mesangium. Kidney Int 41:524-529, 1992
PubMed
8) Arai M, Wada A, Isaka Y et al:Mesangial matrix expansion induced by in vivo transfection of renin and angiotensin converting enzyme genes to rat kidney. J Am Soc Nephrol 4:645, 1993 (abstr)
 
9) Isaka Y, Fujiwara Y, Ueda N et al:Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet derived growth factor gene into the rat kidney. J Clin Invest 92:2597-2601, 1993
 
10) Ketteler M, Noble NA, Border WA:Transforming growth factor-β and angiotensin II:The missing link from glomerular hyperfiltration to glomerulos-clerosis. Annu Rev Physiol 57:279-95, 1995
 
11) Riser BL, Cortes P, Zhao X et al:Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90:1932-1943, 1992.
 
12) Riser BL, Grondin JM, Cortes P et al:Mesangial cell stretch stimulates the secretion and activation of transforming growth factor beta 1(TGF-β1), but not TGF-β2/TGF-β3. J Am Soc Nephrol 4:663, 1993 (abstr)
 
13) Fujiwara Y, Kitamura, E, Ueda, N et al:Mechanism of action of angiotensin II on isolated glomeruli. Kidney Int 36:985-991, 1989. Fujiwara Y, Kitamura E, Ochi S et al:Isotopic measurements of glomerular intracapillary volume as a quantitative index for mesangial cell contractility. Contrib Nephrol 95:12-21, 1991
 
14) Anderson PW, Do YS, Usueh WA:Angiotensin II causes mesangial hypertrophy. Hypertension 21:29-35, 1993. Choi ME, Kim EG, Huang Q et al:Rat mesangial cell hypertrophy in response to transforming growth factor-β1. Kidney Int 44:948-58, 1993
 
15) Gibbons GH, Pratt RE, Dzau VJ:Vascular smooth muscle cell hypertrophy vs. hyperplasia:autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 90:456-461, 1992
 
16) Kagami S, Border WA, Miller DA et al:Angiotensin II stimulates extracellular matrix proteins synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-37, 1994
 
17) Naftilan AJ, Pratt RE Dzau VJ:Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 83:1411-24, 1989
 
18) Wolf G, Mueller E, Stahl RAK et al:Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogeneous transforming growth factor-β. J Clin Invest 92:1366-72, 1993
 
19) Gibbons GH, Pratt RE, Dzau VJ:Vascular smooth muscle cell hypertrophy vs hyperplasia:autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin In vest 90:456-461, 1992
 
20) Kaneto H, Morrissey J, Klahr S:Increased expression of TGF-β1 in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44:313-321, 1993
 
21) Shackland SJ, Scholey JW:Expression of transforming growth factor β1 during diabetic renal hypertrophy. Kidney Int 46:430-442, 1994
 
22) Wolf G, Neilson EG, Goldfarb S et al:The influence of glucose concentration on angiotensin II-induced hypertrophy of proximal tubular cells in culture. Biochem Biophys Res Commum 176:902-909, 1991
 
23) Rosman JB, Meijer S, Sluiter WJ et al:Prospective randomized trial of early dietary protein restriction in chronic renal failure. Lancet ii:1291-1296, 1984
 
24) Okuda S, Nakamura T, Yamamoto T et al:Dietary protein restriction rapidly reduces transforming growth factor-β, in experimental glomerulonephritis. Proc Natl Acad Sci USA 88:9765-9769, 1991
 
25) Gansevoort RT, de Zeeuw D, de Jong PE:Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? journal . Kidney Int 45:861-867, 1994
PubMed
26) Egido J:Nephrology Forum:Vasoactive hormones and renal sclerosis. Kidney Int 49:578-597, 1996. Naftilan AJ, Pratt RE, Dzau VJ:Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 83:1419-1424, 1989
 
27) Kon V, Fogo A, Ichikawa I:Bradykinin causes selective efferent arteriolar dilation during angiotensin converting enzyme inhibition. Kidney Int 44:545-550, 1993
PubMed
28) Lewis EJ, Hunsicker LG, Bain RP et al:The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. New Eng Med 329:1456-1462, 1993
 
29) Kamper AL, Strandgaard S, Leyssac PP:Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423-430, 1992
PubMed
30) Zucchelli P, Zuccala A, Borghi M et al:Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
PubMed
31) Rekola S, Bergstrand A, Bucht H:Deterioratiorl rate in hypertensive IgA nephropathy:comparison of a converting enzyme inhibitor and β-blocking agents. Nephron 59:57-60, 1991
 
32) Cattran DC, Greenwood C, Ritchie S et al:Longterm benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunog lobulin A nephropathy:Acomparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247-154, 1994
 
33) Ihle, BU, Whitworth JA, Shahinfar S et al:Angiotensin-converting enzyme inhibition in non-diabetic progressive renal insufficiency:a controlled double-blind trial. Am J Kidney Dis 27:489-495, 1996
 
34) Maki DD, Ma JZ, Luis TA et al:Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073-1080, 1995
 
35) Rabelink TJ, Koomans HA:Endothelial function and the kidney. An emerging target for cardiovascular therapy. Drugs 53 (Suppl 1):S11-S19, 1997
 
36) Mancini GBJ, Henry GC, Macaya C et al:Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease The TREND (Trial in Reversing ENdothelial Dysfunction) Study. Circulation 94:258-265, 1996
 
37) Kakinuma Y, Kawamura T, Bills T et al:Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
PubMed
38) Ono H, Ono Y, Frohlich ED:ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 27:176-183, 1996
PubMed
39) Mimran A, Ribstein J, Du Cailar G:Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension 26 [part 1]:937-941, 1995
 
40) Rigat B, Hubert C, Alhenc-Gelas, F et al:An insertion/ deletion polymorphism in the angiotensin Iconverting enzyme gene accounting for half of the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
PubMed
41) Marre M, Bernadet P, Gallois Y et al:Relationships between angiotensin I convertirlg enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
PubMed
42) Yoshida H, Mitarai T, Kawamura T et al:Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin In vest 96:2162-2169, 1995
 
43) Parving H-H, Jacobsen P, Tarnow L et al:Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme:observational follow up study. Brit Med J 313:591-594, 1996
PubMed
P.377 掲載の参考文献
1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977, 1993
 
2) Mogensen CE:Long-term antihypertensive treat ment inhibiting Progression of diabetic nephropathy. Br Med J 285:685, 1982
 
3) Walker JD, Bending JJ, Dodds RA et al:Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet ii:1411, 1989
 
4) Taguma Y, Kitamoto Y, Futaki G et al:Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313:1617-1720, 1985
PubMed
5) Bjorck S, Mulec H, Johnsen SA et al:Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304:339-343, 1992
 
6) Melbourne Diabetic Nephropathy Study Group; Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 302:210-216, 1991
 
7) Lewis EJ, Hunsicker LG, Bain RP et al:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456, 1993
PubMed
8) Ravid M, Savin H, Jutrin I et al:Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 45:S-161-S-164, 1994
 
9) Marre M, Chatellier G, Leblanc H et al:Prevention of diabetic nephropathy with enalapril iin normotensive diabetics with microalbuminuria. Br Med J 297:1092-1095, 1988
 
10) Viberti GC, Mogensen CE, Groop LC et al:Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271:275-279, 1994
 
P.382 掲載の参考文献
1) Nakagawa M, Shimamoto K, Masuda A et al:The effects of body fat composition and family history of hypertension on insulinn resistance. J Hypertens 10 (Suppl 4):S88, 1992
 
2) Shimamoto K, Hirata A, Fukuoka M et al:Insulin sensitivity and the effects of insulin on renal sodiuln handling and pressor systems in essential hypertensive patients. Hypertension 23 (Supp. 1):1-29-1-33, 1994
 
3) Hausberg M, Hoffmall RP, Somers VK et al:Contrasting autonolnic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension 29:700-705, 1997
 
4) 平田顯文, 島本和明:インスリン感受性および腎機能・諸昇圧系へのインスリン作用に対する加齢の影響-正常血圧者, 本態性高血圧患者における検討-. 札幌医誌 63:137-148, 1994
 
5) Rett K, Lotz N, Wichlmayr M et al:Verbesserte Insulinwirkung durch ACE-Hemmung beim Typ-II-Diabetiker. Dtsch Med LVochensthr 113:243-249, 1988
 
6) Iimura O, Shimamoto K, Matsuda K et al:Effects of angiotensin receptor antagonist and angiotensin coinverting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential-hypertensives. Am J Hypertents 8:353-357, 1995
 
7) Leighton B, Alison L, Sanderson ME et al:Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Diabetes 45 (Supple 1):S120-S124, 1996
 
8) Tomiyama H, Kusiro T, Abeta H et al:Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 23:450-455, 1994
 
9) Moan A, Risanger T, Edie I et al:The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 3:185-188, 1994
 
10) Shimamoto K, Ura N, Nakagawa M et al:The mechanisms of the improvment of insulin sensitivity by angiotensin converting enzyme inhibitor. Clin Exp Hypertens 18:247-266, 1996
 
11) Chen S, Kashiwabara H, Kosegawa I et al:Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. Clin Exp Hypertens 18:625-636, 1996
 
P.397 掲載の参考文献
1) Robertson MJ, Barnes JC, Drew GM et al:Pharmacological profile of GR117289 in vitro:a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol 107:1173, 1992
PubMed
2) Zhang J, Entzeroth M, Wienen W et al:Characterization of BIBS 39 and BIBS 222:Two new nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol 218:35, 1992
PubMed
3) Ichiki T, Labosky PA, Shiota C et al:Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748-750, 1995
PubMed
4) Hein L, Barsh GS, Pratt RE et al:Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 377:744-747, 1995
PubMed
5) WongPC, Price WA, Chiu AT et al:Nonpeptide angiotensin II receptor antagonists. VIII.:characterization of functional antagonism displayed by DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252:719-725, 1990
 
6) Wong PC, Price WA Jr, Chiu AT et al:Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 15:459-468, 1990
PubMed
7) Wada T, Sanada M, Ojima R et al:Angiotensin II-generating pathways not involving renin or angiotensin converting enzyme in rats. J Hypertens 14 (Suppl 1):S135, 1996
 
8) 吉永馨, 飯村攻, 阿部圭志ほか:本態性高血圧症に対するMK-954 (losartan potassium) の臨床有用性の検討-マレイン酸エナラプリルを対照薬とした二重盲検群間比較試験-. 医学のあゆみ 172:785-823, 1995
 
9) 荒川規矩男, 荻原俊男, 飯村攻ほか:本態性高血圧症に対する TCV-116 (candesartan cilexetil) の臨床的有用性-マレイン酸エナラプリルを対照薬とした二重盲検群問比較試験-. 臨床医薬 12:2613-2661, 1996
 
10) 柊山幸志郎, 瀧下修一, 飯村攻ほか:アンジオテンシンII受容体拮抗薬 TCV-116 (candesartan cilexetil) の本態性高血圧症における長期投与による有効性及び安全性の検討. 臨床医薬 12:3229-3264, 1996
 
11) 荻原俊男, 松岡博昭, 中川雅夫:高齢高血圧症患者に対するアンジオテンシンII受容体拮抗薬 TCV-116 (candesartan cilexetil) の降圧効果および安全性の検討. 臨床医薬 12:3211-3228, 1996
Medical*Online
12) 田川皓一, 竹之山利夫, 飯野耕三:脳血管障害を有する高血圧症患者の脳血流に及ぼすcandesartan cilexetil ( TCV-116) の影響. 臨床医薬 12:3319-3331, 1996
Medical*Online
13) Gottlieb SS, Dickstein K, Fleck E et al:Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88 [part 1]:1602-1609, 1993
 
14) Crozier I, Ikram H, Awan N et al:Losartan in heart failure. Hemodynamic effects and tolerability. Losartan hemodynamic study group. Circulation 91:691-697, 1995
 
15) Pitt B, Segal R, Martinez FA et al:Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 349:747-752, 1997
PubMed
16) Yu H, Rakugi H, Higaki J et al:The role of activated vascular angiotensin II generation in vascular hypertrophy in one-kidney, one clip hypertensive rats. J Hypertens 11:1347-1355, 1993
PubMed
17) Schuh JR, Blehm DJ, Frierdich GE et al.:Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91:1453-1458, 1993
PubMed
18) Miyazaki M, Sakonjo S, Takai N et al.:Anti-atherosclerotic actions of ACE inhibitors. J Hypertens 14 (Suppl 1) S138, 1996
 
19) Kohara K, Mikami H, Okuda N et al:Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension 21:975-979, 1993
PubMed
20) Chan JC, Critchley JA, Tomlinson B, et al:Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin dependent diabetes mellitus. Am J Nephrol 17:72-80, 1997
PubMed
21) Okada M, Kobayashi M, Satoh N et al:Effect of chronic treatment with losartan on development of hypertension in stroke-prone spontaneously hyper tensive rats (SHRSP):Comparative study with enalapril and hydralazine. Hypertens Res 16:49-55, 1993
 
22) Stier Jr CT, Adler LA, Levine S et al:Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 11 (Suppl 3):S37-S42, 1993
 
23) 柊山幸志郎, 荒川規矩男, 藤島正敏:本態性高血圧症におけるMK-954 (losartan potassium) の糖・脂質代謝に及ぼす影響. 臨床医薬 10:141-1561, 994
 
24) Kobayashi R, Nagano M, Nakamura F et al:Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats. Hypertension 21:1051-1055, 1993
PubMed
25) Iimura O, Shimamoto K, Matsuda K et al.:Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 8:353-357, 1995
PubMed
26) Weir MR, Elkins M, Liss C et al:Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 18:411-28, 1996
PubMed
27) Oparil S, Barr E, Elkins M et al:Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 18:608-25, 1996
 
28) 吉永馨, 猿田享男, 飯村攻ほか:腎障害を伴う高血圧症に対するMK-954 (losartan potassium) の臨床的有用性の検討. 臨床医薬 10 (Suppl 6):103-122, 1994
 
P.403 掲載の参考文献
1) De Leeuw P, Van Es P, De Bos R et al:Stimulation of renin by blockade of α 2-adrenoceptors in man:Role of β1adrenoceptor. J Hypertens 6 (Suppl 4):S416-S417, 1988
 
2) Hui T, Krakoff L, Felton, K et al:Diuretic treatment alters clonidine supression of plasma norepinephrine. Hypertension 8:272-276, 1986
 
3) Davis R, Slater J, Rudlf M et al:The effect of isoprenaline on plasma renin activity in man. A dose-response curve. Clin Endocrinol 6:395-399, 1977
 
4) Pringle T, Riddell J, Shanks R:A Comparison of the cardioselectivity of five β-adrenoceptor blocking drugs. J Cardiovas Phamacol 10:228-237, 1987
 
5) Millar E, Connell J, Thomson N:The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. Chest 111:71-74, 1997
PubMed
6) Worth D, Harvey J, Brown J et al:Domperidone treatment in man inhibits the fall in plasma renin activity induced by intravenous gamma-L-glutamyl-L-dopa. Br J Clin Pharmacol 21:497-502, 1986
PubMed
7) Gerber J, Olson R, Nies A:Inter-relationship between prostaglandins and renin release. . Kidney In tern 19:818-821, 1981
 
8) Faver L, Vallotton M:Relationship of renal prostaglandins to three diuretics. Prostaglandins Leukot Med 14:313-319, 1984
 
9) Resnik L, Nicholson J, Laragh J:Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension 10:254-258, 1987
 
10) Fagard R, Lijnen P, Amery A:The acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension. Eur J Pharmacol 32:71-75, 1987
 
11) Chellingsworth M, Kendall M:Effects of nifedepine, verapamil and diltiazem on renal function. Br J Clin Phamacol 25:599-602, 1988
 
12) Reeves R, Smith D, Leenen F:Hemodynamic interaction of non-selectivevs beta-1-selective betablockade with hydralazine in normal humans. Clink Phamacol Ther 41:326-335, 1987
 
13) Puddey I, Beilin L, Vandongen R et al:Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects. Clin Sci 69:327-336, 1985
PubMed
14) Freestone S, Jeffey R, Bonner C et al:Effect of lithium on the renal actions of a human atrial natriuretic peptide in normal man. Clinc Sci 78:371-375, 1990
 
15) Shopsin B, Sathananchan G, Gerhon S:Plasma renin response to lithium in psychiatric patients. Clin Pharmacol Ther 14:561-564, 1973
 
16) Lee D:Cyclosporine and the renin-angiotensin axis. Kidney Int 52:248-260, 1997
PubMed
P.408 掲載の参考文献
1) Goldblatt H, Katz YJ, Lewis HA et al:Studies on experimental hypertension. XX. The bioassay of renin. J Exp Med 77:309, 1943
PubMed
2) Haber E, Koerner T, Page LB et al:Application of a radioimmunoassay for angiotensin I to the physiologic measurments of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29:1349-1355, 1969
 
3) Ikeda I, Iinuma K, Takai M et al:Measurement of plasma renin activity by a simple solid phase radioimmunoassay. J Clin Endocrinol Metab 54:423-428, 1982
PubMed
4) Higaki J, Morishita R, Ogihara T et al:Measurment of enzyme activity and immunoactivity of plasma renin-limitation of the conventional method for assay of plasma renin catalytic activity-. J Clin Chem Clin Biochem 27:201-204, 1989
 
5) Goto T, Hirose S, Imai N et al:An improved method for determination of active and total renin concentration in human plasma using an excess of sheep substrate. Clinica Chim Acta 138:87-98, 1984
 
6) Higaki J, Ogihara T, Imai N et al:A new sensitive direct radioimmunoassay for human plasma renin and its clinical application. J Lab Clin Med 104:947-954, 1984
PubMed
7) 荻原俊男ほか:ホルモンと臨床 36:383, 1989
 
8) Galen FX, Devaux C, Atlas S et al:New monoclonal antibodies directed against human renin. Powerful tools for the investigation of the renin system. J Clin Invest 74:723-735, 1984
PubMed
9) レニンIRMA研究会:活性型レニン測定法の進歩. 尾前照雄編, 自然科学社, 東京, 1990s
 
10) 檜垣實男, 荻原俊男, 熊原雄一:パスツール社レニン RIAキット (D-7110) の基礎的検討ならびに臨床応用. 医学と薬学 19:83-88, 1988
 
11) Higaki J, Morishita R, Ogihara T et al:Effects of aging on human plasma renin:simultaneous multiple assay of enzyme activity and immunoactivity of plasma renin. Acta Endocrinologica 120:81-86 1989
PubMed
12) Cushman DW, Cheung HS:Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20:1637-1648, 1971
PubMed
13) Higaki J, Hirose S, Ogihara T et al:A novel purification method of human renin. Life Sci 32:1591-1598, 1983
PubMed
14) 日和田邦男, 村上英紀, 宍戸道弘ほか:レニン基質と高血圧. 最新医学 34:2392, 1979
Medical*Online
15) Eggena P, Barrett JD, Hidaka H et al:A direct radioimmunoassay for human renin substrate and identification of multiple substrate types in plasma. Circ Res 41 (Suppl II):S34-S37, 1977
 
16) Workman RJ, Sussaman CR, Burkitt DW et al:Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J Lab Clin Med 93:847-856, 1979
 
17) Shimamoto K, Ishida H, Nakahashi Y et al:A very sensitive direct radioimmunoassay system for plasma angiotensin II and its clinical application in various hypertensive diseases. Jpn Circ J 48:1228-1235, 1984
PubMed

書評

最近チェックした商品履歴

Loading...